,source,target,Unnamed: 0,value,type,source layer,target layer,normalized value,unique,fan_in,fan_out,fan_tot,nodes_in_SG,log(Nodes in SG),weighted_val_log
0,A1AG1,Neutrophil degranulation,1196.5,0.0042260875704912,0.5,0.0,1.0,0.0023958898728786,True,0,2,2,9,3.169925001442312,0.0013331821947107061
1,A1AG1,Platelet degranulation ,1194.5,0.0042260875704912,0.5,0.0,1.0,0.0023958898728786,True,0,2,2,9,3.169925001442312,0.0013331821947107061
2,A1AG2,Neutrophil degranulation,1686.5,0.0058251181856547,0.5,0.0,1.0,0.00330242604691445,True,0,2,2,9,3.169925001442312,0.0018376201906998677
3,A1AG2,Platelet degranulation ,1684.5,0.0058251181856547,0.5,0.0,1.0,0.00330242604691445,True,0,2,2,9,3.169925001442312,0.0018376201906998677
4,A2GL,Neutrophil degranulation,1190.5,0.0008748236675522,0.5,0.0,1.0,0.000495962549446,True,0,1,1,5,2.321928094887362,0.00037676604606252375
5,A2MG,HDL assembly,176.5,0.013778568465644299,0.5,0.0,1.0,0.00781146440980285,True,0,3,3,12,3.584962500721156,0.0038434344746625894
6,A2MG,Intrinsic Pathway of Fibrin Clot Formation,178.5,0.013778568465644299,0.5,0.0,1.0,0.00781146440980285,True,0,3,3,12,3.584962500721156,0.0038434344746625894
7,A2MG,Platelet degranulation ,174.5,0.013778568465644299,0.5,0.0,1.0,0.00781146440980285,True,0,3,3,12,3.584962500721156,0.0038434344746625894
8,ABC transporter disorders,Disorders of transmembrane transporters,2286.5,0.0051705750352248996,0.5,2.0,3.0,0.073560285038369,True,1,1,2,6,2.584962500721156,0.002000251467393591
9,ABC transporters in lipid homeostasis,ABC transporters in lipid homeostasis,2112.5,0.008712599806883,0.5,1.0,2.0,0.08247116028617141,False,2,2,4,5,2.321928094887362,0.003752312496699279
10,ABC transporters in lipid homeostasis,ABC-family proteins mediated transport,2210.5,0.0068139375635925,0.5,2.0,3.0,0.0969399314383446,True,2,2,4,5,2.321928094887362,0.0029346031768150197
11,ABC-family proteins mediated transport,Transport of small molecules,2394.5,0.0060950791268101,0.5,3.0,4.0,0.1424723520074088,True,1,1,2,5,2.321928094887362,0.0026250076995195564
12,ADIPO,AMPK inhibits chREBP transcriptional activation activity,1862.5,0.029345657715771703,0.5,0.0,1.0,0.0166368923883914,True,0,2,2,7,2.807354922057604,0.010453134188769865
13,ADIPO,Transcriptional regulation of white adipocyte differentiation,1860.5,0.029345657715771703,0.5,0.0,1.0,0.0166368923883914,True,0,2,2,7,2.807354922057604,0.010453134188769865
14,AMBP,Scavenging of heme from plasma,1192.5,0.0060109258106339995,0.5,0.0,1.0,0.00340776570198925,True,0,1,1,5,2.321928094887362,0.002588764838958371
15,AMPK inhibits chREBP transcriptional activation activity,AMPK inhibits chREBP transcriptional activation activity,2076.5,0.0096005112059167,0.5,1.0,2.0,0.090875894226983,False,2,2,4,5,2.321928094887362,0.004134715121909245
16,AMPK inhibits chREBP transcriptional activation activity,Integration of energy metabolism,2202.5,0.00805636931672,0.5,2.0,3.0,0.11461565092373174,True,2,2,4,5,2.321928094887362,0.0034696894078930633
17,ANGI,Adherens junctions interactions,1238.5,0.0009914310036452,0.5,0.0,1.0,0.00056207058222775,True,0,2,2,9,3.169925001442312,0.0003127616594064844
18,ANGI,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",1240.5,0.0009914310036452,0.5,0.0,1.0,0.00056207058222775,True,0,2,2,9,3.169925001442312,0.0003127616594064844
19,ANGT,Class A/1 (Rhodopsin-like receptors),164.5,0.0318765003694034,0.5,0.0,1.0,0.0180716994487147,True,0,5,5,16,4.0,0.00796912509235085
20,ANGT,G alpha (i) signalling events,168.5,0.0318765003694034,0.5,0.0,1.0,0.0180716994487147,True,0,5,5,16,4.0,0.00796912509235085
21,ANGT,G alpha (q) signalling events,166.5,0.0318765003694034,0.5,0.0,1.0,0.0180716994487147,True,0,5,5,16,4.0,0.00796912509235085
22,ANGT,Metabolism of Angiotensinogen to Angiotensins,172.5,0.0318765003694034,0.5,0.0,1.0,0.0180716994487147,True,0,5,5,16,4.0,0.00796912509235085
23,ANGT,PPARA activates gene expression,170.5,0.0318765003694034,0.5,0.0,1.0,0.0180716994487147,True,0,5,5,16,4.0,0.00796912509235085
24,ANT3,Common Pathway of Fibrin Clot Formation,158.5,0.0027786943898537,0.5,0.0,1.0,0.00157532129598095,True,0,4,4,10,3.321928094887362,0.0008364703601291883
25,ANT3,Intrinsic Pathway of Fibrin Clot Formation,156.5,0.0027786943898537,0.5,0.0,1.0,0.00157532129598095,True,0,4,4,10,3.321928094887362,0.0008364703601291883
26,ANT3,Post-translational protein phosphorylation,162.5,0.0027786943898537,0.5,0.0,1.0,0.00157532129598095,True,0,4,4,10,3.321928094887362,0.0008364703601291883
27,ANT3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),160.5,0.0027786943898537,0.5,0.0,1.0,0.00157532129598095,True,0,4,4,10,3.321928094887362,0.0008364703601291883
28,APOA,LDL remodeling,1608.5,0.0008379728957245999,0.5,0.0,1.0,0.0004750707932869,True,0,1,1,6,2.584962500721156,0.00032417216709751927
29,APOA1,ABC transporters in lipid homeostasis,1062.5,0.0483938299634116,0.5,0.0,1.0,0.0274358458468177,True,0,17,17,44,5.459431618637297,0.00886426158323986
30,APOA1,Amyloid fiber formation,1066.5,0.0483938299634116,0.5,0.0,1.0,0.0274358458468177,True,0,17,17,44,5.459431618637297,0.00886426158323986
31,APOA1,Chylomicron assembly,1042.5,0.0483938299634116,0.5,0.0,1.0,0.0274358458468177,True,0,17,17,44,5.459431618637297,0.00886426158323986
32,APOA1,Chylomicron remodeling,1046.5,0.0483938299634116,0.5,0.0,1.0,0.0274358458468177,True,0,17,17,44,5.459431618637297,0.00886426158323986
33,APOA1,Defective ABCA1 causes TGD,1038.5,0.0483938299634116,0.5,0.0,1.0,0.0274358458468177,True,0,17,17,44,5.459431618637297,0.00886426158323986
34,APOA1,HDL assembly,1044.5,0.0483938299634116,0.5,0.0,1.0,0.0274358458468177,True,0,17,17,44,5.459431618637297,0.00886426158323986
35,APOA1,HDL clearance,1050.5,0.0483938299634116,0.5,0.0,1.0,0.0274358458468177,True,0,17,17,44,5.459431618637297,0.00886426158323986
36,APOA1,HDL remodeling,1048.5,0.0483938299634116,0.5,0.0,1.0,0.0274358458468177,True,0,17,17,44,5.459431618637297,0.00886426158323986
37,APOA1,Heme signaling,1060.5,0.0483938299634116,0.5,0.0,1.0,0.0274358458468177,True,0,17,17,44,5.459431618637297,0.00886426158323986
38,APOA1,PPARA activates gene expression,1036.5,0.0483938299634116,0.5,0.0,1.0,0.0274358458468177,True,0,17,17,44,5.459431618637297,0.00886426158323986
39,APOA1,Platelet degranulation ,1040.5,0.0483938299634116,0.5,0.0,1.0,0.0274358458468177,True,0,17,17,44,5.459431618637297,0.00886426158323986
40,APOA1,Post-translational protein phosphorylation,1068.5,0.0483938299634116,0.5,0.0,1.0,0.0274358458468177,True,0,17,17,44,5.459431618637297,0.00886426158323986
41,APOA1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),1064.5,0.0483938299634116,0.5,0.0,1.0,0.0274358458468177,True,0,17,17,44,5.459431618637297,0.00886426158323986
42,APOA1,Retinoid metabolism and transport,1058.5,0.0483938299634116,0.5,0.0,1.0,0.0274358458468177,True,0,17,17,44,5.459431618637297,0.00886426158323986
43,APOA1,Scavenging by Class A Receptors,1056.5,0.0483938299634116,0.5,0.0,1.0,0.0274358458468177,True,0,17,17,44,5.459431618637297,0.00886426158323986
44,APOA1,Scavenging by Class B Receptors,1054.5,0.0483938299634116,0.5,0.0,1.0,0.0274358458468177,True,0,17,17,44,5.459431618637297,0.00886426158323986
45,APOA1,Scavenging of heme from plasma,1052.5,0.0483938299634116,0.5,0.0,1.0,0.0274358458468177,True,0,17,17,44,5.459431618637297,0.00886426158323986
46,APOA4,Amyloid fiber formation,1576.5,0.0391978785651633,0.5,0.0,1.0,0.02222239807531625,True,0,5,5,17,4.087462841250339,0.009589782240851594
47,APOA4,Assembly of active LPL and LIPC lipase complexes,1570.5,0.0391978785651633,0.5,0.0,1.0,0.02222239807531625,True,0,5,5,17,4.087462841250339,0.009589782240851594
48,APOA4,Chylomicron assembly,1568.5,0.0391978785651633,0.5,0.0,1.0,0.02222239807531625,True,0,5,5,17,4.087462841250339,0.009589782240851594
49,APOA4,Chylomicron remodeling,1572.5,0.0391978785651633,0.5,0.0,1.0,0.02222239807531625,True,0,5,5,17,4.087462841250339,0.009589782240851594
50,APOA4,Retinoid metabolism and transport,1574.5,0.0391978785651633,0.5,0.0,1.0,0.02222239807531625,True,0,5,5,17,4.087462841250339,0.009589782240851594
51,APOB,Cargo recognition for clathrin-mediated endocytosis,1264.5,0.0330116453512744,0.5,0.0,1.0,0.0187152455941623,True,0,19,19,44,5.459431618637297,0.006046718350419466
52,APOB,Cell surface interactions at the vascular wall,1280.5,0.0330116453512744,0.5,0.0,1.0,0.0187152455941623,True,0,19,19,44,5.459431618637297,0.006046718350419466
53,APOB,Chylomicron assembly,1268.5,0.0330116453512744,0.5,0.0,1.0,0.0187152455941623,True,0,19,19,44,5.459431618637297,0.006046718350419466
54,APOB,Chylomicron clearance,1274.5,0.0330116453512744,0.5,0.0,1.0,0.0187152455941623,True,0,19,19,44,5.459431618637297,0.006046718350419466
55,APOB,Chylomicron remodeling,1270.5,0.0330116453512744,0.5,0.0,1.0,0.0187152455941623,True,0,19,19,44,5.459431618637297,0.006046718350419466
56,APOB,Heme signaling,1292.5,0.0330116453512744,0.5,0.0,1.0,0.0187152455941623,True,0,19,19,44,5.459431618637297,0.006046718350419466
57,APOB,LDL clearance,1276.5,0.0330116453512744,0.5,0.0,1.0,0.0187152455941623,True,0,19,19,44,5.459431618637297,0.006046718350419466
58,APOB,LDL remodeling,1272.5,0.0330116453512744,0.5,0.0,1.0,0.0187152455941623,True,0,19,19,44,5.459431618637297,0.006046718350419466
59,APOB,Platelet sensitization by LDL,1296.5,0.0330116453512744,0.5,0.0,1.0,0.0187152455941623,True,0,19,19,44,5.459431618637297,0.006046718350419466
60,APOB,Post-translational protein phosphorylation,1298.5,0.0330116453512744,0.5,0.0,1.0,0.0187152455941623,True,0,19,19,44,5.459431618637297,0.006046718350419466
61,APOB,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),1294.5,0.0330116453512744,0.5,0.0,1.0,0.0187152455941623,True,0,19,19,44,5.459431618637297,0.006046718350419466
62,APOB,Regulation of TLR by endogenous ligand,1262.5,0.0330116453512744,0.5,0.0,1.0,0.0187152455941623,True,0,19,19,44,5.459431618637297,0.006046718350419466
63,APOB,Retinoid metabolism and transport,1290.5,0.0330116453512744,0.5,0.0,1.0,0.0187152455941623,True,0,19,19,44,5.459431618637297,0.006046718350419466
64,APOB,Scavenging by Class A Receptors,1284.5,0.0330116453512744,0.5,0.0,1.0,0.0187152455941623,True,0,19,19,44,5.459431618637297,0.006046718350419466
65,APOB,Scavenging by Class B Receptors,1282.5,0.0330116453512744,0.5,0.0,1.0,0.0187152455941623,True,0,19,19,44,5.459431618637297,0.006046718350419466
66,APOB,Scavenging by Class F Receptors,1286.5,0.0330116453512744,0.5,0.0,1.0,0.0187152455941623,True,0,19,19,44,5.459431618637297,0.006046718350419466
67,APOB,Scavenging by Class H Receptors,1288.5,0.0330116453512744,0.5,0.0,1.0,0.0187152455941623,True,0,19,19,44,5.459431618637297,0.006046718350419466
68,APOB,VLDL assembly,1266.5,0.0330116453512744,0.5,0.0,1.0,0.0187152455941623,True,0,19,19,44,5.459431618637297,0.006046718350419466
69,APOB,VLDL clearance,1278.5,0.0330116453512744,0.5,0.0,1.0,0.0187152455941623,True,0,19,19,44,5.459431618637297,0.006046718350419466
70,APOC4,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,1774.5,0.0040192965210353,0.5,0.0,1.0,0.0022786541145255,True,0,3,3,12,3.584962500721156,0.001121154411022925
71,APOC4,VLDL assembly,1770.5,0.0040192965210353,0.5,0.0,1.0,0.0022786541145255,True,0,3,3,12,3.584962500721156,0.001121154411022925
72,APOC4,VLDL clearance,1772.5,0.0040192965210353,0.5,0.0,1.0,0.0022786541145255,True,0,3,3,12,3.584962500721156,0.001121154411022925
73,APOE,Amyloid fiber formation,1090.5,0.0815079300317353,0.5,0.0,1.0,0.0462091759493847,True,0,12,12,36,5.169925001442312,0.0157657857723267
74,APOE,Chylomicron assembly,1074.5,0.0815079300317353,0.5,0.0,1.0,0.0462091759493847,True,0,12,12,36,5.169925001442312,0.0157657857723267
75,APOE,Chylomicron clearance,1080.5,0.0815079300317353,0.5,0.0,1.0,0.0462091759493847,True,0,12,12,36,5.169925001442312,0.0157657857723267
76,APOE,Chylomicron remodeling,1076.5,0.0815079300317353,0.5,0.0,1.0,0.0462091759493847,True,0,12,12,36,5.169925001442312,0.0157657857723267
77,APOE,HDL remodeling,1078.5,0.0815079300317353,0.5,0.0,1.0,0.0462091759493847,True,0,12,12,36,5.169925001442312,0.0157657857723267
78,APOE,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,1082.5,0.0815079300317353,0.5,0.0,1.0,0.0462091759493847,True,0,12,12,36,5.169925001442312,0.0157657857723267
79,APOE,Nuclear signaling by ERBB4,1070.5,0.0815079300317353,0.5,0.0,1.0,0.0462091759493847,True,0,12,12,36,5.169925001442312,0.0157657857723267
80,APOE,Post-translational protein phosphorylation,1092.5,0.0815079300317353,0.5,0.0,1.0,0.0462091759493847,True,0,12,12,36,5.169925001442312,0.0157657857723267
81,APOE,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),1088.5,0.0815079300317353,0.5,0.0,1.0,0.0462091759493847,True,0,12,12,36,5.169925001442312,0.0157657857723267
82,APOE,Retinoid metabolism and transport,1086.5,0.0815079300317353,0.5,0.0,1.0,0.0462091759493847,True,0,12,12,36,5.169925001442312,0.0157657857723267
83,APOE,Scavenging by Class A Receptors,1084.5,0.0815079300317353,0.5,0.0,1.0,0.0462091759493847,True,0,12,12,36,5.169925001442312,0.0157657857723267
84,APOE,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,1072.5,0.0815079300317353,0.5,0.0,1.0,0.0462091759493847,True,0,12,12,36,5.169925001442312,0.0157657857723267
85,APOF,LDL remodeling,1846.5,0.0007942111926262,0.5,0.0,1.0,0.00045026103259825003,True,0,1,1,6,2.584962500721156,0.00030724282940453875
86,APOH,Platelet degranulation ,1188.5,0.0072278724135577,0.5,0.0,1.0,0.00409768752522305,True,0,1,1,6,2.584962500721156,0.0027961227335178977
87,Activation of C3 and C5,Complement cascade,1882.5,0.0029779984803877998,0.5,1.0,2.0,0.028188944224663302,True,3,1,4,8,3.0,0.0009926661601292665
88,Activation of Matrix Metalloproteinases,Activation of Matrix Metalloproteinases,2062.5,0.0016699481789642,0.5,1.0,2.0,0.0158072868018291,False,2,2,4,5,2.321928094887362,0.0007192075338772324
89,Activation of Matrix Metalloproteinases,Degradation of the extracellular matrix,2282.5,0.0011375982508435001,0.5,2.0,3.0,0.0161842833768231,True,2,2,4,5,2.321928094887362,0.000489936899143591
90,Adaptive Immune System,Immune System,2422.5,0.004330569866371901,0.5,3.0,4.0,0.10122698353176504,True,3,1,4,49,5.614709844115208,0.0007712900553375491
91,Adherens junctions interactions,Cell-cell junction organization,1944.5,0.0008919766760604,0.5,1.0,2.0,0.00844321477554765,True,1,1,2,6,2.584962500721156,0.0003450636811217011
92,Advanced glycosylation endproduct receptor signaling,Advanced glycosylation endproduct receptor signaling,2080.5,0.0017431016610569001,0.5,1.0,2.0,0.01649973827221475,False,2,2,4,5,2.321928094887362,0.000750713023756
93,Advanced glycosylation endproduct receptor signaling,Innate Immune System,2200.5,0.0019416995109212,0.5,2.0,3.0,0.02762400091076605,True,2,2,4,5,2.321928094887362,0.0008362444621763331
94,Amyloid fiber formation,Amyloid fiber formation,2205.5,0.019321779300712952,0.5,1.5,2.5,0.22407407714769553,False,9,2,11,11,3.4594316186372973,0.00558524677771315
95,Amyloid fiber formation,Metabolism of proteins,2342.5,0.0059302786307767,0.5,3.0,4.0,0.13862014372702655,True,9,2,11,11,3.4594316186372973,0.0017142349624221485
96,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,Signaling by the B Cell Receptor (BCR),2040.5,0.0004122500284527,0.5,1.0,2.0,0.0039022494924706,True,34,1,35,39,5.285402218862249,7.799785359409073e-05
97,Antigen processing-Cross presentation,Class I MHC mediated antigen processing & presentation,1870.5,0.0055512050615649,0.5,1.0,2.0,0.0525462356313037,True,5,1,6,10,3.321928094887362,0.0016710792356127524
98,Antimicrobial peptides,Innate Immune System,2296.5,0.0049071028641601,0.5,2.0,3.0,0.0698119421807237,True,1,1,2,7,2.807354922057604,0.0017479453080921884
99,Apoptosis,Programmed Cell Death,2416.5,0.019805527094010997,0.5,3.0,4.0,0.46295379750171306,True,2,1,3,9,3.169925001442312,0.006247948164388591
100,Apoptotic cleavage of cellular proteins,Apoptotic execution phase,1866.5,0.022453736565063998,0.5,1.0,2.0,0.21254111841771006,True,1,1,2,6,2.584962500721156,0.00868629102309988
101,Apoptotic execution phase,Apoptosis,2248.5,0.0192373530409002,0.5,2.0,3.0,0.2736842930296638,True,1,1,2,6,2.584962500721156,0.007442024027634188
102,Arachidonic acid metabolism,Fatty acid metabolism,1922.5,0.0037574344428815,0.5,1.0,2.0,0.035566878437232996,True,2,1,3,7,2.807354922057604,0.0013384251536416175
103,Assembly of active LPL and LIPC lipase complexes,Plasma lipoprotein remodeling,1996.5,0.008017176576252,0.5,1.0,2.0,0.07588846832380311,True,1,1,2,6,2.584962500721156,0.003101467264618097
104,Assembly of collagen fibrils and other multimeric structures,Collagen formation,2312.5,0.00013260144699917578,0.5,2.0,3.0,0.0018864826777114999,True,1,1,2,6,2.584962500721156,5.1297242014993434e-05
105,Atorvastatin ADME,Atorvastatin ADME,2200.5,0.008882988896994501,0.5,1.5,2.5,0.10572016263049061,False,3,2,5,5,2.321928094887362,0.0038256950835617583
106,Atorvastatin ADME,Drug ADME,2378.5,0.0082917783393793,0.5,3.0,4.0,0.193820151922081,True,3,2,5,5,2.321928094887362,0.003571074555511392
107,Autophagy,root,2462.5,0.0089863820325198,0.5,4.0,5.0,0.5166330403354641,True,2,1,3,6,2.584962500721156,0.0034764071161623306
108,BLVRB,Cytoprotection by HMOX1,1746.5,0.0006250408836265,0.5,0.0,1.0,0.00035435354763405005,True,0,2,2,9,3.169925001442312,0.00019717844533927682
109,BLVRB,Heme degradation,1748.5,0.0006250408836265,0.5,0.0,1.0,0.00035435354763405005,True,0,2,2,9,3.169925001442312,0.00019717844533927682
110,Binding and Uptake of Ligands by Scavenger Receptors,Vesicle-mediated transport,2402.5,0.0130602827412243,0.5,3.0,4.0,0.30528384641296413,True,5,1,6,50,5.643856189774724,0.0023140707881406175
111,C1QA,Initial triggering of complement,1176.5,0.0016856864356173,0.5,0.0,1.0,0.0009556638362501,True,0,2,2,7,2.807354922057604,0.0006004536235773866
112,C1QA,Regulation of Complement cascade,1178.5,0.0016856864356173,0.5,0.0,1.0,0.0009556638362501,True,0,2,2,7,2.807354922057604,0.0006004536235773866
113,C1QC,Initial triggering of complement,1180.5,0.0030377658531797,0.5,0.0,1.0,0.0017221963157199498,True,0,2,2,7,2.807354922057604,0.001082074029653942
114,C1QC,Regulation of Complement cascade,1182.5,0.0030377658531797,0.5,0.0,1.0,0.0017221963157199498,True,0,2,2,7,2.807354922057604,0.001082074029653942
115,C4BPA,Regulation of Complement cascade,1242.5,0.0044548263281512,0.5,0.0,1.0,0.0025255684145253,True,0,1,1,6,2.584962500721156,0.001723362070787637
116,CAH2,Erythrocytes take up carbon dioxide and release oxygen,152.5,0.0197299617499226,0.5,0.0,1.0,0.0111854794204911,True,0,3,3,8,3.0,0.0065766539166408665
117,CAH2,Erythrocytes take up oxygen and release carbon dioxide,154.5,0.0197299617499226,0.5,0.0,1.0,0.0111854794204911,True,0,3,3,8,3.0,0.0065766539166408665
118,CAH2,Reversible hydration of carbon dioxide,150.5,0.0197299617499226,0.5,0.0,1.0,0.0111854794204911,True,0,3,3,8,3.0,0.0065766539166408665
119,CATA,Detoxification of Reactive Oxygen Species,1256.5,0.0039372526459904005,0.5,0.0,1.0,0.0022321410960248,True,0,4,4,15,3.9068905956085187,0.0010077714104449226
120,CATA,FOXO-mediated transcription,1254.5,0.0039372526459904005,0.5,0.0,1.0,0.0022321410960248,True,0,4,4,15,3.9068905956085187,0.0010077714104449226
121,CATA,Neutrophil degranulation,1258.5,0.0039372526459904005,0.5,0.0,1.0,0.0022321410960248,True,0,4,4,15,3.9068905956085187,0.0010077714104449226
122,CATA,Peroxisomal protein import,1260.5,0.0039372526459904005,0.5,0.0,1.0,0.0022321410960248,True,0,4,4,15,3.9068905956085187,0.0010077714104449226
123,CBG,Metabolism of steroid hormones,1606.5,0.00022735813682916197,0.5,0.0,1.0,0.00012889582822395566,True,0,1,1,6,2.584962500721156,8.795413347997633e-05
124,CBPN,Regulation of Complement cascade,1676.5,0.0011455354875899,0.5,0.0,1.0,0.00064943682021725,True,0,1,1,6,2.584962500721156,0.0004431536191609422
125,CD14,Antigen processing-Cross presentation,1610.5,0.0398987418884729,0.5,0.0,1.0,0.02261973753186575,True,0,10,10,23,4.523561956057013,0.008820204581270034
126,CD14,Caspase activation via Death Receptors in the presence of ligand,1622.5,0.0398987418884729,0.5,0.0,1.0,0.02261973753186575,True,0,10,10,23,4.523561956057013,0.008820204581270034
127,CD14,IRAK4 deficiency (TLR2/4),1626.5,0.0398987418884729,0.5,0.0,1.0,0.02261973753186575,True,0,10,10,23,4.523561956057013,0.008820204581270034
128,CD14,MyD88 deficiency (TLR2/4),1624.5,0.0398987418884729,0.5,0.0,1.0,0.02261973753186575,True,0,10,10,23,4.523561956057013,0.008820204581270034
129,CD14,Neutrophil degranulation,1628.5,0.0398987418884729,0.5,0.0,1.0,0.02261973753186575,True,0,10,10,23,4.523561956057013,0.008820204581270034
130,CD14,Regulation of TLR by endogenous ligand,1620.5,0.0398987418884729,0.5,0.0,1.0,0.02261973753186575,True,0,10,10,23,4.523561956057013,0.008820204581270034
131,CD14,Toll Like Receptor 2 (TLR2) Cascade,1618.5,0.0398987418884729,0.5,0.0,1.0,0.02261973753186575,True,0,10,10,23,4.523561956057013,0.008820204581270034
132,CD14,Toll Like Receptor 4 (TLR4) Cascade,1612.5,0.0398987418884729,0.5,0.0,1.0,0.02261973753186575,True,0,10,10,23,4.523561956057013,0.008820204581270034
133,CD14,Toll Like Receptor 7/8 (TLR7/8) Cascade,1616.5,0.0398987418884729,0.5,0.0,1.0,0.02261973753186575,True,0,10,10,23,4.523561956057013,0.008820204581270034
134,CD14,Toll Like Receptor 9 (TLR9) Cascade,1614.5,0.0398987418884729,0.5,0.0,1.0,0.02261973753186575,True,0,10,10,23,4.523561956057013,0.008820204581270034
135,CD22 mediated BCR regulation,Signaling by the B Cell Receptor (BCR),2038.5,0.0008078224989242001,0.5,1.0,2.0,0.0076466336418815,True,34,1,35,39,5.285402218862249,0.000152840307222275
136,CERU,Defective CP causes aceruloplasminemia (ACERULOP),74.5,0.0112547211706467,0.5,0.0,1.0,0.00638062321829535,True,0,5,5,15,3.9068905956085187,0.0028807362006239437
137,CERU,Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages),72.5,0.0112547211706467,0.5,0.0,1.0,0.00638062321829535,True,0,5,5,15,3.9068905956085187,0.0028807362006239437
138,CERU,Metal ion SLC transporters,70.5,0.0112547211706467,0.5,0.0,1.0,0.00638062321829535,True,0,5,5,15,3.9068905956085187,0.0028807362006239437
139,CERU,Post-translational protein phosphorylation,78.5,0.0112547211706467,0.5,0.0,1.0,0.00638062321829535,True,0,5,5,15,3.9068905956085187,0.0028807362006239437
140,CERU,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),76.5,0.0112547211706467,0.5,0.0,1.0,0.00638062321829535,True,0,5,5,15,3.9068905956085187,0.0028807362006239437
141,CFAH,Regulation of Complement cascade,1630.5,0.0044963044420543,0.5,0.0,1.0,0.0025490835432084996,True,0,1,1,6,2.584962500721156,0.0017394079955898453
142,CO3,Activation of C3 and C5,182.5,0.049097484015334,0.5,0.0,1.0,0.027834767447208197,True,0,10,10,25,4.643856189774724,0.010572567712893742
143,CO3,Cell recruitment (pro-inflammatory response),190.5,0.049097484015334,0.5,0.0,1.0,0.027834767447208197,True,0,10,10,25,4.643856189774724,0.010572567712893742
144,CO3,Class A/1 (Rhodopsin-like receptors),186.5,0.049097484015334,0.5,0.0,1.0,0.027834767447208197,True,0,10,10,25,4.643856189774724,0.010572567712893742
145,CO3,G alpha (i) signalling events,188.5,0.049097484015334,0.5,0.0,1.0,0.027834767447208197,True,0,10,10,25,4.643856189774724,0.010572567712893742
146,CO3,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,192.5,0.049097484015334,0.5,0.0,1.0,0.027834767447208197,True,0,10,10,25,4.643856189774724,0.010572567712893742
147,CO3,Initial triggering of complement,180.5,0.049097484015334,0.5,0.0,1.0,0.027834767447208197,True,0,10,10,25,4.643856189774724,0.010572567712893742
148,CO3,Neutrophil degranulation,194.5,0.049097484015334,0.5,0.0,1.0,0.027834767447208197,True,0,10,10,25,4.643856189774724,0.010572567712893742
149,CO3,Post-translational protein phosphorylation,198.5,0.049097484015334,0.5,0.0,1.0,0.027834767447208197,True,0,10,10,25,4.643856189774724,0.010572567712893742
150,CO3,Regulation of Complement cascade,184.5,0.049097484015334,0.5,0.0,1.0,0.027834767447208197,True,0,10,10,25,4.643856189774724,0.010572567712893742
151,CO3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),196.5,0.049097484015334,0.5,0.0,1.0,0.027834767447208197,True,0,10,10,25,4.643856189774724,0.010572567712893742
152,CO5,Activation of C3 and C5,202.5,0.0194262341995955,0.5,0.0,1.0,0.01101328758825745,True,0,5,5,14,3.807354922057604,0.005102291380047386
153,CO5,Class A/1 (Rhodopsin-like receptors),206.5,0.0194262341995955,0.5,0.0,1.0,0.01101328758825745,True,0,5,5,14,3.807354922057604,0.005102291380047386
154,CO5,G alpha (i) signalling events,208.5,0.0194262341995955,0.5,0.0,1.0,0.01101328758825745,True,0,5,5,14,3.807354922057604,0.005102291380047386
155,CO5,Regulation of Complement cascade,204.5,0.0194262341995955,0.5,0.0,1.0,0.01101328758825745,True,0,5,5,14,3.807354922057604,0.005102291380047386
156,CO5,Terminal pathway of complement,200.5,0.0194262341995955,0.5,0.0,1.0,0.01101328758825745,True,0,5,5,14,3.807354922057604,0.005102291380047386
157,CO6,Regulation of Complement cascade,1674.5,0.0039827013339917006,0.5,0.0,1.0,0.00225790725668805,True,0,2,2,7,2.807354922057604,0.0014186668392725513
158,CO6,Terminal pathway of complement,1672.5,0.0039827013339917006,0.5,0.0,1.0,0.00225790725668805,True,0,2,2,7,2.807354922057604,0.0014186668392725513
159,CO7,Regulation of Complement cascade,1666.5,0.007318446257314,0.5,0.0,1.0,0.0041490364268687505,True,0,2,2,7,2.807354922057604,0.0026068831553190527
160,CO7,Terminal pathway of complement,1664.5,0.007318446257314,0.5,0.0,1.0,0.0041490364268687505,True,0,2,2,7,2.807354922057604,0.0026068831553190527
161,CO8A,Regulation of Complement cascade,1582.5,0.00033351994945589997,0.5,0.0,1.0,0.00018908199510204998,True,0,2,2,7,2.807354922057604,0.00011880220304009586
162,CO8A,Terminal pathway of complement,1580.5,0.00033351994945589997,0.5,0.0,1.0,0.00018908199510204998,True,0,2,2,7,2.807354922057604,0.00011880220304009586
163,CO8G,Regulation of Complement cascade,1586.5,0.010589993402364401,0.5,0.0,1.0,0.0060037700410518,True,0,2,2,7,2.807354922057604,0.0037722317613487367
164,CO8G,Terminal pathway of complement,1584.5,0.010589993402364401,0.5,0.0,1.0,0.0060037700410518,True,0,2,2,7,2.807354922057604,0.0037722317613487367
165,CO9,Regulation of Complement cascade,1186.5,0.0127208935064753,0.5,0.0,1.0,0.007211838235190501,True,0,2,2,7,2.807354922057604,0.004531273693442271
166,CO9,Terminal pathway of complement,1184.5,0.0127208935064753,0.5,0.0,1.0,0.007211838235190501,True,0,2,2,7,2.807354922057604,0.004531273693442271
167,CPN2,Regulation of Complement cascade,1688.5,0.0030623422913058,0.5,0.0,1.0,0.00173612940116495,True,0,1,1,6,2.584962500721156,0.001184675712104707
168,CRP,Initial triggering of complement,1172.5,0.0007994885379573,0.5,0.0,1.0,0.0004532529105524,True,0,1,1,6,2.584962500721156,0.0003092843852606209
169,CXCL7,Class A/1 (Rhodopsin-like receptors),1206.5,0.022904340907663003,0.5,0.0,1.0,0.012985125724513,True,0,4,4,15,3.9068905956085187,0.005862549858296078
170,CXCL7,G alpha (i) signalling events,1208.5,0.022904340907663003,0.5,0.0,1.0,0.012985125724513,True,0,4,4,15,3.9068905956085187,0.005862549858296078
171,CXCL7,Neutrophil degranulation,1212.5,0.022904340907663003,0.5,0.0,1.0,0.012985125724513,True,0,4,4,15,3.9068905956085187,0.005862549858296078
172,CXCL7,Platelet degranulation ,1210.5,0.022904340907663003,0.5,0.0,1.0,0.012985125724513,True,0,4,4,15,3.9068905956085187,0.005862549858296078
173,CYTC,Amyloid fiber formation,214.5,0.020022884284020298,0.5,0.0,1.0,0.01135154558009535,True,0,4,4,10,3.321928094887362,0.0060274887691990275
174,CYTC,Neutrophil degranulation,210.5,0.020022884284020298,0.5,0.0,1.0,0.01135154558009535,True,0,4,4,10,3.321928094887362,0.0060274887691990275
175,CYTC,Post-translational protein phosphorylation,216.5,0.020022884284020298,0.5,0.0,1.0,0.01135154558009535,True,0,4,4,10,3.321928094887362,0.0060274887691990275
176,CYTC,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),212.5,0.020022884284020298,0.5,0.0,1.0,0.01135154558009535,True,0,4,4,10,3.321928094887362,0.0060274887691990275
177,Cargo recognition for clathrin-mediated endocytosis,Clathrin-mediated endocytosis,1986.5,0.0118577414965657,0.5,1.0,2.0,0.11224223782465989,True,2,1,3,7,2.807354922057604,0.004223812743945737
178,Caspase activation via Death Receptors in the presence of ligand,Caspase activation via extrinsic apoptotic signalling pathway,1954.5,0.0104244491065802,0.5,1.0,2.0,0.09867507198995065,True,1,1,2,6,2.584962500721156,0.00403272740075416
179,Caspase activation via extrinsic apoptotic signalling pathway,Apoptosis,2196.5,0.008187476690516799,0.5,2.0,3.0,0.1164808778513789,True,1,1,2,6,2.584962500721156,0.003167348341893798
180,Cell junction organization,Cell-Cell communication,2348.5,0.0009484229244364,0.5,3.0,4.0,0.0221693667844026,True,1,1,2,6,2.584962500721156,0.00036690007076381487
181,Cell recruitment (pro-inflammatory response),Leishmania infection,2026.5,0.009230373612304301,0.5,1.0,2.0,0.08737226987978991,True,1,1,2,6,2.584962500721156,0.0035707959437435554
182,Cell surface interactions at the vascular wall,Cell surface interactions at the vascular wall,2112.5,0.02694832103060355,0.5,1.5,2.5,0.31018459703683526,False,38,2,40,40,5.321928094887363,0.005063638694497226
183,Cell surface interactions at the vascular wall,Hemostasis,2336.5,0.0106316080156215,0.5,3.0,4.0,0.24851362354652917,True,38,2,40,40,5.321928094887363,0.0019976985457272538
184,Cell-Cell communication,root,2478.5,0.0003402269264000248,0.5,4.0,5.0,0.0195598707860385,True,1,1,2,6,2.584962500721156,0.00013161774157462936
185,Cell-cell junction organization,Cell junction organization,2154.5,0.0008699541714893,0.5,2.0,3.0,0.0123765879789222,True,1,1,2,6,2.584962500721156,0.0003365442134060355
186,Cellular response to chemical stress,Cellular responses to stress,2266.5,6.17854138527126e-05,0.5,2.0,3.0,0.0008790033261786,True,2,1,3,11,3.4594316186372973,1.7859989924313193e-05
187,Cellular responses to stimuli,root,2490.5,0.004714748627890888,0.5,4.0,5.0,0.27105401364309717,True,1,1,2,14,3.807354922057604,0.001238326534932788
188,Cellular responses to stress,Cellular responses to stimuli,2362.5,0.0093791051627323,0.5,3.0,4.0,0.21923639455007699,True,2,1,3,14,3.807354922057604,0.00246341761005658
189,Chaperone Mediated Autophagy,Autophagy,2426.5,0.006862700677427,0.5,3.0,4.0,0.1604154903149812,True,3,2,5,5,2.321928094887362,0.0029556043068422033
190,Chaperone Mediated Autophagy,Chaperone Mediated Autophagy,2172.5,0.012620203801739,0.5,1.5,2.5,0.1452621424465181,False,3,2,5,5,2.321928094887362,0.0054352259355177025
191,Chylomicron assembly,Plasma lipoprotein assembly,1992.5,0.0043908740783352995,0.5,1.0,2.0,0.0415628501179073,True,4,1,5,9,3.169925001442312,0.0013851665501036954
192,Chylomicron clearance,Plasma lipoprotein clearance,2006.5,0.0013207552177537,0.5,1.0,2.0,0.0125019187930696,True,2,1,3,7,2.807354922057604,0.00047046250097428874
193,Chylomicron remodeling,Plasma lipoprotein remodeling,1998.5,0.0021736121977504004,0.5,1.0,2.0,0.0205748368953017,True,4,1,5,9,3.169925001442312,0.0006856983041432872
194,Class A/1 (Rhodopsin-like receptors),GPCR ligand binding,1934.5,0.0131363607090012,0.5,1.0,2.0,0.1243453083605563,True,8,1,9,13,3.700439718141092,0.0035499458738920417
195,Class I MHC mediated antigen processing & presentation,Adaptive Immune System,2240.5,0.0033469914405014,0.5,2.0,3.0,0.047616685321647,True,1,1,2,10,3.321928094887362,0.0010075448188215186
196,Clathrin-mediated endocytosis,Membrane Trafficking,2256.5,0.0108060023768088,0.5,2.0,3.0,0.1537338902439461,True,1,1,2,7,2.807354922057604,0.0038491757105256646
197,Collagen biosynthesis and modifying enzymes,Collagen biosynthesis and modifying enzymes,2068.5,0.00020896238342994983,0.5,1.0,2.0,0.00197798253100275,False,2,2,4,5,2.321928094887362,8.999520006242342e-05
198,Collagen biosynthesis and modifying enzymes,Collagen formation,2236.5,0.000213746338403,0.5,2.0,3.0,0.0030409077272297,True,2,2,4,5,2.321928094887362,9.205553732419475e-05
199,Collagen formation,Extracellular matrix organization,2452.5,0.0001148771262842208,0.5,3.0,4.0,0.00268525051653105,True,2,1,3,7,2.807354922057604,4.092005801675533e-05
200,Common Pathway of Fibrin Clot Formation,Common Pathway of Fibrin Clot Formation,2058.5,0.0205977749140469,0.5,1.0,2.0,0.19497307739680894,False,11,2,13,14,3.807354922057604,0.005409996003975188
201,Common Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),2276.5,0.0159221114456471,0.5,2.0,3.0,0.22651930363167636,True,11,2,13,14,3.807354922057604,0.0041819351680095875
202,Complement cascade,Innate Immune System,2322.5,0.011536468000583801,0.5,2.0,3.0,0.164126014742586,True,4,1,5,63,5.977279923499917,0.001930053159335522
203,Crosslinking of collagen fibrils,Assembly of collagen fibrils and other multimeric structures,1906.5,0.00016765825194200315,0.5,1.0,2.0,0.00158700857099935,True,1,1,2,6,2.584962500721156,6.485906541979996e-05
204,Cytokine Signaling in Immune system,Immune System,2354.5,0.005331082336111801,0.5,3.0,4.0,0.1246139423900322,True,1,1,2,9,3.169925001442312,0.0016817692322960841
205,Cytoprotection by HMOX1,Cellular response to chemical stress,2036.5,0.0012388355120685,0.5,1.0,2.0,0.011726488573857701,True,3,1,4,8,3.0,0.0004129451706895
206,DDX58/IFIH1-mediated induction of interferon-alpha/beta,Innate Immune System,2332.5,0.0011591852237226,0.5,2.0,3.0,0.016491395036026098,True,1,1,2,6,2.584962500721156,0.000448434057901888
207,Defective ABCA1 causes TGD,ABC transporter disorders,1960.5,0.0062535876736301,0.5,1.0,2.0,0.05919480325357475,True,1,1,2,6,2.584962500721156,0.0024192179468311304
208,Defective CP causes aceruloplasminemia (ACERULOP),SLC transporter disorders,1964.5,0.0059532988195101,0.5,1.0,2.0,0.0563523485593157,True,1,1,2,6,2.584962500721156,0.0023030503606335647
209,Defective Intrinsic Pathway for Apoptosis,Diseases of programmed cell death,2326.5,0.0016786770891225001,0.5,2.0,3.0,0.0238820565066737,True,1,1,2,6,2.584962500721156,0.000649400944367348
210,Defective SERPING1 causes hereditary angioedema,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),2016.5,0.0009111806910617,0.5,1.0,2.0,0.0086249948910605,True,1,1,2,6,2.584962500721156,0.0003524928082351282
211,Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages),SLC transporter disorders,1962.5,0.0067154980990798,0.5,1.0,2.0,0.06356712490032615,True,1,1,2,6,2.584962500721156,0.0025979092916072486
212,Defective factor IX causes hemophilia B,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),2020.5,0.0029140810362292,0.5,1.0,2.0,0.02758391864112605,True,2,1,3,7,2.807354922057604,0.0010380166089200339
213,Defective factor IX causes thrombophilia,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),2022.5,0.0054181639845582,0.5,1.0,2.0,0.0512869040621214,True,2,1,3,7,2.807354922057604,0.0019299889522294696
214,Defective factor VIII causes hemophilia A,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),2018.5,0.0006644781101683001,0.5,1.0,2.0,0.00628977365482245,True,4,1,5,9,3.169925001442312,0.00020961950515105667
215,Defective factor XII causes hereditary angioedema,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),2014.5,0.005985610927206101,0.5,1.0,2.0,0.0566582064056588,True,2,1,3,7,2.807354922057604,0.0021321176315031256
216,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),Diseases of hemostasis,2222.5,0.006875840718084799,0.5,2.0,3.0,0.0978206098267648,True,5,1,6,14,3.807354922057604,0.0018059363675947755
217,Degradation of the extracellular matrix,Extracellular matrix organization,2384.5,0.0012001335267345001,0.5,3.0,4.0,0.0280530970508195,True,1,1,2,5,2.321928094887362,0.000516869376522497
218,Detoxification of Reactive Oxygen Species,Cellular response to chemical stress,2034.5,0.0001934756866587145,0.5,1.0,2.0,0.0018313895644906,True,2,1,3,7,2.807354922057604,6.891743011849379e-05
219,Developmental Biology,root,2460.5,0.00375018925849479,0.5,4.0,5.0,0.21560085821393304,True,2,1,3,7,2.807354922057604,0.0013358443668911486
220,Disease,root,2474.5,0.013007282984340101,0.5,4.0,5.0,0.7477972926573885,True,7,1,8,95,6.569855608330948,0.0019798430528436776
221,Diseases associated with O-glycosylation of proteins,Diseases of glycosylation,1936.5,0.013340816855847901,0.5,1.0,2.0,0.1262806360505493,True,2,1,3,7,2.807354922057604,0.00475209484594487
222,Diseases associated with glycosaminoglycan metabolism,Diseases of glycosylation,1932.5,0.004182997066843001,0.5,1.0,2.0,0.03959514142996225,True,1,1,2,6,2.584962500721156,0.0016182041579620684
223,Diseases associated with the TLR signaling cascade,Diseases of Immune System,2308.5,0.0115462547414335,0.5,2.0,3.0,0.16426524789201358,True,2,1,3,11,3.4594316186372973,0.0033376161214545637
224,Diseases of Immune System,Disease,2386.5,0.0080202556668719,0.5,3.0,4.0,0.18747331491297675,True,1,1,2,11,3.4594316186372973,0.0023183738113693817
225,Diseases of glycosylation,Diseases of metabolism,2176.5,0.0093032348529388,0.5,2.0,3.0,0.1323544485669193,True,2,1,3,9,3.169925001442312,0.002934843836591036
226,Diseases of hemostasis,Disease,2442.5,0.0052615459946303,0.5,3.0,4.0,0.12298853180638705,True,1,1,2,14,3.807354922057604,0.0013819426090664565
227,Diseases of metabolism,Disease,2396.5,0.0066806528377362,0.5,3.0,4.0,0.15616012572348453,True,1,1,2,9,3.169925001442312,0.0021075113243046793
228,Diseases of programmed cell death,Disease,2346.5,0.0002456160229002,0.5,3.0,4.0,0.00574126959556465,True,1,1,2,6,2.584962500721156,9.501724796072583e-05
229,Diseases of signal transduction by growth factor receptors and second messengers,Disease,2368.5,0.000463571336647,0.5,3.0,4.0,0.0108359706709645,True,1,1,2,13,3.700439718141092,0.00012527466246089103
230,Disorders of transmembrane transporters,Disease,2358.5,0.0038061005552994,0.5,3.0,4.0,0.08896752393335974,True,2,1,3,10,3.321928094887362,0.001145750433658455
231,Dissolution of Fibrin Clot,Dissolution of Fibrin Clot,2147.5,0.0026726688987994,0.5,1.5,2.5,0.0305746563333317,False,3,2,5,5,2.321928094887362,0.0011510558422047313
232,Dissolution of Fibrin Clot,Hemostasis,2438.5,0.0022770963494812,0.5,3.0,4.0,0.053227081373079,True,3,2,5,5,2.321928094887362,0.0009806920181960515
233,Drug ADME,root,2480.5,0.0018786937504666,0.5,4.0,5.0,0.10800734496379999,True,1,1,2,5,2.321928094887362,0.0008091093581249493
234,ECM proteoglycans,ECM proteoglycans,2117.5,0.0053894849315955,0.5,1.5,2.5,0.06359890492793498,False,3,2,5,5,2.321928094887362,0.0023211248201279663
235,ECM proteoglycans,Extracellular matrix organization,2350.5,0.0034339872638508,0.5,3.0,4.0,0.08026938322954294,True,3,2,5,5,2.321928094887362,0.0014789378152631314
236,Elastic fibre formation,Extracellular matrix organization,2382.5,0.0032807884294261,0.5,3.0,4.0,0.07668836355594105,True,1,1,2,6,2.584962500721156,0.0012691822138660895
237,Erythrocytes take up carbon dioxide and release oxygen,Erythrocytes take up carbon dioxide and release oxygen,2070.5,0.0035029296217126,0.5,1.0,2.0,0.03315780326272,False,4,2,6,7,2.807354922057604,0.0012477687071876134
238,Erythrocytes take up carbon dioxide and release oxygen,O2/CO2 exchange in erythrocytes,2246.5,0.0035607848402166003,0.5,2.0,3.0,0.0506582625766401,True,4,2,6,7,2.807354922057604,0.0012683771518304434
239,Erythrocytes take up oxygen and release carbon dioxide,Erythrocytes take up oxygen and release carbon dioxide,2072.5,0.0018347276459782,0.5,1.0,2.0,0.0173670455577923,False,4,2,6,7,2.807354922057604,0.0006535431738832177
240,Erythrocytes take up oxygen and release carbon dioxide,O2/CO2 exchange in erythrocytes,2206.5,0.001156341483663,0.5,2.0,3.0,0.01645093796346935,True,4,2,6,7,2.807354922057604,0.0004118971472319142
241,Extracellular matrix organization,root,2466.5,0.015739082717301997,0.5,4.0,5.0,0.904850264200372,True,6,1,7,23,4.523561956057013,0.003479356062809639
242,Extrinsic Pathway of Fibrin Clot Formation,Extrinsic Pathway of Fibrin Clot Formation,2054.5,0.0021439201636031,0.5,1.0,2.0,0.02029377997065735,False,3,2,5,6,2.584962500721156,0.0008293815337765969
243,Extrinsic Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),2144.5,0.0023000808447528,0.5,2.0,3.0,0.032722589150851494,True,3,2,5,6,2.584962500721156,0.0008897927316590166
244,F13A,Common Pathway of Fibrin Clot Formation,84.5,0.0177292088226974,0.5,0.0,1.0,0.01005119538200065,True,0,3,3,12,3.584962500721156,0.004945437733067212
245,F13A,Interleukin-4 and Interleukin-13 signaling,80.5,0.0177292088226974,0.5,0.0,1.0,0.01005119538200065,True,0,3,3,12,3.584962500721156,0.004945437733067212
246,F13A,Platelet degranulation ,82.5,0.0177292088226974,0.5,0.0,1.0,0.01005119538200065,True,0,3,3,12,3.584962500721156,0.004945437733067212
247,F13B,Common Pathway of Fibrin Clot Formation,1430.5,0.0018626646620927998,0.5,0.0,1.0,0.0010559978528695,True,0,1,1,5,2.321928094887362,0.0008022060055150668
248,FA10,Common Pathway of Fibrin Clot Formation,132.5,0.0167864156064712,0.5,0.0,1.0,0.0095166989520763,True,0,7,7,17,4.087462841250339,0.004106805678345029
249,FA10,Defective factor IX causes hemophilia B,124.5,0.0167864156064712,0.5,0.0,1.0,0.0095166989520763,True,0,7,7,17,4.087462841250339,0.004106805678345029
250,FA10,Defective factor IX causes thrombophilia,126.5,0.0167864156064712,0.5,0.0,1.0,0.0095166989520763,True,0,7,7,17,4.087462841250339,0.004106805678345029
251,FA10,Defective factor VIII causes hemophilia A,122.5,0.0167864156064712,0.5,0.0,1.0,0.0095166989520763,True,0,7,7,17,4.087462841250339,0.004106805678345029
252,FA10,Extrinsic Pathway of Fibrin Clot Formation,128.5,0.0167864156064712,0.5,0.0,1.0,0.0095166989520763,True,0,7,7,17,4.087462841250339,0.004106805678345029
253,FA10,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",120.5,0.0167864156064712,0.5,0.0,1.0,0.0095166989520763,True,0,7,7,17,4.087462841250339,0.004106805678345029
254,FA10,Intrinsic Pathway of Fibrin Clot Formation,130.5,0.0167864156064712,0.5,0.0,1.0,0.0095166989520763,True,0,7,7,17,4.087462841250339,0.004106805678345029
255,FA12,Defective SERPING1 causes hereditary angioedema,146.5,0.0090114981922745,0.5,0.0,1.0,0.00510887597528535,True,0,3,3,10,3.321928094887362,0.002712731261746367
256,FA12,Defective factor XII causes hereditary angioedema,144.5,0.0090114981922745,0.5,0.0,1.0,0.00510887597528535,True,0,3,3,10,3.321928094887362,0.002712731261746367
257,FA12,Intrinsic Pathway of Fibrin Clot Formation,148.5,0.0090114981922745,0.5,0.0,1.0,0.00510887597528535,True,0,3,3,10,3.321928094887362,0.002712731261746367
258,FA9,Defective factor IX causes hemophilia B,112.5,0.0276072920776381,0.5,0.0,1.0,0.01565136320607005,True,0,6,6,16,4.0,0.006901823019409525
259,FA9,Defective factor IX causes thrombophilia,114.5,0.0276072920776381,0.5,0.0,1.0,0.01565136320607005,True,0,6,6,16,4.0,0.006901823019409525
260,FA9,Defective factor VIII causes hemophilia A,110.5,0.0276072920776381,0.5,0.0,1.0,0.01565136320607005,True,0,6,6,16,4.0,0.006901823019409525
261,FA9,Extrinsic Pathway of Fibrin Clot Formation,116.5,0.0276072920776381,0.5,0.0,1.0,0.01565136320607005,True,0,6,6,16,4.0,0.006901823019409525
262,FA9,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",108.5,0.0276072920776381,0.5,0.0,1.0,0.01565136320607005,True,0,6,6,16,4.0,0.006901823019409525
263,FA9,Intrinsic Pathway of Fibrin Clot Formation,118.5,0.0276072920776381,0.5,0.0,1.0,0.01565136320607005,True,0,6,6,16,4.0,0.006901823019409525
264,FBLN1,Molecules associated with elastic fibres,1724.5,0.000847647193526,0.5,0.0,1.0,0.00048055542931095,True,0,1,1,5,2.321928094887362,0.000365061775768349
265,FCERI mediated Ca+2 mobilization,Fc epsilon receptor (FCERI) signaling,1928.5,0.0030045491589589003,0.5,1.0,2.0,0.02844026591011695,True,32,1,33,37,5.20945336562895,0.0005767494107505373
266,FCERI mediated MAPK activation,Fc epsilon receptor (FCERI) signaling,1926.5,0.0029390891772903,0.5,1.0,2.0,0.0278206390753965,True,32,1,33,37,5.20945336562895,0.0005641837964577798
267,FCERI mediated NF-kB activation,Fc epsilon receptor (FCERI) signaling,1930.5,0.0009476007842538999,0.5,1.0,2.0,0.00896973783918925,True,32,1,33,37,5.20945336562895,0.0001819002336225912
268,FCGR activation,Fcgamma receptor (FCGR) dependent phagocytosis,1908.5,0.0018236207805335,0.5,1.0,2.0,0.017261910913636602,True,32,1,33,37,5.20945336562895,0.0003500599108085748
269,FCN2,Initial triggering of complement,1858.5,0.0034970645526738,0.5,0.0,1.0,0.00198258588039155,True,0,1,1,6,2.584962500721156,0.001352849239282266
270,FCN3,Initial triggering of complement,68.5,0.0025082766201121997,0.5,0.0,1.0,0.0014220137307298,True,0,1,1,6,2.584962500721156,0.0009703338518111724
271,FETUA,Neutrophil degranulation,1200.5,0.0289087513586797,0.5,0.0,1.0,0.0163891976828528,True,0,4,4,13,3.700439718141092,0.007812247613967874
272,FETUA,Platelet degranulation ,1198.5,0.0289087513586797,0.5,0.0,1.0,0.0163891976828528,True,0,4,4,13,3.700439718141092,0.007812247613967874
273,FETUA,Post-translational protein phosphorylation,1204.5,0.0289087513586797,0.5,0.0,1.0,0.0163891976828528,True,0,4,4,13,3.700439718141092,0.007812247613967874
274,FETUA,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),1202.5,0.0289087513586797,0.5,0.0,1.0,0.0163891976828528,True,0,4,4,13,3.700439718141092,0.007812247613967874
275,FHR1,Regulation of Complement cascade,1842.5,0.0006315885638507001,0.5,0.0,1.0,0.0003580656147596,True,0,1,1,6,2.584962500721156,0.0002443318089428758
276,FHR5,Regulation of Complement cascade,1864.5,0.0009958921363248,0.5,0.0,1.0,0.0005645997258932501,True,0,1,1,6,2.584962500721156,0.00038526366864005364
277,FIBA,Amyloid fiber formation,1132.5,0.07131482194399,0.5,0.0,1.0,0.040430411540641545,True,0,21,21,44,5.459431618637297,0.013062682514519808
278,FIBA,Antigen processing-Cross presentation,1094.5,0.07131482194399,0.5,0.0,1.0,0.040430411540641545,True,0,21,21,44,5.459431618637297,0.013062682514519808
279,FIBA,Common Pathway of Fibrin Clot Formation,1122.5,0.07131482194399,0.5,0.0,1.0,0.040430411540641545,True,0,21,21,44,5.459431618637297,0.013062682514519808
280,FIBA,GRB2:SOS provides linkage to MAPK signaling for Integrins ,1126.5,0.07131482194399,0.5,0.0,1.0,0.040430411540641545,True,0,21,21,44,5.459431618637297,0.013062682514519808
281,FIBA,IRAK4 deficiency (TLR2/4),1104.5,0.07131482194399,0.5,0.0,1.0,0.040430411540641545,True,0,21,21,44,5.459431618637297,0.013062682514519808
282,FIBA,Integrin cell surface interactions,1124.5,0.07131482194399,0.5,0.0,1.0,0.040430411540641545,True,0,21,21,44,5.459431618637297,0.013062682514519808
283,FIBA,MyD88 deficiency (TLR2/4),1102.5,0.07131482194399,0.5,0.0,1.0,0.040430411540641545,True,0,21,21,44,5.459431618637297,0.013062682514519808
284,FIBA,Paradoxical activation of RAF signaling by kinase inactive BRAF,1116.5,0.07131482194399,0.5,0.0,1.0,0.040430411540641545,True,0,21,21,44,5.459431618637297,0.013062682514519808
285,FIBA,Platelet degranulation ,1120.5,0.07131482194399,0.5,0.0,1.0,0.040430411540641545,True,0,21,21,44,5.459431618637297,0.013062682514519808
286,FIBA,Post-translational protein phosphorylation,1134.5,0.07131482194399,0.5,0.0,1.0,0.040430411540641545,True,0,21,21,44,5.459431618637297,0.013062682514519808
287,FIBA,RAF/MAP kinase cascade,1106.5,0.07131482194399,0.5,0.0,1.0,0.040430411540641545,True,0,21,21,44,5.459431618637297,0.013062682514519808
288,FIBA,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),1130.5,0.07131482194399,0.5,0.0,1.0,0.040430411540641545,True,0,21,21,44,5.459431618637297,0.013062682514519808
289,FIBA,Regulation of TLR by endogenous ligand,1100.5,0.07131482194399,0.5,0.0,1.0,0.040430411540641545,True,0,21,21,44,5.459431618637297,0.013062682514519808
290,FIBA,Signaling by BRAF and RAF1 fusions,1114.5,0.07131482194399,0.5,0.0,1.0,0.040430411540641545,True,0,21,21,44,5.459431618637297,0.013062682514519808
291,FIBA,Signaling by RAF1 mutants,1118.5,0.07131482194399,0.5,0.0,1.0,0.040430411540641545,True,0,21,21,44,5.459431618637297,0.013062682514519808
292,FIBA,Signaling by RAS mutants,1108.5,0.07131482194399,0.5,0.0,1.0,0.040430411540641545,True,0,21,21,44,5.459431618637297,0.013062682514519808
293,FIBA,Signaling by high-kinase activity BRAF mutants,1112.5,0.07131482194399,0.5,0.0,1.0,0.040430411540641545,True,0,21,21,44,5.459431618637297,0.013062682514519808
294,FIBA,Signaling by moderate kinase activity BRAF mutants,1110.5,0.07131482194399,0.5,0.0,1.0,0.040430411540641545,True,0,21,21,44,5.459431618637297,0.013062682514519808
295,FIBA,Toll Like Receptor 2 (TLR2) Cascade,1098.5,0.07131482194399,0.5,0.0,1.0,0.040430411540641545,True,0,21,21,44,5.459431618637297,0.013062682514519808
296,FIBA,Toll Like Receptor 4 (TLR4) Cascade,1096.5,0.07131482194399,0.5,0.0,1.0,0.040430411540641545,True,0,21,21,44,5.459431618637297,0.013062682514519808
297,FIBA,p130Cas linkage to MAPK signaling for integrins,1128.5,0.07131482194399,0.5,0.0,1.0,0.040430411540641545,True,0,21,21,44,5.459431618637297,0.013062682514519808
298,FIBB,Antigen processing-Cross presentation,1136.5,0.042109228297683,0.5,0.0,1.0,0.02387292547783785,True,0,18,18,39,5.285402218862249,0.007967081132899581
299,FIBB,Common Pathway of Fibrin Clot Formation,1164.5,0.042109228297683,0.5,0.0,1.0,0.02387292547783785,True,0,18,18,39,5.285402218862249,0.007967081132899581
300,FIBB,GRB2:SOS provides linkage to MAPK signaling for Integrins ,1168.5,0.042109228297683,0.5,0.0,1.0,0.02387292547783785,True,0,18,18,39,5.285402218862249,0.007967081132899581
301,FIBB,IRAK4 deficiency (TLR2/4),1146.5,0.042109228297683,0.5,0.0,1.0,0.02387292547783785,True,0,18,18,39,5.285402218862249,0.007967081132899581
302,FIBB,Integrin cell surface interactions,1166.5,0.042109228297683,0.5,0.0,1.0,0.02387292547783785,True,0,18,18,39,5.285402218862249,0.007967081132899581
303,FIBB,MyD88 deficiency (TLR2/4),1144.5,0.042109228297683,0.5,0.0,1.0,0.02387292547783785,True,0,18,18,39,5.285402218862249,0.007967081132899581
304,FIBB,Paradoxical activation of RAF signaling by kinase inactive BRAF,1158.5,0.042109228297683,0.5,0.0,1.0,0.02387292547783785,True,0,18,18,39,5.285402218862249,0.007967081132899581
305,FIBB,Platelet degranulation ,1162.5,0.042109228297683,0.5,0.0,1.0,0.02387292547783785,True,0,18,18,39,5.285402218862249,0.007967081132899581
306,FIBB,RAF/MAP kinase cascade,1148.5,0.042109228297683,0.5,0.0,1.0,0.02387292547783785,True,0,18,18,39,5.285402218862249,0.007967081132899581
307,FIBB,Regulation of TLR by endogenous ligand,1142.5,0.042109228297683,0.5,0.0,1.0,0.02387292547783785,True,0,18,18,39,5.285402218862249,0.007967081132899581
308,FIBB,Signaling by BRAF and RAF1 fusions,1156.5,0.042109228297683,0.5,0.0,1.0,0.02387292547783785,True,0,18,18,39,5.285402218862249,0.007967081132899581
309,FIBB,Signaling by RAF1 mutants,1160.5,0.042109228297683,0.5,0.0,1.0,0.02387292547783785,True,0,18,18,39,5.285402218862249,0.007967081132899581
310,FIBB,Signaling by RAS mutants,1150.5,0.042109228297683,0.5,0.0,1.0,0.02387292547783785,True,0,18,18,39,5.285402218862249,0.007967081132899581
311,FIBB,Signaling by high-kinase activity BRAF mutants,1154.5,0.042109228297683,0.5,0.0,1.0,0.02387292547783785,True,0,18,18,39,5.285402218862249,0.007967081132899581
312,FIBB,Signaling by moderate kinase activity BRAF mutants,1152.5,0.042109228297683,0.5,0.0,1.0,0.02387292547783785,True,0,18,18,39,5.285402218862249,0.007967081132899581
313,FIBB,Toll Like Receptor 2 (TLR2) Cascade,1140.5,0.042109228297683,0.5,0.0,1.0,0.02387292547783785,True,0,18,18,39,5.285402218862249,0.007967081132899581
314,FIBB,Toll Like Receptor 4 (TLR4) Cascade,1138.5,0.042109228297683,0.5,0.0,1.0,0.02387292547783785,True,0,18,18,39,5.285402218862249,0.007967081132899581
315,FIBB,p130Cas linkage to MAPK signaling for integrins,1170.5,0.042109228297683,0.5,0.0,1.0,0.02387292547783785,True,0,18,18,39,5.285402218862249,0.007967081132899581
316,FOXO-mediated transcription,Generic Transcription Pathway,1920.5,0.0006693609590223,0.5,1.0,2.0,0.0063359934077578,True,1,1,2,6,2.584962500721156,0.0002589441660509817
317,Factors involved in megakaryocyte development and platelet production,Factors involved in megakaryocyte development and platelet production,2158.5,0.00340873191966825,0.5,1.5,2.5,0.03912976236725582,False,3,2,5,5,2.321928094887362,0.0014680609305576318
318,Factors involved in megakaryocyte development and platelet production,Hemostasis,2412.5,0.00018469364441763388,0.5,3.0,4.0,0.00431721022377785,True,3,2,5,5,2.321928094887362,7.954322307581771e-05
319,Fatty acid metabolism,Metabolism of lipids,2218.5,0.0028602245091054,0.5,2.0,3.0,0.04069159208215175,True,1,1,2,7,2.807354922057604,0.001018832526885858
320,Fc epsilon receptor (FCERI) signaling,Innate Immune System,2228.5,0.0041301359389413,0.5,2.0,3.0,0.058758257030597755,True,4,1,5,40,5.321928094887363,0.0007760600792237336
321,Fcgamma receptor (FCGR) dependent phagocytosis,Innate Immune System,2280.5,0.008978229681768,0.5,2.0,3.0,0.12773069340092724,True,3,1,4,39,5.285402218862249,0.0016986842836155393
322,Formation of Fibrin Clot (Clotting Cascade),Hemostasis,2392.5,0.0145102779892115,0.5,3.0,4.0,0.33917745617294454,True,3,1,4,21,4.392317422778761,0.003303558598465705
323,Formation of the cornified envelope,Formation of the cornified envelope,2124.5,9.459031103687182e-06,0.5,1.0,2.0,8.953668108197485e-05,False,2,2,4,5,2.321928094887362,4.073782958445164e-06
324,Formation of the cornified envelope,Keratinization,2304.5,4.5894822801475006e-06,0.5,2.0,3.0,6.529324541395191e-05,True,2,2,4,5,2.321928094887362,1.9765824317527537e-06
325,G alpha (i) signalling events,GPCR downstream signalling,1940.5,0.012932185523457899,0.5,1.0,2.0,0.12241264017578674,True,7,1,8,12,3.584962500721156,0.003607341923620245
326,G alpha (q) signalling events,GPCR downstream signalling,1938.5,0.0045914916269687,0.5,1.0,2.0,0.04346184265472725,True,4,1,5,9,3.169925001442312,0.001448454340364386
327,GELS,Amyloid fiber formation,1546.5,0.0945919618197598,0.5,0.0,1.0,0.05362688765896635,True,0,4,4,14,3.807354922057604,0.024844534790215877
328,GELS,Apoptotic cleavage of cellular proteins,1542.5,0.0945919618197598,0.5,0.0,1.0,0.05362688765896635,True,0,4,4,14,3.807354922057604,0.024844534790215877
329,GELS,Neutrophil degranulation,1544.5,0.0945919618197598,0.5,0.0,1.0,0.05362688765896635,True,0,4,4,14,3.807354922057604,0.024844534790215877
330,GELS,Sensory processing of sound by outer hair cells of the cochlea,1548.5,0.0945919618197598,0.5,0.0,1.0,0.05362688765896635,True,0,4,4,14,3.807354922057604,0.024844534790215877
331,GP1b-IX-V activation signalling,GP1b-IX-V activation signalling,2126.5,0.001979104374199,0.5,1.0,2.0,0.01873367739657745,False,2,2,4,5,2.321928094887362,0.0008523538599480219
332,GP1b-IX-V activation signalling,"Platelet activation, signaling and aggregation",2290.5,0.0006440312735555,0.5,2.0,3.0,0.00916244783870785,True,2,2,4,5,2.321928094887362,0.0002773691721865066
333,GPCR downstream signalling,Signaling by GPCR,2314.5,0.0125477134618269,0.5,2.0,3.0,0.17851271329468688,True,2,1,3,14,3.807354922057604,0.0032956511065287694
334,GPCR ligand binding,Signaling by GPCR,2284.5,0.008518888176629,0.5,2.0,3.0,0.12119577381891154,True,1,1,2,13,3.700439718141092,0.002302128618624936
335,GRB2:SOS provides linkage to MAPK signaling for Integrins ,GRB2:SOS provides linkage to MAPK signaling for Integrins ,2106.5,0.0073676984688072,0.5,1.0,2.0,0.06974068071864695,False,4,2,6,7,2.807354922057604,0.002624427147033895
336,GRB2:SOS provides linkage to MAPK signaling for Integrins ,Integrin signaling,2274.5,0.0015260534877348999,0.5,2.0,3.0,0.0217107243927068,True,4,2,6,7,2.807354922057604,0.0005435912202424352
337,"Gamma carboxylation, hypusine formation and arylsulfatase activation",Post-translational protein modification,2224.5,0.008459225347555301,0.5,2.0,3.0,0.12034696789636705,True,1,1,2,8,3.0,0.002819741782518434
338,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins","Gamma carboxylation, hypusine formation and arylsulfatase activation",1872.5,0.012180515398841,0.5,1.0,2.0,0.11529753002455055,True,3,1,4,8,3.0,0.0040601717996136665
339,Gene Silencing by RNA,Gene expression (Transcription),2424.5,0.00017351319763797242,0.5,3.0,4.0,0.0040558675051598995,True,1,1,2,5,2.321928094887362,7.472806673903037e-05
340,Gene expression (Transcription),root,2464.5,0.0039477531292826,0.5,4.0,5.0,0.22695893567561126,True,2,1,3,16,4.0,0.00098693828232065
341,Generic Transcription Pathway,RNA Polymerase II Transcription,2316.5,0.028037329863453,0.5,2.0,3.0,0.39887903423118315,True,4,1,5,13,3.700439718141092,0.007576756277369515
342,Glycosaminoglycan metabolism,Metabolism of carbohydrates,2264.5,0.0016041283168758999,0.5,2.0,3.0,0.022821472548726098,True,1,1,2,6,2.584962500721156,0.0006205615425478622
343,HBA,Cytoprotection by HMOX1,1796.5,0.0187954235291567,0.5,0.0,1.0,0.010655662983514,True,0,5,5,14,3.807354922057604,0.004936609250760135
344,HBA,Erythrocytes take up carbon dioxide and release oxygen,1798.5,0.0187954235291567,0.5,0.0,1.0,0.010655662983514,True,0,5,5,14,3.807354922057604,0.004936609250760135
345,HBA,Erythrocytes take up oxygen and release carbon dioxide,1800.5,0.0187954235291567,0.5,0.0,1.0,0.010655662983514,True,0,5,5,14,3.807354922057604,0.004936609250760135
346,HBA,Heme signaling,1804.5,0.0187954235291567,0.5,0.0,1.0,0.010655662983514,True,0,5,5,14,3.807354922057604,0.004936609250760135
347,HBA,Scavenging of heme from plasma,1802.5,0.0187954235291567,0.5,0.0,1.0,0.010655662983514,True,0,5,5,14,3.807354922057604,0.004936609250760135
348,HBB,Chaperone Mediated Autophagy,1792.5,0.0181633206615425,0.5,0.0,1.0,0.0102973057952462,True,0,9,9,22,4.459431618637297,0.004073012485634393
349,HBB,Cytoprotection by HMOX1,1778.5,0.0181633206615425,0.5,0.0,1.0,0.0102973057952462,True,0,9,9,22,4.459431618637297,0.004073012485634393
350,HBB,Erythrocytes take up carbon dioxide and release oxygen,1782.5,0.0181633206615425,0.5,0.0,1.0,0.0102973057952462,True,0,9,9,22,4.459431618637297,0.004073012485634393
351,HBB,Erythrocytes take up oxygen and release carbon dioxide,1784.5,0.0181633206615425,0.5,0.0,1.0,0.0102973057952462,True,0,9,9,22,4.459431618637297,0.004073012485634393
352,HBB,Factors involved in megakaryocyte development and platelet production,1780.5,0.0181633206615425,0.5,0.0,1.0,0.0102973057952462,True,0,9,9,22,4.459431618637297,0.004073012485634393
353,HBB,Heme signaling,1790.5,0.0181633206615425,0.5,0.0,1.0,0.0102973057952462,True,0,9,9,22,4.459431618637297,0.004073012485634393
354,HBB,Late endosomal microautophagy,1794.5,0.0181633206615425,0.5,0.0,1.0,0.0102973057952462,True,0,9,9,22,4.459431618637297,0.004073012485634393
355,HBB,Neutrophil degranulation,1786.5,0.0181633206615425,0.5,0.0,1.0,0.0102973057952462,True,0,9,9,22,4.459431618637297,0.004073012485634393
356,HBB,Scavenging of heme from plasma,1788.5,0.0181633206615425,0.5,0.0,1.0,0.0102973057952462,True,0,9,9,22,4.459431618637297,0.004073012485634393
357,HBD,Factors involved in megakaryocyte development and platelet production,1034.5,0.0032207955235324997,0.5,0.0,1.0,0.0018259610688918001,True,0,1,1,4,2.0,0.0016103977617662499
358,HDL assembly,Plasma lipoprotein assembly,1994.5,0.0017477064536306,0.5,1.0,2.0,0.0165433260181061,True,2,1,3,7,2.807354922057604,0.0006225455997382931
359,HDL clearance,Plasma lipoprotein clearance,2004.5,0.0027302451525434996,0.5,1.0,2.0,0.025843776896314202,True,1,1,2,6,2.584962500721156,0.0010562030016999522
360,HDL remodeling,Plasma lipoprotein remodeling,2002.5,0.007758793944496399,0.5,1.0,2.0,0.07344268682218541,True,3,1,4,8,3.0,0.0025862646481654666
361,HEMO,Scavenging of heme from plasma,1236.5,0.0007847525767984,0.5,0.0,1.0,0.0004448986728517,True,0,1,1,5,2.321928094887362,0.00033797453871476095
362,HEP2,Common Pathway of Fibrin Clot Formation,1434.5,0.011492597904769,0.5,0.0,1.0,0.00651548234006475,True,0,4,4,10,3.321928094887362,0.0034596166974404916
363,HEP2,Intrinsic Pathway of Fibrin Clot Formation,1432.5,0.011492597904769,0.5,0.0,1.0,0.00651548234006475,True,0,4,4,10,3.321928094887362,0.0034596166974404916
364,HEP2,Post-translational protein phosphorylation,1438.5,0.011492597904769,0.5,0.0,1.0,0.00651548234006475,True,0,4,4,10,3.321928094887362,0.0034596166974404916
365,HEP2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),1436.5,0.011492597904769,0.5,0.0,1.0,0.00651548234006475,True,0,4,4,10,3.321928094887362,0.0034596166974404916
366,HRG,Dissolution of Fibrin Clot,1304.5,0.0023085203050598998,0.5,0.0,1.0,0.001308766164442,True,0,2,2,7,2.807354922057604,0.0008223115242471401
367,HRG,Platelet degranulation ,1302.5,0.0023085203050598998,0.5,0.0,1.0,0.001308766164442,True,0,2,2,7,2.807354922057604,0.0008223115242471401
368,HV102,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,1716.5,0.0228452394974544,0.5,0.0,1.0,0.01295161944528195,True,0,17,17,33,5.044394119358453,0.004528837152074045
369,HV102,CD22 mediated BCR regulation,1714.5,0.0228452394974544,0.5,0.0,1.0,0.01295161944528195,True,0,17,17,33,5.044394119358453,0.004528837152074045
370,HV102,Cell surface interactions at the vascular wall,1718.5,0.0228452394974544,0.5,0.0,1.0,0.01295161944528195,True,0,17,17,33,5.044394119358453,0.004528837152074045
371,HV102,FCERI mediated Ca+2 mobilization,1704.5,0.0228452394974544,0.5,0.0,1.0,0.01295161944528195,True,0,17,17,33,5.044394119358453,0.004528837152074045
372,HV102,FCERI mediated MAPK activation,1702.5,0.0228452394974544,0.5,0.0,1.0,0.01295161944528195,True,0,17,17,33,5.044394119358453,0.004528837152074045
373,HV102,FCERI mediated NF-kB activation,1706.5,0.0228452394974544,0.5,0.0,1.0,0.01295161944528195,True,0,17,17,33,5.044394119358453,0.004528837152074045
374,HV102,FCGR activation,1694.5,0.0228452394974544,0.5,0.0,1.0,0.01295161944528195,True,0,17,17,33,5.044394119358453,0.004528837152074045
375,HV102,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,1720.5,0.0228452394974544,0.5,0.0,1.0,0.01295161944528195,True,0,17,17,33,5.044394119358453,0.004528837152074045
376,HV102,Initial triggering of complement,1690.5,0.0228452394974544,0.5,0.0,1.0,0.01295161944528195,True,0,17,17,33,5.044394119358453,0.004528837152074045
377,HV102,Leishmania parasite growth and survival,1710.5,0.0228452394974544,0.5,0.0,1.0,0.01295161944528195,True,0,17,17,33,5.044394119358453,0.004528837152074045
378,HV102,Parasite infection,1708.5,0.0228452394974544,0.5,0.0,1.0,0.01295161944528195,True,0,17,17,33,5.044394119358453,0.004528837152074045
379,HV102,Potential therapeutics for SARS,1712.5,0.0228452394974544,0.5,0.0,1.0,0.01295161944528195,True,0,17,17,33,5.044394119358453,0.004528837152074045
380,HV102,Regulation of Complement cascade,1692.5,0.0228452394974544,0.5,0.0,1.0,0.01295161944528195,True,0,17,17,33,5.044394119358453,0.004528837152074045
381,HV102,Regulation of actin dynamics for phagocytic cup formation,1696.5,0.0228452394974544,0.5,0.0,1.0,0.01295161944528195,True,0,17,17,33,5.044394119358453,0.004528837152074045
382,HV102,Role of LAT2/NTAL/LAB on calcium mobilization,1700.5,0.0228452394974544,0.5,0.0,1.0,0.01295161944528195,True,0,17,17,33,5.044394119358453,0.004528837152074045
383,HV102,Role of phospholipids in phagocytosis,1698.5,0.0228452394974544,0.5,0.0,1.0,0.01295161944528195,True,0,17,17,33,5.044394119358453,0.004528837152074045
384,HV102,Scavenging of heme from plasma,1722.5,0.0228452394974544,0.5,0.0,1.0,0.01295161944528195,True,0,17,17,33,5.044394119358453,0.004528837152074045
385,HV146,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,772.5,0.0164381036549504,0.5,0.0,1.0,0.00931923094808175,True,0,17,17,33,5.044394119358453,0.003258687419340858
386,HV146,CD22 mediated BCR regulation,770.5,0.0164381036549504,0.5,0.0,1.0,0.00931923094808175,True,0,17,17,33,5.044394119358453,0.003258687419340858
387,HV146,Cell surface interactions at the vascular wall,774.5,0.0164381036549504,0.5,0.0,1.0,0.00931923094808175,True,0,17,17,33,5.044394119358453,0.003258687419340858
388,HV146,FCERI mediated Ca+2 mobilization,760.5,0.0164381036549504,0.5,0.0,1.0,0.00931923094808175,True,0,17,17,33,5.044394119358453,0.003258687419340858
389,HV146,FCERI mediated MAPK activation,758.5,0.0164381036549504,0.5,0.0,1.0,0.00931923094808175,True,0,17,17,33,5.044394119358453,0.003258687419340858
390,HV146,FCERI mediated NF-kB activation,762.5,0.0164381036549504,0.5,0.0,1.0,0.00931923094808175,True,0,17,17,33,5.044394119358453,0.003258687419340858
391,HV146,FCGR activation,750.5,0.0164381036549504,0.5,0.0,1.0,0.00931923094808175,True,0,17,17,33,5.044394119358453,0.003258687419340858
392,HV146,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,776.5,0.0164381036549504,0.5,0.0,1.0,0.00931923094808175,True,0,17,17,33,5.044394119358453,0.003258687419340858
393,HV146,Initial triggering of complement,746.5,0.0164381036549504,0.5,0.0,1.0,0.00931923094808175,True,0,17,17,33,5.044394119358453,0.003258687419340858
394,HV146,Leishmania parasite growth and survival,766.5,0.0164381036549504,0.5,0.0,1.0,0.00931923094808175,True,0,17,17,33,5.044394119358453,0.003258687419340858
395,HV146,Parasite infection,764.5,0.0164381036549504,0.5,0.0,1.0,0.00931923094808175,True,0,17,17,33,5.044394119358453,0.003258687419340858
396,HV146,Potential therapeutics for SARS,768.5,0.0164381036549504,0.5,0.0,1.0,0.00931923094808175,True,0,17,17,33,5.044394119358453,0.003258687419340858
397,HV146,Regulation of Complement cascade,748.5,0.0164381036549504,0.5,0.0,1.0,0.00931923094808175,True,0,17,17,33,5.044394119358453,0.003258687419340858
398,HV146,Regulation of actin dynamics for phagocytic cup formation,752.5,0.0164381036549504,0.5,0.0,1.0,0.00931923094808175,True,0,17,17,33,5.044394119358453,0.003258687419340858
399,HV146,Role of LAT2/NTAL/LAB on calcium mobilization,756.5,0.0164381036549504,0.5,0.0,1.0,0.00931923094808175,True,0,17,17,33,5.044394119358453,0.003258687419340858
400,HV146,Role of phospholipids in phagocytosis,754.5,0.0164381036549504,0.5,0.0,1.0,0.00931923094808175,True,0,17,17,33,5.044394119358453,0.003258687419340858
401,HV146,Scavenging of heme from plasma,778.5,0.0164381036549504,0.5,0.0,1.0,0.00931923094808175,True,0,17,17,33,5.044394119358453,0.003258687419340858
402,HV169,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,738.5,0.0014467198805741999,0.5,0.0,1.0,0.0008201868638413,True,0,17,17,33,5.044394119358453,0.00028679755117115905
403,HV169,CD22 mediated BCR regulation,736.5,0.0014467198805741999,0.5,0.0,1.0,0.0008201868638413,True,0,17,17,33,5.044394119358453,0.00028679755117115905
404,HV169,Cell surface interactions at the vascular wall,740.5,0.0014467198805741999,0.5,0.0,1.0,0.0008201868638413,True,0,17,17,33,5.044394119358453,0.00028679755117115905
405,HV169,FCERI mediated Ca+2 mobilization,726.5,0.0014467198805741999,0.5,0.0,1.0,0.0008201868638413,True,0,17,17,33,5.044394119358453,0.00028679755117115905
406,HV169,FCERI mediated MAPK activation,724.5,0.0014467198805741999,0.5,0.0,1.0,0.0008201868638413,True,0,17,17,33,5.044394119358453,0.00028679755117115905
407,HV169,FCERI mediated NF-kB activation,728.5,0.0014467198805741999,0.5,0.0,1.0,0.0008201868638413,True,0,17,17,33,5.044394119358453,0.00028679755117115905
408,HV169,FCGR activation,716.5,0.0014467198805741999,0.5,0.0,1.0,0.0008201868638413,True,0,17,17,33,5.044394119358453,0.00028679755117115905
409,HV169,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,742.5,0.0014467198805741999,0.5,0.0,1.0,0.0008201868638413,True,0,17,17,33,5.044394119358453,0.00028679755117115905
410,HV169,Initial triggering of complement,712.5,0.0014467198805741999,0.5,0.0,1.0,0.0008201868638413,True,0,17,17,33,5.044394119358453,0.00028679755117115905
411,HV169,Leishmania parasite growth and survival,732.5,0.0014467198805741999,0.5,0.0,1.0,0.0008201868638413,True,0,17,17,33,5.044394119358453,0.00028679755117115905
412,HV169,Parasite infection,730.5,0.0014467198805741999,0.5,0.0,1.0,0.0008201868638413,True,0,17,17,33,5.044394119358453,0.00028679755117115905
413,HV169,Potential therapeutics for SARS,734.5,0.0014467198805741999,0.5,0.0,1.0,0.0008201868638413,True,0,17,17,33,5.044394119358453,0.00028679755117115905
414,HV169,Regulation of Complement cascade,714.5,0.0014467198805741999,0.5,0.0,1.0,0.0008201868638413,True,0,17,17,33,5.044394119358453,0.00028679755117115905
415,HV169,Regulation of actin dynamics for phagocytic cup formation,718.5,0.0014467198805741999,0.5,0.0,1.0,0.0008201868638413,True,0,17,17,33,5.044394119358453,0.00028679755117115905
416,HV169,Role of LAT2/NTAL/LAB on calcium mobilization,722.5,0.0014467198805741999,0.5,0.0,1.0,0.0008201868638413,True,0,17,17,33,5.044394119358453,0.00028679755117115905
417,HV169,Role of phospholipids in phagocytosis,720.5,0.0014467198805741999,0.5,0.0,1.0,0.0008201868638413,True,0,17,17,33,5.044394119358453,0.00028679755117115905
418,HV169,Scavenging of heme from plasma,744.5,0.0014467198805741999,0.5,0.0,1.0,0.0008201868638413,True,0,17,17,33,5.044394119358453,0.00028679755117115905
419,HV205,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,976.5,0.0131149332437615,0.5,0.0,1.0,0.0074352306283505,True,0,17,17,33,5.044394119358453,0.002599902571734315
420,HV205,CD22 mediated BCR regulation,974.5,0.0131149332437615,0.5,0.0,1.0,0.0074352306283505,True,0,17,17,33,5.044394119358453,0.002599902571734315
421,HV205,Cell surface interactions at the vascular wall,978.5,0.0131149332437615,0.5,0.0,1.0,0.0074352306283505,True,0,17,17,33,5.044394119358453,0.002599902571734315
422,HV205,FCERI mediated Ca+2 mobilization,964.5,0.0131149332437615,0.5,0.0,1.0,0.0074352306283505,True,0,17,17,33,5.044394119358453,0.002599902571734315
423,HV205,FCERI mediated MAPK activation,962.5,0.0131149332437615,0.5,0.0,1.0,0.0074352306283505,True,0,17,17,33,5.044394119358453,0.002599902571734315
424,HV205,FCERI mediated NF-kB activation,966.5,0.0131149332437615,0.5,0.0,1.0,0.0074352306283505,True,0,17,17,33,5.044394119358453,0.002599902571734315
425,HV205,FCGR activation,954.5,0.0131149332437615,0.5,0.0,1.0,0.0074352306283505,True,0,17,17,33,5.044394119358453,0.002599902571734315
426,HV205,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,980.5,0.0131149332437615,0.5,0.0,1.0,0.0074352306283505,True,0,17,17,33,5.044394119358453,0.002599902571734315
427,HV205,Initial triggering of complement,950.5,0.0131149332437615,0.5,0.0,1.0,0.0074352306283505,True,0,17,17,33,5.044394119358453,0.002599902571734315
428,HV205,Leishmania parasite growth and survival,970.5,0.0131149332437615,0.5,0.0,1.0,0.0074352306283505,True,0,17,17,33,5.044394119358453,0.002599902571734315
429,HV205,Parasite infection,968.5,0.0131149332437615,0.5,0.0,1.0,0.0074352306283505,True,0,17,17,33,5.044394119358453,0.002599902571734315
430,HV205,Potential therapeutics for SARS,972.5,0.0131149332437615,0.5,0.0,1.0,0.0074352306283505,True,0,17,17,33,5.044394119358453,0.002599902571734315
431,HV205,Regulation of Complement cascade,952.5,0.0131149332437615,0.5,0.0,1.0,0.0074352306283505,True,0,17,17,33,5.044394119358453,0.002599902571734315
432,HV205,Regulation of actin dynamics for phagocytic cup formation,956.5,0.0131149332437615,0.5,0.0,1.0,0.0074352306283505,True,0,17,17,33,5.044394119358453,0.002599902571734315
433,HV205,Role of LAT2/NTAL/LAB on calcium mobilization,960.5,0.0131149332437615,0.5,0.0,1.0,0.0074352306283505,True,0,17,17,33,5.044394119358453,0.002599902571734315
434,HV205,Role of phospholipids in phagocytosis,958.5,0.0131149332437615,0.5,0.0,1.0,0.0074352306283505,True,0,17,17,33,5.044394119358453,0.002599902571734315
435,HV205,Scavenging of heme from plasma,982.5,0.0131149332437615,0.5,0.0,1.0,0.0074352306283505,True,0,17,17,33,5.044394119358453,0.002599902571734315
436,HV307,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,942.5,0.0160392935669741,0.5,0.0,1.0,0.0090931341067251,True,0,17,17,33,5.044394119358453,0.003179627362069397
437,HV307,CD22 mediated BCR regulation,940.5,0.0160392935669741,0.5,0.0,1.0,0.0090931341067251,True,0,17,17,33,5.044394119358453,0.003179627362069397
438,HV307,Cell surface interactions at the vascular wall,944.5,0.0160392935669741,0.5,0.0,1.0,0.0090931341067251,True,0,17,17,33,5.044394119358453,0.003179627362069397
439,HV307,FCERI mediated Ca+2 mobilization,930.5,0.0160392935669741,0.5,0.0,1.0,0.0090931341067251,True,0,17,17,33,5.044394119358453,0.003179627362069397
440,HV307,FCERI mediated MAPK activation,928.5,0.0160392935669741,0.5,0.0,1.0,0.0090931341067251,True,0,17,17,33,5.044394119358453,0.003179627362069397
441,HV307,FCERI mediated NF-kB activation,932.5,0.0160392935669741,0.5,0.0,1.0,0.0090931341067251,True,0,17,17,33,5.044394119358453,0.003179627362069397
442,HV307,FCGR activation,920.5,0.0160392935669741,0.5,0.0,1.0,0.0090931341067251,True,0,17,17,33,5.044394119358453,0.003179627362069397
443,HV307,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,946.5,0.0160392935669741,0.5,0.0,1.0,0.0090931341067251,True,0,17,17,33,5.044394119358453,0.003179627362069397
444,HV307,Initial triggering of complement,916.5,0.0160392935669741,0.5,0.0,1.0,0.0090931341067251,True,0,17,17,33,5.044394119358453,0.003179627362069397
445,HV307,Leishmania parasite growth and survival,936.5,0.0160392935669741,0.5,0.0,1.0,0.0090931341067251,True,0,17,17,33,5.044394119358453,0.003179627362069397
446,HV307,Parasite infection,934.5,0.0160392935669741,0.5,0.0,1.0,0.0090931341067251,True,0,17,17,33,5.044394119358453,0.003179627362069397
447,HV307,Potential therapeutics for SARS,938.5,0.0160392935669741,0.5,0.0,1.0,0.0090931341067251,True,0,17,17,33,5.044394119358453,0.003179627362069397
448,HV307,Regulation of Complement cascade,918.5,0.0160392935669741,0.5,0.0,1.0,0.0090931341067251,True,0,17,17,33,5.044394119358453,0.003179627362069397
449,HV307,Regulation of actin dynamics for phagocytic cup formation,922.5,0.0160392935669741,0.5,0.0,1.0,0.0090931341067251,True,0,17,17,33,5.044394119358453,0.003179627362069397
450,HV307,Role of LAT2/NTAL/LAB on calcium mobilization,926.5,0.0160392935669741,0.5,0.0,1.0,0.0090931341067251,True,0,17,17,33,5.044394119358453,0.003179627362069397
451,HV307,Role of phospholipids in phagocytosis,924.5,0.0160392935669741,0.5,0.0,1.0,0.0090931341067251,True,0,17,17,33,5.044394119358453,0.003179627362069397
452,HV307,Scavenging of heme from plasma,948.5,0.0160392935669741,0.5,0.0,1.0,0.0090931341067251,True,0,17,17,33,5.044394119358453,0.003179627362069397
453,HV313,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,874.5,0.005238097022722699,0.5,0.0,1.0,0.0029696269659737,True,0,17,17,33,5.044394119358453,0.0010383996370586684
454,HV313,CD22 mediated BCR regulation,872.5,0.005238097022722699,0.5,0.0,1.0,0.0029696269659737,True,0,17,17,33,5.044394119358453,0.0010383996370586684
455,HV313,Cell surface interactions at the vascular wall,876.5,0.005238097022722699,0.5,0.0,1.0,0.0029696269659737,True,0,17,17,33,5.044394119358453,0.0010383996370586684
456,HV313,FCERI mediated Ca+2 mobilization,862.5,0.005238097022722699,0.5,0.0,1.0,0.0029696269659737,True,0,17,17,33,5.044394119358453,0.0010383996370586684
457,HV313,FCERI mediated MAPK activation,860.5,0.005238097022722699,0.5,0.0,1.0,0.0029696269659737,True,0,17,17,33,5.044394119358453,0.0010383996370586684
458,HV313,FCERI mediated NF-kB activation,864.5,0.005238097022722699,0.5,0.0,1.0,0.0029696269659737,True,0,17,17,33,5.044394119358453,0.0010383996370586684
459,HV313,FCGR activation,852.5,0.005238097022722699,0.5,0.0,1.0,0.0029696269659737,True,0,17,17,33,5.044394119358453,0.0010383996370586684
460,HV313,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,878.5,0.005238097022722699,0.5,0.0,1.0,0.0029696269659737,True,0,17,17,33,5.044394119358453,0.0010383996370586684
461,HV313,Initial triggering of complement,848.5,0.005238097022722699,0.5,0.0,1.0,0.0029696269659737,True,0,17,17,33,5.044394119358453,0.0010383996370586684
462,HV313,Leishmania parasite growth and survival,868.5,0.005238097022722699,0.5,0.0,1.0,0.0029696269659737,True,0,17,17,33,5.044394119358453,0.0010383996370586684
463,HV313,Parasite infection,866.5,0.005238097022722699,0.5,0.0,1.0,0.0029696269659737,True,0,17,17,33,5.044394119358453,0.0010383996370586684
464,HV313,Potential therapeutics for SARS,870.5,0.005238097022722699,0.5,0.0,1.0,0.0029696269659737,True,0,17,17,33,5.044394119358453,0.0010383996370586684
465,HV313,Regulation of Complement cascade,850.5,0.005238097022722699,0.5,0.0,1.0,0.0029696269659737,True,0,17,17,33,5.044394119358453,0.0010383996370586684
466,HV313,Regulation of actin dynamics for phagocytic cup formation,854.5,0.005238097022722699,0.5,0.0,1.0,0.0029696269659737,True,0,17,17,33,5.044394119358453,0.0010383996370586684
467,HV313,Role of LAT2/NTAL/LAB on calcium mobilization,858.5,0.005238097022722699,0.5,0.0,1.0,0.0029696269659737,True,0,17,17,33,5.044394119358453,0.0010383996370586684
468,HV313,Role of phospholipids in phagocytosis,856.5,0.005238097022722699,0.5,0.0,1.0,0.0029696269659737,True,0,17,17,33,5.044394119358453,0.0010383996370586684
469,HV313,Scavenging of heme from plasma,880.5,0.005238097022722699,0.5,0.0,1.0,0.0029696269659737,True,0,17,17,33,5.044394119358453,0.0010383996370586684
470,HV323,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,840.5,0.0130036254580854,0.5,0.0,1.0,0.00737212706222095,True,0,17,17,33,5.044394119358453,0.002577836931532067
471,HV323,CD22 mediated BCR regulation,838.5,0.0130036254580854,0.5,0.0,1.0,0.00737212706222095,True,0,17,17,33,5.044394119358453,0.002577836931532067
472,HV323,Cell surface interactions at the vascular wall,842.5,0.0130036254580854,0.5,0.0,1.0,0.00737212706222095,True,0,17,17,33,5.044394119358453,0.002577836931532067
473,HV323,FCERI mediated Ca+2 mobilization,828.5,0.0130036254580854,0.5,0.0,1.0,0.00737212706222095,True,0,17,17,33,5.044394119358453,0.002577836931532067
474,HV323,FCERI mediated MAPK activation,826.5,0.0130036254580854,0.5,0.0,1.0,0.00737212706222095,True,0,17,17,33,5.044394119358453,0.002577836931532067
475,HV323,FCERI mediated NF-kB activation,830.5,0.0130036254580854,0.5,0.0,1.0,0.00737212706222095,True,0,17,17,33,5.044394119358453,0.002577836931532067
476,HV323,FCGR activation,818.5,0.0130036254580854,0.5,0.0,1.0,0.00737212706222095,True,0,17,17,33,5.044394119358453,0.002577836931532067
477,HV323,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,844.5,0.0130036254580854,0.5,0.0,1.0,0.00737212706222095,True,0,17,17,33,5.044394119358453,0.002577836931532067
478,HV323,Initial triggering of complement,814.5,0.0130036254580854,0.5,0.0,1.0,0.00737212706222095,True,0,17,17,33,5.044394119358453,0.002577836931532067
479,HV323,Leishmania parasite growth and survival,834.5,0.0130036254580854,0.5,0.0,1.0,0.00737212706222095,True,0,17,17,33,5.044394119358453,0.002577836931532067
480,HV323,Parasite infection,832.5,0.0130036254580854,0.5,0.0,1.0,0.00737212706222095,True,0,17,17,33,5.044394119358453,0.002577836931532067
481,HV323,Potential therapeutics for SARS,836.5,0.0130036254580854,0.5,0.0,1.0,0.00737212706222095,True,0,17,17,33,5.044394119358453,0.002577836931532067
482,HV323,Regulation of Complement cascade,816.5,0.0130036254580854,0.5,0.0,1.0,0.00737212706222095,True,0,17,17,33,5.044394119358453,0.002577836931532067
483,HV323,Regulation of actin dynamics for phagocytic cup formation,820.5,0.0130036254580854,0.5,0.0,1.0,0.00737212706222095,True,0,17,17,33,5.044394119358453,0.002577836931532067
484,HV323,Role of LAT2/NTAL/LAB on calcium mobilization,824.5,0.0130036254580854,0.5,0.0,1.0,0.00737212706222095,True,0,17,17,33,5.044394119358453,0.002577836931532067
485,HV323,Role of phospholipids in phagocytosis,822.5,0.0130036254580854,0.5,0.0,1.0,0.00737212706222095,True,0,17,17,33,5.044394119358453,0.002577836931532067
486,HV323,Scavenging of heme from plasma,846.5,0.0130036254580854,0.5,0.0,1.0,0.00737212706222095,True,0,17,17,33,5.044394119358453,0.002577836931532067
487,HV348,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,806.5,0.0008594521555764,0.5,0.0,1.0,0.00048724799981599996,True,0,17,17,33,5.044394119358453,0.00017037767772310885
488,HV348,CD22 mediated BCR regulation,804.5,0.0008594521555764,0.5,0.0,1.0,0.00048724799981599996,True,0,17,17,33,5.044394119358453,0.00017037767772310885
489,HV348,Cell surface interactions at the vascular wall,808.5,0.0008594521555764,0.5,0.0,1.0,0.00048724799981599996,True,0,17,17,33,5.044394119358453,0.00017037767772310885
490,HV348,FCERI mediated Ca+2 mobilization,794.5,0.0008594521555764,0.5,0.0,1.0,0.00048724799981599996,True,0,17,17,33,5.044394119358453,0.00017037767772310885
491,HV348,FCERI mediated MAPK activation,792.5,0.0008594521555764,0.5,0.0,1.0,0.00048724799981599996,True,0,17,17,33,5.044394119358453,0.00017037767772310885
492,HV348,FCERI mediated NF-kB activation,796.5,0.0008594521555764,0.5,0.0,1.0,0.00048724799981599996,True,0,17,17,33,5.044394119358453,0.00017037767772310885
493,HV348,FCGR activation,784.5,0.0008594521555764,0.5,0.0,1.0,0.00048724799981599996,True,0,17,17,33,5.044394119358453,0.00017037767772310885
494,HV348,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,810.5,0.0008594521555764,0.5,0.0,1.0,0.00048724799981599996,True,0,17,17,33,5.044394119358453,0.00017037767772310885
495,HV348,Initial triggering of complement,780.5,0.0008594521555764,0.5,0.0,1.0,0.00048724799981599996,True,0,17,17,33,5.044394119358453,0.00017037767772310885
496,HV348,Leishmania parasite growth and survival,800.5,0.0008594521555764,0.5,0.0,1.0,0.00048724799981599996,True,0,17,17,33,5.044394119358453,0.00017037767772310885
497,HV348,Parasite infection,798.5,0.0008594521555764,0.5,0.0,1.0,0.00048724799981599996,True,0,17,17,33,5.044394119358453,0.00017037767772310885
498,HV348,Potential therapeutics for SARS,802.5,0.0008594521555764,0.5,0.0,1.0,0.00048724799981599996,True,0,17,17,33,5.044394119358453,0.00017037767772310885
499,HV348,Regulation of Complement cascade,782.5,0.0008594521555764,0.5,0.0,1.0,0.00048724799981599996,True,0,17,17,33,5.044394119358453,0.00017037767772310885
500,HV348,Regulation of actin dynamics for phagocytic cup formation,786.5,0.0008594521555764,0.5,0.0,1.0,0.00048724799981599996,True,0,17,17,33,5.044394119358453,0.00017037767772310885
501,HV348,Role of LAT2/NTAL/LAB on calcium mobilization,790.5,0.0008594521555764,0.5,0.0,1.0,0.00048724799981599996,True,0,17,17,33,5.044394119358453,0.00017037767772310885
502,HV348,Role of phospholipids in phagocytosis,788.5,0.0008594521555764,0.5,0.0,1.0,0.00048724799981599996,True,0,17,17,33,5.044394119358453,0.00017037767772310885
503,HV348,Scavenging of heme from plasma,812.5,0.0008594521555764,0.5,0.0,1.0,0.00048724799981599996,True,0,17,17,33,5.044394119358453,0.00017037767772310885
504,HV353,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,908.5,0.0004574901552896,0.5,0.0,1.0,0.0002593642492535,True,0,17,17,33,5.044394119358453,9.069278578648879e-05
505,HV353,CD22 mediated BCR regulation,906.5,0.0004574901552896,0.5,0.0,1.0,0.0002593642492535,True,0,17,17,33,5.044394119358453,9.069278578648879e-05
506,HV353,Cell surface interactions at the vascular wall,910.5,0.0004574901552896,0.5,0.0,1.0,0.0002593642492535,True,0,17,17,33,5.044394119358453,9.069278578648879e-05
507,HV353,FCERI mediated Ca+2 mobilization,896.5,0.0004574901552896,0.5,0.0,1.0,0.0002593642492535,True,0,17,17,33,5.044394119358453,9.069278578648879e-05
508,HV353,FCERI mediated MAPK activation,894.5,0.0004574901552896,0.5,0.0,1.0,0.0002593642492535,True,0,17,17,33,5.044394119358453,9.069278578648879e-05
509,HV353,FCERI mediated NF-kB activation,898.5,0.0004574901552896,0.5,0.0,1.0,0.0002593642492535,True,0,17,17,33,5.044394119358453,9.069278578648879e-05
510,HV353,FCGR activation,886.5,0.0004574901552896,0.5,0.0,1.0,0.0002593642492535,True,0,17,17,33,5.044394119358453,9.069278578648879e-05
511,HV353,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,912.5,0.0004574901552896,0.5,0.0,1.0,0.0002593642492535,True,0,17,17,33,5.044394119358453,9.069278578648879e-05
512,HV353,Initial triggering of complement,882.5,0.0004574901552896,0.5,0.0,1.0,0.0002593642492535,True,0,17,17,33,5.044394119358453,9.069278578648879e-05
513,HV353,Leishmania parasite growth and survival,902.5,0.0004574901552896,0.5,0.0,1.0,0.0002593642492535,True,0,17,17,33,5.044394119358453,9.069278578648879e-05
514,HV353,Parasite infection,900.5,0.0004574901552896,0.5,0.0,1.0,0.0002593642492535,True,0,17,17,33,5.044394119358453,9.069278578648879e-05
515,HV353,Potential therapeutics for SARS,904.5,0.0004574901552896,0.5,0.0,1.0,0.0002593642492535,True,0,17,17,33,5.044394119358453,9.069278578648879e-05
516,HV353,Regulation of Complement cascade,884.5,0.0004574901552896,0.5,0.0,1.0,0.0002593642492535,True,0,17,17,33,5.044394119358453,9.069278578648879e-05
517,HV353,Regulation of actin dynamics for phagocytic cup formation,888.5,0.0004574901552896,0.5,0.0,1.0,0.0002593642492535,True,0,17,17,33,5.044394119358453,9.069278578648879e-05
518,HV353,Role of LAT2/NTAL/LAB on calcium mobilization,892.5,0.0004574901552896,0.5,0.0,1.0,0.0002593642492535,True,0,17,17,33,5.044394119358453,9.069278578648879e-05
519,HV353,Role of phospholipids in phagocytosis,890.5,0.0004574901552896,0.5,0.0,1.0,0.0002593642492535,True,0,17,17,33,5.044394119358453,9.069278578648879e-05
520,HV353,Scavenging of heme from plasma,914.5,0.0004574901552896,0.5,0.0,1.0,0.0002593642492535,True,0,17,17,33,5.044394119358453,9.069278578648879e-05
521,HV434,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,1534.5,0.0163099533070645,0.5,0.0,1.0,0.009246578851885349,True,0,17,17,33,5.044394119358453,0.003233282911910698
522,HV434,CD22 mediated BCR regulation,1532.5,0.0163099533070645,0.5,0.0,1.0,0.009246578851885349,True,0,17,17,33,5.044394119358453,0.003233282911910698
523,HV434,Cell surface interactions at the vascular wall,1536.5,0.0163099533070645,0.5,0.0,1.0,0.009246578851885349,True,0,17,17,33,5.044394119358453,0.003233282911910698
524,HV434,FCERI mediated Ca+2 mobilization,1522.5,0.0163099533070645,0.5,0.0,1.0,0.009246578851885349,True,0,17,17,33,5.044394119358453,0.003233282911910698
525,HV434,FCERI mediated MAPK activation,1520.5,0.0163099533070645,0.5,0.0,1.0,0.009246578851885349,True,0,17,17,33,5.044394119358453,0.003233282911910698
526,HV434,FCERI mediated NF-kB activation,1524.5,0.0163099533070645,0.5,0.0,1.0,0.009246578851885349,True,0,17,17,33,5.044394119358453,0.003233282911910698
527,HV434,FCGR activation,1512.5,0.0163099533070645,0.5,0.0,1.0,0.009246578851885349,True,0,17,17,33,5.044394119358453,0.003233282911910698
528,HV434,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,1538.5,0.0163099533070645,0.5,0.0,1.0,0.009246578851885349,True,0,17,17,33,5.044394119358453,0.003233282911910698
529,HV434,Initial triggering of complement,1508.5,0.0163099533070645,0.5,0.0,1.0,0.009246578851885349,True,0,17,17,33,5.044394119358453,0.003233282911910698
530,HV434,Leishmania parasite growth and survival,1528.5,0.0163099533070645,0.5,0.0,1.0,0.009246578851885349,True,0,17,17,33,5.044394119358453,0.003233282911910698
531,HV434,Parasite infection,1526.5,0.0163099533070645,0.5,0.0,1.0,0.009246578851885349,True,0,17,17,33,5.044394119358453,0.003233282911910698
532,HV434,Potential therapeutics for SARS,1530.5,0.0163099533070645,0.5,0.0,1.0,0.009246578851885349,True,0,17,17,33,5.044394119358453,0.003233282911910698
533,HV434,Regulation of Complement cascade,1510.5,0.0163099533070645,0.5,0.0,1.0,0.009246578851885349,True,0,17,17,33,5.044394119358453,0.003233282911910698
534,HV434,Regulation of actin dynamics for phagocytic cup formation,1514.5,0.0163099533070645,0.5,0.0,1.0,0.009246578851885349,True,0,17,17,33,5.044394119358453,0.003233282911910698
535,HV434,Role of LAT2/NTAL/LAB on calcium mobilization,1518.5,0.0163099533070645,0.5,0.0,1.0,0.009246578851885349,True,0,17,17,33,5.044394119358453,0.003233282911910698
536,HV434,Role of phospholipids in phagocytosis,1516.5,0.0163099533070645,0.5,0.0,1.0,0.009246578851885349,True,0,17,17,33,5.044394119358453,0.003233282911910698
537,HV434,Scavenging of heme from plasma,1540.5,0.0163099533070645,0.5,0.0,1.0,0.009246578851885349,True,0,17,17,33,5.044394119358453,0.003233282911910698
538,Heme degradation,Heme degradation,2082.5,0.00018878766619849453,0.5,1.0,2.0,0.0017870140054875002,False,2,2,4,5,2.321928094887362,8.130642228507628e-05
539,Heme degradation,Metabolism of porphyrins,2174.5,0.00021033091618360495,0.5,2.0,3.0,0.0029923174968836,True,2,2,4,5,2.321928094887362,9.058459503837831e-05
540,Heme signaling,Cellular responses to stress,2298.5,0.0082301734675662,0.5,2.0,3.0,0.11708831262770064,True,5,2,7,8,3.0,0.0027433911558553997
541,Heme signaling,Heme signaling,2100.5,0.0105594514818268,0.5,1.0,2.0,0.09995296868838259,False,5,2,7,8,3.0,0.0035198171606089334
542,Hemostasis,root,2458.5,0.0091939337437765,0.5,4.0,5.0,0.5285653253446418,True,7,1,8,84,6.392317422778761,0.0014382786610399375
543,IGHD,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,1032.5,0.0011047102595486001,0.5,0.0,1.0,0.00062629183119605,True,0,3,3,11,3.4594316186372973,0.0003193328793080049
544,IGHD,CD22 mediated BCR regulation,1030.5,0.0011047102595486001,0.5,0.0,1.0,0.00062629183119605,True,0,3,3,11,3.4594316186372973,0.0003193328793080049
545,IGHD,Potential therapeutics for SARS,1028.5,0.0011047102595486001,0.5,0.0,1.0,0.00062629183119605,True,0,3,3,11,3.4594316186372973,0.0003193328793080049
546,IGHM,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,1024.5,0.0012976989408524,0.5,0.0,1.0,0.00073570263241665,True,0,4,4,13,3.700439718141092,0.00035068776677824016
547,IGHM,CD22 mediated BCR regulation,1022.5,0.0012976989408524,0.5,0.0,1.0,0.00073570263241665,True,0,4,4,13,3.700439718141092,0.00035068776677824016
548,IGHM,Cell surface interactions at the vascular wall,1026.5,0.0012976989408524,0.5,0.0,1.0,0.00073570263241665,True,0,4,4,13,3.700439718141092,0.00035068776677824016
549,IGHM,Potential therapeutics for SARS,1020.5,0.0012976989408524,0.5,0.0,1.0,0.00073570263241665,True,0,4,4,13,3.700439718141092,0.00035068776677824016
550,IGJ,Cell surface interactions at the vascular wall,232.5,0.0014492200477005,0.5,0.0,1.0,0.00082160428006815,True,0,2,2,7,2.807354922057604,0.0005162225966919488
551,IGJ,Scavenging of heme from plasma,234.5,0.0014492200477005,0.5,0.0,1.0,0.00082160428006815,True,0,2,2,7,2.807354922057604,0.0005162225966919488
552,IGKC,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,1012.5,0.0158173353615165,0.5,0.0,1.0,0.0089672996539865,True,0,17,17,33,5.044394119358453,0.0031356263977898994
553,IGKC,CD22 mediated BCR regulation,1010.5,0.0158173353615165,0.5,0.0,1.0,0.0089672996539865,True,0,17,17,33,5.044394119358453,0.0031356263977898994
554,IGKC,Cell surface interactions at the vascular wall,1014.5,0.0158173353615165,0.5,0.0,1.0,0.0089672996539865,True,0,17,17,33,5.044394119358453,0.0031356263977898994
555,IGKC,FCERI mediated Ca+2 mobilization,1000.5,0.0158173353615165,0.5,0.0,1.0,0.0089672996539865,True,0,17,17,33,5.044394119358453,0.0031356263977898994
556,IGKC,FCERI mediated MAPK activation,998.5,0.0158173353615165,0.5,0.0,1.0,0.0089672996539865,True,0,17,17,33,5.044394119358453,0.0031356263977898994
557,IGKC,FCERI mediated NF-kB activation,1002.5,0.0158173353615165,0.5,0.0,1.0,0.0089672996539865,True,0,17,17,33,5.044394119358453,0.0031356263977898994
558,IGKC,FCGR activation,990.5,0.0158173353615165,0.5,0.0,1.0,0.0089672996539865,True,0,17,17,33,5.044394119358453,0.0031356263977898994
559,IGKC,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,1016.5,0.0158173353615165,0.5,0.0,1.0,0.0089672996539865,True,0,17,17,33,5.044394119358453,0.0031356263977898994
560,IGKC,Initial triggering of complement,986.5,0.0158173353615165,0.5,0.0,1.0,0.0089672996539865,True,0,17,17,33,5.044394119358453,0.0031356263977898994
561,IGKC,Leishmania parasite growth and survival,1006.5,0.0158173353615165,0.5,0.0,1.0,0.0089672996539865,True,0,17,17,33,5.044394119358453,0.0031356263977898994
562,IGKC,Parasite infection,1004.5,0.0158173353615165,0.5,0.0,1.0,0.0089672996539865,True,0,17,17,33,5.044394119358453,0.0031356263977898994
563,IGKC,Potential therapeutics for SARS,1008.5,0.0158173353615165,0.5,0.0,1.0,0.0089672996539865,True,0,17,17,33,5.044394119358453,0.0031356263977898994
564,IGKC,Regulation of Complement cascade,988.5,0.0158173353615165,0.5,0.0,1.0,0.0089672996539865,True,0,17,17,33,5.044394119358453,0.0031356263977898994
565,IGKC,Regulation of actin dynamics for phagocytic cup formation,992.5,0.0158173353615165,0.5,0.0,1.0,0.0089672996539865,True,0,17,17,33,5.044394119358453,0.0031356263977898994
566,IGKC,Role of LAT2/NTAL/LAB on calcium mobilization,996.5,0.0158173353615165,0.5,0.0,1.0,0.0089672996539865,True,0,17,17,33,5.044394119358453,0.0031356263977898994
567,IGKC,Role of phospholipids in phagocytosis,994.5,0.0158173353615165,0.5,0.0,1.0,0.0089672996539865,True,0,17,17,33,5.044394119358453,0.0031356263977898994
568,IGKC,Scavenging of heme from plasma,1018.5,0.0158173353615165,0.5,0.0,1.0,0.0089672996539865,True,0,17,17,33,5.044394119358453,0.0031356263977898994
569,IGLC7,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,60.5,0.0133516207039022,0.5,0.0,1.0,0.0075694155166969,True,0,17,17,33,5.044394119358453,0.0026468234614467952
570,IGLC7,CD22 mediated BCR regulation,58.5,0.0133516207039022,0.5,0.0,1.0,0.0075694155166969,True,0,17,17,33,5.044394119358453,0.0026468234614467952
571,IGLC7,Cell surface interactions at the vascular wall,62.5,0.0133516207039022,0.5,0.0,1.0,0.0075694155166969,True,0,17,17,33,5.044394119358453,0.0026468234614467952
572,IGLC7,FCERI mediated Ca+2 mobilization,48.5,0.0133516207039022,0.5,0.0,1.0,0.0075694155166969,True,0,17,17,33,5.044394119358453,0.0026468234614467952
573,IGLC7,FCERI mediated MAPK activation,46.5,0.0133516207039022,0.5,0.0,1.0,0.0075694155166969,True,0,17,17,33,5.044394119358453,0.0026468234614467952
574,IGLC7,FCERI mediated NF-kB activation,50.5,0.0133516207039022,0.5,0.0,1.0,0.0075694155166969,True,0,17,17,33,5.044394119358453,0.0026468234614467952
575,IGLC7,FCGR activation,38.5,0.0133516207039022,0.5,0.0,1.0,0.0075694155166969,True,0,17,17,33,5.044394119358453,0.0026468234614467952
576,IGLC7,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,64.5,0.0133516207039022,0.5,0.0,1.0,0.0075694155166969,True,0,17,17,33,5.044394119358453,0.0026468234614467952
577,IGLC7,Initial triggering of complement,34.5,0.0133516207039022,0.5,0.0,1.0,0.0075694155166969,True,0,17,17,33,5.044394119358453,0.0026468234614467952
578,IGLC7,Leishmania parasite growth and survival,54.5,0.0133516207039022,0.5,0.0,1.0,0.0075694155166969,True,0,17,17,33,5.044394119358453,0.0026468234614467952
579,IGLC7,Parasite infection,52.5,0.0133516207039022,0.5,0.0,1.0,0.0075694155166969,True,0,17,17,33,5.044394119358453,0.0026468234614467952
580,IGLC7,Potential therapeutics for SARS,56.5,0.0133516207039022,0.5,0.0,1.0,0.0075694155166969,True,0,17,17,33,5.044394119358453,0.0026468234614467952
581,IGLC7,Regulation of Complement cascade,36.5,0.0133516207039022,0.5,0.0,1.0,0.0075694155166969,True,0,17,17,33,5.044394119358453,0.0026468234614467952
582,IGLC7,Regulation of actin dynamics for phagocytic cup formation,40.5,0.0133516207039022,0.5,0.0,1.0,0.0075694155166969,True,0,17,17,33,5.044394119358453,0.0026468234614467952
583,IGLC7,Role of LAT2/NTAL/LAB on calcium mobilization,44.5,0.0133516207039022,0.5,0.0,1.0,0.0075694155166969,True,0,17,17,33,5.044394119358453,0.0026468234614467952
584,IGLC7,Role of phospholipids in phagocytosis,42.5,0.0133516207039022,0.5,0.0,1.0,0.0075694155166969,True,0,17,17,33,5.044394119358453,0.0026468234614467952
585,IGLC7,Scavenging of heme from plasma,66.5,0.0133516207039022,0.5,0.0,1.0,0.0075694155166969,True,0,17,17,33,5.044394119358453,0.0026468234614467952
586,IPSP,Common Pathway of Fibrin Clot Formation,1428.5,0.0036463601117746,0.5,0.0,1.0,0.0020672258013939,True,0,2,2,6,2.584962500721156,0.0014106046454280608
587,IPSP,Intrinsic Pathway of Fibrin Clot Formation,1426.5,0.0036463601117746,0.5,0.0,1.0,0.0020672258013939,True,0,2,2,6,2.584962500721156,0.0014106046454280608
588,IRAK4 deficiency (TLR2/4),Diseases associated with the TLR signaling cascade,1958.5,0.0042495826402493,0.5,1.0,2.0,0.0402254228177057,True,5,1,6,10,3.321928094887362,0.0012792518437679766
589,ITIH4,Platelet degranulation ,1848.5,0.0014878619024147,0.5,0.0,1.0,0.0008435114523249,True,0,1,1,6,2.584962500721156,0.0005755835537264523
590,Immune System,root,2482.5,0.0331449778254565,0.5,4.0,5.0,1.905526674010694,True,3,1,4,120,6.906890595608519,0.004798827687603806
591,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,Adaptive Immune System,2270.5,0.0073932307490107,0.5,2.0,3.0,0.10518136910240419,True,34,2,36,37,5.20945336562895,0.0014191951112932357
592,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,2052.5,0.0115166888331461,0.5,1.0,2.0,0.1090139237170053,False,34,2,36,37,5.20945336562895,0.00221072884712457
593,Infectious disease,Disease,2376.5,0.0056235696042643,0.5,3.0,4.0,0.13145082640070915,True,2,1,3,47,5.554588851677638,0.0010124186964019539
594,Initial triggering of complement,Complement cascade,1878.5,0.0092683214196259,0.5,1.0,2.0,0.0877314737649111,True,41,1,42,46,5.523561956057013,0.0016779609776011416
595,Innate Immune System,Immune System,2340.5,0.0340033005101177,0.5,3.0,4.0,0.7948264655632964,True,8,1,9,106,6.727920454563199,0.005054058046577383
596,Integration of energy metabolism,Metabolism,2434.5,0.0038239242858676002,0.5,3.0,4.0,0.08938415327693,True,1,1,2,5,2.321928094887362,0.0016468745497707157
597,Integrin cell surface interactions,Extracellular matrix organization,2406.5,0.011921490810905998,0.5,3.0,4.0,0.278664607944701,True,7,2,9,9,3.169925001442312,0.003760811629764658
598,Integrin cell surface interactions,Integrin cell surface interactions,2110.5,0.018285361956939597,0.5,1.5,2.5,0.2142551625627299,False,7,2,9,9,3.169925001442312,0.005768389456728402
599,Integrin signaling,Signal Transduction,2352.5,0.00020666860529571345,0.5,3.0,4.0,0.004830874492351801,True,2,1,3,8,3.0,6.888953509857115e-05
600,Interleukin-1 family signaling,Signaling by Interleukins,1948.5,0.0029995767188564,0.5,1.0,2.0,0.02839319811017255,True,1,1,2,6,2.584962500721156,0.0011603946742049737
601,Interleukin-4 and Interleukin-13 signaling,Signaling by Interleukins,1950.5,0.014924221397143101,0.5,1.0,2.0,0.14126872371869176,True,3,1,4,8,3.0,0.004974740465714367
602,Intrinsic Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),2320.5,0.009566656920672,0.5,2.0,3.0,0.13610207861886525,True,11,2,13,14,3.807354922057604,0.0025126779920748507
603,Intrinsic Pathway of Fibrin Clot Formation,Intrinsic Pathway of Fibrin Clot Formation,2056.5,0.010912494300618199,0.5,1.0,2.0,0.1032947784285041,False,11,2,13,14,3.807354922057604,0.0028661615541533945
604,Iron uptake and transport,Transport of small molecules,2430.5,0.0005197475583845,0.5,3.0,4.0,0.01214908872428805,True,1,1,2,5,2.321928094887362,0.00022384308951208637
605,K2C1,Formation of the cornified envelope,1342.5,0.00014713208954544773,0.5,0.0,1.0,8.341338825509453e-05,True,0,2,2,8,3.0,4.904402984848258e-05
606,K2C1,Neutrophil degranulation,1340.5,0.00014713208954544773,0.5,0.0,1.0,8.341338825509453e-05,True,0,2,2,8,3.0,4.904402984848258e-05
607,KAIN,Platelet degranulation ,1744.5,0.0025322067992887996,0.5,0.0,1.0,0.00143558043349905,True,0,1,1,6,2.584962500721156,0.0009795913088032657
608,KNG1,Class A/1 (Rhodopsin-like receptors),218.5,0.0140374996214752,0.5,0.0,1.0,0.0079582598852113,True,0,7,7,19,4.247927513443585,0.0033045525322760727
609,KNG1,G alpha (i) signalling events,222.5,0.0140374996214752,0.5,0.0,1.0,0.0079582598852113,True,0,7,7,19,4.247927513443585,0.0033045525322760727
610,KNG1,G alpha (q) signalling events,220.5,0.0140374996214752,0.5,0.0,1.0,0.0079582598852113,True,0,7,7,19,4.247927513443585,0.0033045525322760727
611,KNG1,Intrinsic Pathway of Fibrin Clot Formation,226.5,0.0140374996214752,0.5,0.0,1.0,0.0079582598852113,True,0,7,7,19,4.247927513443585,0.0033045525322760727
612,KNG1,Platelet degranulation ,224.5,0.0140374996214752,0.5,0.0,1.0,0.0079582598852113,True,0,7,7,19,4.247927513443585,0.0033045525322760727
613,KNG1,Post-translational protein phosphorylation,230.5,0.0140374996214752,0.5,0.0,1.0,0.0079582598852113,True,0,7,7,19,4.247927513443585,0.0033045525322760727
614,KNG1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),228.5,0.0140374996214752,0.5,0.0,1.0,0.0079582598852113,True,0,7,7,19,4.247927513443585,0.0033045525322760727
615,KV105,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,330.5,0.0125278533525429,0.5,0.0,1.0,0.0071023982526651,True,0,17,17,33,5.044394119358453,0.0024835199344289526
616,KV105,CD22 mediated BCR regulation,328.5,0.0125278533525429,0.5,0.0,1.0,0.0071023982526651,True,0,17,17,33,5.044394119358453,0.0024835199344289526
617,KV105,Cell surface interactions at the vascular wall,332.5,0.0125278533525429,0.5,0.0,1.0,0.0071023982526651,True,0,17,17,33,5.044394119358453,0.0024835199344289526
618,KV105,FCERI mediated Ca+2 mobilization,318.5,0.0125278533525429,0.5,0.0,1.0,0.0071023982526651,True,0,17,17,33,5.044394119358453,0.0024835199344289526
619,KV105,FCERI mediated MAPK activation,316.5,0.0125278533525429,0.5,0.0,1.0,0.0071023982526651,True,0,17,17,33,5.044394119358453,0.0024835199344289526
620,KV105,FCERI mediated NF-kB activation,320.5,0.0125278533525429,0.5,0.0,1.0,0.0071023982526651,True,0,17,17,33,5.044394119358453,0.0024835199344289526
621,KV105,FCGR activation,308.5,0.0125278533525429,0.5,0.0,1.0,0.0071023982526651,True,0,17,17,33,5.044394119358453,0.0024835199344289526
622,KV105,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,334.5,0.0125278533525429,0.5,0.0,1.0,0.0071023982526651,True,0,17,17,33,5.044394119358453,0.0024835199344289526
623,KV105,Initial triggering of complement,304.5,0.0125278533525429,0.5,0.0,1.0,0.0071023982526651,True,0,17,17,33,5.044394119358453,0.0024835199344289526
624,KV105,Leishmania parasite growth and survival,324.5,0.0125278533525429,0.5,0.0,1.0,0.0071023982526651,True,0,17,17,33,5.044394119358453,0.0024835199344289526
625,KV105,Parasite infection,322.5,0.0125278533525429,0.5,0.0,1.0,0.0071023982526651,True,0,17,17,33,5.044394119358453,0.0024835199344289526
626,KV105,Potential therapeutics for SARS,326.5,0.0125278533525429,0.5,0.0,1.0,0.0071023982526651,True,0,17,17,33,5.044394119358453,0.0024835199344289526
627,KV105,Regulation of Complement cascade,306.5,0.0125278533525429,0.5,0.0,1.0,0.0071023982526651,True,0,17,17,33,5.044394119358453,0.0024835199344289526
628,KV105,Regulation of actin dynamics for phagocytic cup formation,310.5,0.0125278533525429,0.5,0.0,1.0,0.0071023982526651,True,0,17,17,33,5.044394119358453,0.0024835199344289526
629,KV105,Role of LAT2/NTAL/LAB on calcium mobilization,314.5,0.0125278533525429,0.5,0.0,1.0,0.0071023982526651,True,0,17,17,33,5.044394119358453,0.0024835199344289526
630,KV105,Role of phospholipids in phagocytosis,312.5,0.0125278533525429,0.5,0.0,1.0,0.0071023982526651,True,0,17,17,33,5.044394119358453,0.0024835199344289526
631,KV105,Scavenging of heme from plasma,336.5,0.0125278533525429,0.5,0.0,1.0,0.0071023982526651,True,0,17,17,33,5.044394119358453,0.0024835199344289526
632,KV116,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,1400.5,0.0112082480047991,0.5,0.0,1.0,0.00635427625184995,True,0,17,17,33,5.044394119358453,0.0022219215508530814
633,KV116,CD22 mediated BCR regulation,1398.5,0.0112082480047991,0.5,0.0,1.0,0.00635427625184995,True,0,17,17,33,5.044394119358453,0.0022219215508530814
634,KV116,Cell surface interactions at the vascular wall,1402.5,0.0112082480047991,0.5,0.0,1.0,0.00635427625184995,True,0,17,17,33,5.044394119358453,0.0022219215508530814
635,KV116,FCERI mediated Ca+2 mobilization,1388.5,0.0112082480047991,0.5,0.0,1.0,0.00635427625184995,True,0,17,17,33,5.044394119358453,0.0022219215508530814
636,KV116,FCERI mediated MAPK activation,1386.5,0.0112082480047991,0.5,0.0,1.0,0.00635427625184995,True,0,17,17,33,5.044394119358453,0.0022219215508530814
637,KV116,FCERI mediated NF-kB activation,1390.5,0.0112082480047991,0.5,0.0,1.0,0.00635427625184995,True,0,17,17,33,5.044394119358453,0.0022219215508530814
638,KV116,FCGR activation,1378.5,0.0112082480047991,0.5,0.0,1.0,0.00635427625184995,True,0,17,17,33,5.044394119358453,0.0022219215508530814
639,KV116,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,1404.5,0.0112082480047991,0.5,0.0,1.0,0.00635427625184995,True,0,17,17,33,5.044394119358453,0.0022219215508530814
640,KV116,Initial triggering of complement,1374.5,0.0112082480047991,0.5,0.0,1.0,0.00635427625184995,True,0,17,17,33,5.044394119358453,0.0022219215508530814
641,KV116,Leishmania parasite growth and survival,1394.5,0.0112082480047991,0.5,0.0,1.0,0.00635427625184995,True,0,17,17,33,5.044394119358453,0.0022219215508530814
642,KV116,Parasite infection,1392.5,0.0112082480047991,0.5,0.0,1.0,0.00635427625184995,True,0,17,17,33,5.044394119358453,0.0022219215508530814
643,KV116,Potential therapeutics for SARS,1396.5,0.0112082480047991,0.5,0.0,1.0,0.00635427625184995,True,0,17,17,33,5.044394119358453,0.0022219215508530814
644,KV116,Regulation of Complement cascade,1376.5,0.0112082480047991,0.5,0.0,1.0,0.00635427625184995,True,0,17,17,33,5.044394119358453,0.0022219215508530814
645,KV116,Regulation of actin dynamics for phagocytic cup formation,1380.5,0.0112082480047991,0.5,0.0,1.0,0.00635427625184995,True,0,17,17,33,5.044394119358453,0.0022219215508530814
646,KV116,Role of LAT2/NTAL/LAB on calcium mobilization,1384.5,0.0112082480047991,0.5,0.0,1.0,0.00635427625184995,True,0,17,17,33,5.044394119358453,0.0022219215508530814
647,KV116,Role of phospholipids in phagocytosis,1382.5,0.0112082480047991,0.5,0.0,1.0,0.00635427625184995,True,0,17,17,33,5.044394119358453,0.0022219215508530814
648,KV116,Scavenging of heme from plasma,1406.5,0.0112082480047991,0.5,0.0,1.0,0.00635427625184995,True,0,17,17,33,5.044394119358453,0.0022219215508530814
649,KV117,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,262.5,0.0113776765323324,0.5,0.0,1.0,0.00645033012828365,True,0,17,17,33,5.044394119358453,0.0022555090389684727
650,KV117,CD22 mediated BCR regulation,260.5,0.0113776765323324,0.5,0.0,1.0,0.00645033012828365,True,0,17,17,33,5.044394119358453,0.0022555090389684727
651,KV117,Cell surface interactions at the vascular wall,264.5,0.0113776765323324,0.5,0.0,1.0,0.00645033012828365,True,0,17,17,33,5.044394119358453,0.0022555090389684727
652,KV117,FCERI mediated Ca+2 mobilization,250.5,0.0113776765323324,0.5,0.0,1.0,0.00645033012828365,True,0,17,17,33,5.044394119358453,0.0022555090389684727
653,KV117,FCERI mediated MAPK activation,248.5,0.0113776765323324,0.5,0.0,1.0,0.00645033012828365,True,0,17,17,33,5.044394119358453,0.0022555090389684727
654,KV117,FCERI mediated NF-kB activation,252.5,0.0113776765323324,0.5,0.0,1.0,0.00645033012828365,True,0,17,17,33,5.044394119358453,0.0022555090389684727
655,KV117,FCGR activation,240.5,0.0113776765323324,0.5,0.0,1.0,0.00645033012828365,True,0,17,17,33,5.044394119358453,0.0022555090389684727
656,KV117,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,266.5,0.0113776765323324,0.5,0.0,1.0,0.00645033012828365,True,0,17,17,33,5.044394119358453,0.0022555090389684727
657,KV117,Initial triggering of complement,236.5,0.0113776765323324,0.5,0.0,1.0,0.00645033012828365,True,0,17,17,33,5.044394119358453,0.0022555090389684727
658,KV117,Leishmania parasite growth and survival,256.5,0.0113776765323324,0.5,0.0,1.0,0.00645033012828365,True,0,17,17,33,5.044394119358453,0.0022555090389684727
659,KV117,Parasite infection,254.5,0.0113776765323324,0.5,0.0,1.0,0.00645033012828365,True,0,17,17,33,5.044394119358453,0.0022555090389684727
660,KV117,Potential therapeutics for SARS,258.5,0.0113776765323324,0.5,0.0,1.0,0.00645033012828365,True,0,17,17,33,5.044394119358453,0.0022555090389684727
661,KV117,Regulation of Complement cascade,238.5,0.0113776765323324,0.5,0.0,1.0,0.00645033012828365,True,0,17,17,33,5.044394119358453,0.0022555090389684727
662,KV117,Regulation of actin dynamics for phagocytic cup formation,242.5,0.0113776765323324,0.5,0.0,1.0,0.00645033012828365,True,0,17,17,33,5.044394119358453,0.0022555090389684727
663,KV117,Role of LAT2/NTAL/LAB on calcium mobilization,246.5,0.0113776765323324,0.5,0.0,1.0,0.00645033012828365,True,0,17,17,33,5.044394119358453,0.0022555090389684727
664,KV117,Role of phospholipids in phagocytosis,244.5,0.0113776765323324,0.5,0.0,1.0,0.00645033012828365,True,0,17,17,33,5.044394119358453,0.0022555090389684727
665,KV117,Scavenging of heme from plasma,268.5,0.0113776765323324,0.5,0.0,1.0,0.00645033012828365,True,0,17,17,33,5.044394119358453,0.0022555090389684727
666,KV230,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,1466.5,0.0110919131177628,0.5,0.0,1.0,0.00628832267822805,True,0,17,17,33,5.044394119358453,0.002198859338765043
667,KV230,CD22 mediated BCR regulation,1464.5,0.0110919131177628,0.5,0.0,1.0,0.00628832267822805,True,0,17,17,33,5.044394119358453,0.002198859338765043
668,KV230,Cell surface interactions at the vascular wall,1468.5,0.0110919131177628,0.5,0.0,1.0,0.00628832267822805,True,0,17,17,33,5.044394119358453,0.002198859338765043
669,KV230,FCERI mediated Ca+2 mobilization,1454.5,0.0110919131177628,0.5,0.0,1.0,0.00628832267822805,True,0,17,17,33,5.044394119358453,0.002198859338765043
670,KV230,FCERI mediated MAPK activation,1452.5,0.0110919131177628,0.5,0.0,1.0,0.00628832267822805,True,0,17,17,33,5.044394119358453,0.002198859338765043
671,KV230,FCERI mediated NF-kB activation,1456.5,0.0110919131177628,0.5,0.0,1.0,0.00628832267822805,True,0,17,17,33,5.044394119358453,0.002198859338765043
672,KV230,FCGR activation,1444.5,0.0110919131177628,0.5,0.0,1.0,0.00628832267822805,True,0,17,17,33,5.044394119358453,0.002198859338765043
673,KV230,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,1470.5,0.0110919131177628,0.5,0.0,1.0,0.00628832267822805,True,0,17,17,33,5.044394119358453,0.002198859338765043
674,KV230,Initial triggering of complement,1440.5,0.0110919131177628,0.5,0.0,1.0,0.00628832267822805,True,0,17,17,33,5.044394119358453,0.002198859338765043
675,KV230,Leishmania parasite growth and survival,1460.5,0.0110919131177628,0.5,0.0,1.0,0.00628832267822805,True,0,17,17,33,5.044394119358453,0.002198859338765043
676,KV230,Parasite infection,1458.5,0.0110919131177628,0.5,0.0,1.0,0.00628832267822805,True,0,17,17,33,5.044394119358453,0.002198859338765043
677,KV230,Potential therapeutics for SARS,1462.5,0.0110919131177628,0.5,0.0,1.0,0.00628832267822805,True,0,17,17,33,5.044394119358453,0.002198859338765043
678,KV230,Regulation of Complement cascade,1442.5,0.0110919131177628,0.5,0.0,1.0,0.00628832267822805,True,0,17,17,33,5.044394119358453,0.002198859338765043
679,KV230,Regulation of actin dynamics for phagocytic cup formation,1446.5,0.0110919131177628,0.5,0.0,1.0,0.00628832267822805,True,0,17,17,33,5.044394119358453,0.002198859338765043
680,KV230,Role of LAT2/NTAL/LAB on calcium mobilization,1450.5,0.0110919131177628,0.5,0.0,1.0,0.00628832267822805,True,0,17,17,33,5.044394119358453,0.002198859338765043
681,KV230,Role of phospholipids in phagocytosis,1448.5,0.0110919131177628,0.5,0.0,1.0,0.00628832267822805,True,0,17,17,33,5.044394119358453,0.002198859338765043
682,KV230,Scavenging of heme from plasma,1472.5,0.0110919131177628,0.5,0.0,1.0,0.00628832267822805,True,0,17,17,33,5.044394119358453,0.002198859338765043
683,KV320,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,364.5,0.012711385553779,0.5,0.0,1.0,0.0072064479049626495,True,0,17,17,33,5.044394119358453,0.002519903332889389
684,KV320,CD22 mediated BCR regulation,362.5,0.012711385553779,0.5,0.0,1.0,0.0072064479049626495,True,0,17,17,33,5.044394119358453,0.002519903332889389
685,KV320,Cell surface interactions at the vascular wall,366.5,0.012711385553779,0.5,0.0,1.0,0.0072064479049626495,True,0,17,17,33,5.044394119358453,0.002519903332889389
686,KV320,FCERI mediated Ca+2 mobilization,352.5,0.012711385553779,0.5,0.0,1.0,0.0072064479049626495,True,0,17,17,33,5.044394119358453,0.002519903332889389
687,KV320,FCERI mediated MAPK activation,350.5,0.012711385553779,0.5,0.0,1.0,0.0072064479049626495,True,0,17,17,33,5.044394119358453,0.002519903332889389
688,KV320,FCERI mediated NF-kB activation,354.5,0.012711385553779,0.5,0.0,1.0,0.0072064479049626495,True,0,17,17,33,5.044394119358453,0.002519903332889389
689,KV320,FCGR activation,342.5,0.012711385553779,0.5,0.0,1.0,0.0072064479049626495,True,0,17,17,33,5.044394119358453,0.002519903332889389
690,KV320,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,368.5,0.012711385553779,0.5,0.0,1.0,0.0072064479049626495,True,0,17,17,33,5.044394119358453,0.002519903332889389
691,KV320,Initial triggering of complement,338.5,0.012711385553779,0.5,0.0,1.0,0.0072064479049626495,True,0,17,17,33,5.044394119358453,0.002519903332889389
692,KV320,Leishmania parasite growth and survival,358.5,0.012711385553779,0.5,0.0,1.0,0.0072064479049626495,True,0,17,17,33,5.044394119358453,0.002519903332889389
693,KV320,Parasite infection,356.5,0.012711385553779,0.5,0.0,1.0,0.0072064479049626495,True,0,17,17,33,5.044394119358453,0.002519903332889389
694,KV320,Potential therapeutics for SARS,360.5,0.012711385553779,0.5,0.0,1.0,0.0072064479049626495,True,0,17,17,33,5.044394119358453,0.002519903332889389
695,KV320,Regulation of Complement cascade,340.5,0.012711385553779,0.5,0.0,1.0,0.0072064479049626495,True,0,17,17,33,5.044394119358453,0.002519903332889389
696,KV320,Regulation of actin dynamics for phagocytic cup formation,344.5,0.012711385553779,0.5,0.0,1.0,0.0072064479049626495,True,0,17,17,33,5.044394119358453,0.002519903332889389
697,KV320,Role of LAT2/NTAL/LAB on calcium mobilization,348.5,0.012711385553779,0.5,0.0,1.0,0.0072064479049626495,True,0,17,17,33,5.044394119358453,0.002519903332889389
698,KV320,Role of phospholipids in phagocytosis,346.5,0.012711385553779,0.5,0.0,1.0,0.0072064479049626495,True,0,17,17,33,5.044394119358453,0.002519903332889389
699,KV320,Scavenging of heme from plasma,370.5,0.012711385553779,0.5,0.0,1.0,0.0072064479049626495,True,0,17,17,33,5.044394119358453,0.002519903332889389
700,KV401,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,1500.5,0.0160097045636297,0.5,0.0,1.0,0.00907635925474235,True,0,17,17,33,5.044394119358453,0.0031737616420950505
701,KV401,CD22 mediated BCR regulation,1498.5,0.0160097045636297,0.5,0.0,1.0,0.00907635925474235,True,0,17,17,33,5.044394119358453,0.0031737616420950505
702,KV401,Cell surface interactions at the vascular wall,1502.5,0.0160097045636297,0.5,0.0,1.0,0.00907635925474235,True,0,17,17,33,5.044394119358453,0.0031737616420950505
703,KV401,FCERI mediated Ca+2 mobilization,1488.5,0.0160097045636297,0.5,0.0,1.0,0.00907635925474235,True,0,17,17,33,5.044394119358453,0.0031737616420950505
704,KV401,FCERI mediated MAPK activation,1486.5,0.0160097045636297,0.5,0.0,1.0,0.00907635925474235,True,0,17,17,33,5.044394119358453,0.0031737616420950505
705,KV401,FCERI mediated NF-kB activation,1490.5,0.0160097045636297,0.5,0.0,1.0,0.00907635925474235,True,0,17,17,33,5.044394119358453,0.0031737616420950505
706,KV401,FCGR activation,1478.5,0.0160097045636297,0.5,0.0,1.0,0.00907635925474235,True,0,17,17,33,5.044394119358453,0.0031737616420950505
707,KV401,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,1504.5,0.0160097045636297,0.5,0.0,1.0,0.00907635925474235,True,0,17,17,33,5.044394119358453,0.0031737616420950505
708,KV401,Initial triggering of complement,1474.5,0.0160097045636297,0.5,0.0,1.0,0.00907635925474235,True,0,17,17,33,5.044394119358453,0.0031737616420950505
709,KV401,Leishmania parasite growth and survival,1494.5,0.0160097045636297,0.5,0.0,1.0,0.00907635925474235,True,0,17,17,33,5.044394119358453,0.0031737616420950505
710,KV401,Parasite infection,1492.5,0.0160097045636297,0.5,0.0,1.0,0.00907635925474235,True,0,17,17,33,5.044394119358453,0.0031737616420950505
711,KV401,Potential therapeutics for SARS,1496.5,0.0160097045636297,0.5,0.0,1.0,0.00907635925474235,True,0,17,17,33,5.044394119358453,0.0031737616420950505
712,KV401,Regulation of Complement cascade,1476.5,0.0160097045636297,0.5,0.0,1.0,0.00907635925474235,True,0,17,17,33,5.044394119358453,0.0031737616420950505
713,KV401,Regulation of actin dynamics for phagocytic cup formation,1480.5,0.0160097045636297,0.5,0.0,1.0,0.00907635925474235,True,0,17,17,33,5.044394119358453,0.0031737616420950505
714,KV401,Role of LAT2/NTAL/LAB on calcium mobilization,1484.5,0.0160097045636297,0.5,0.0,1.0,0.00907635925474235,True,0,17,17,33,5.044394119358453,0.0031737616420950505
715,KV401,Role of phospholipids in phagocytosis,1482.5,0.0160097045636297,0.5,0.0,1.0,0.00907635925474235,True,0,17,17,33,5.044394119358453,0.0031737616420950505
716,KV401,Scavenging of heme from plasma,1506.5,0.0160097045636297,0.5,0.0,1.0,0.00907635925474235,True,0,17,17,33,5.044394119358453,0.0031737616420950505
717,KVD16,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,296.5,0.008383835993267901,0.5,0.0,1.0,0.0047530363290156,True,0,17,17,33,5.044394119358453,0.0016620105001498493
718,KVD16,CD22 mediated BCR regulation,294.5,0.008383835993267901,0.5,0.0,1.0,0.0047530363290156,True,0,17,17,33,5.044394119358453,0.0016620105001498493
719,KVD16,Cell surface interactions at the vascular wall,298.5,0.008383835993267901,0.5,0.0,1.0,0.0047530363290156,True,0,17,17,33,5.044394119358453,0.0016620105001498493
720,KVD16,FCERI mediated Ca+2 mobilization,284.5,0.008383835993267901,0.5,0.0,1.0,0.0047530363290156,True,0,17,17,33,5.044394119358453,0.0016620105001498493
721,KVD16,FCERI mediated MAPK activation,282.5,0.008383835993267901,0.5,0.0,1.0,0.0047530363290156,True,0,17,17,33,5.044394119358453,0.0016620105001498493
722,KVD16,FCERI mediated NF-kB activation,286.5,0.008383835993267901,0.5,0.0,1.0,0.0047530363290156,True,0,17,17,33,5.044394119358453,0.0016620105001498493
723,KVD16,FCGR activation,274.5,0.008383835993267901,0.5,0.0,1.0,0.0047530363290156,True,0,17,17,33,5.044394119358453,0.0016620105001498493
724,KVD16,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,300.5,0.008383835993267901,0.5,0.0,1.0,0.0047530363290156,True,0,17,17,33,5.044394119358453,0.0016620105001498493
725,KVD16,Initial triggering of complement,270.5,0.008383835993267901,0.5,0.0,1.0,0.0047530363290156,True,0,17,17,33,5.044394119358453,0.0016620105001498493
726,KVD16,Leishmania parasite growth and survival,290.5,0.008383835993267901,0.5,0.0,1.0,0.0047530363290156,True,0,17,17,33,5.044394119358453,0.0016620105001498493
727,KVD16,Parasite infection,288.5,0.008383835993267901,0.5,0.0,1.0,0.0047530363290156,True,0,17,17,33,5.044394119358453,0.0016620105001498493
728,KVD16,Potential therapeutics for SARS,292.5,0.008383835993267901,0.5,0.0,1.0,0.0047530363290156,True,0,17,17,33,5.044394119358453,0.0016620105001498493
729,KVD16,Regulation of Complement cascade,272.5,0.008383835993267901,0.5,0.0,1.0,0.0047530363290156,True,0,17,17,33,5.044394119358453,0.0016620105001498493
730,KVD16,Regulation of actin dynamics for phagocytic cup formation,276.5,0.008383835993267901,0.5,0.0,1.0,0.0047530363290156,True,0,17,17,33,5.044394119358453,0.0016620105001498493
731,KVD16,Role of LAT2/NTAL/LAB on calcium mobilization,280.5,0.008383835993267901,0.5,0.0,1.0,0.0047530363290156,True,0,17,17,33,5.044394119358453,0.0016620105001498493
732,KVD16,Role of phospholipids in phagocytosis,278.5,0.008383835993267901,0.5,0.0,1.0,0.0047530363290156,True,0,17,17,33,5.044394119358453,0.0016620105001498493
733,KVD16,Scavenging of heme from plasma,302.5,0.008383835993267901,0.5,0.0,1.0,0.0047530363290156,True,0,17,17,33,5.044394119358453,0.0016620105001498493
734,KVD20,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,26.5,0.017316172672680402,0.5,0.0,1.0,0.0098170333793322,True,0,17,17,33,5.044394119358453,0.0034327557012699622
735,KVD20,CD22 mediated BCR regulation,24.5,0.017316172672680402,0.5,0.0,1.0,0.0098170333793322,True,0,17,17,33,5.044394119358453,0.0034327557012699622
736,KVD20,Cell surface interactions at the vascular wall,28.5,0.017316172672680402,0.5,0.0,1.0,0.0098170333793322,True,0,17,17,33,5.044394119358453,0.0034327557012699622
737,KVD20,FCERI mediated Ca+2 mobilization,14.5,0.017316172672680402,0.5,0.0,1.0,0.0098170333793322,True,0,17,17,33,5.044394119358453,0.0034327557012699622
738,KVD20,FCERI mediated MAPK activation,12.5,0.017316172672680402,0.5,0.0,1.0,0.0098170333793322,True,0,17,17,33,5.044394119358453,0.0034327557012699622
739,KVD20,FCERI mediated NF-kB activation,16.5,0.017316172672680402,0.5,0.0,1.0,0.0098170333793322,True,0,17,17,33,5.044394119358453,0.0034327557012699622
740,KVD20,FCGR activation,4.5,0.017316172672680402,0.5,0.0,1.0,0.0098170333793322,True,0,17,17,33,5.044394119358453,0.0034327557012699622
741,KVD20,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,30.5,0.017316172672680402,0.5,0.0,1.0,0.0098170333793322,True,0,17,17,33,5.044394119358453,0.0034327557012699622
742,KVD20,Initial triggering of complement,0.5,0.017316172672680402,0.5,0.0,1.0,0.0098170333793322,True,0,17,17,33,5.044394119358453,0.0034327557012699622
743,KVD20,Leishmania parasite growth and survival,20.5,0.017316172672680402,0.5,0.0,1.0,0.0098170333793322,True,0,17,17,33,5.044394119358453,0.0034327557012699622
744,KVD20,Parasite infection,18.5,0.017316172672680402,0.5,0.0,1.0,0.0098170333793322,True,0,17,17,33,5.044394119358453,0.0034327557012699622
745,KVD20,Potential therapeutics for SARS,22.5,0.017316172672680402,0.5,0.0,1.0,0.0098170333793322,True,0,17,17,33,5.044394119358453,0.0034327557012699622
746,KVD20,Regulation of Complement cascade,2.5,0.017316172672680402,0.5,0.0,1.0,0.0098170333793322,True,0,17,17,33,5.044394119358453,0.0034327557012699622
747,KVD20,Regulation of actin dynamics for phagocytic cup formation,6.5,0.017316172672680402,0.5,0.0,1.0,0.0098170333793322,True,0,17,17,33,5.044394119358453,0.0034327557012699622
748,KVD20,Role of LAT2/NTAL/LAB on calcium mobilization,10.5,0.017316172672680402,0.5,0.0,1.0,0.0098170333793322,True,0,17,17,33,5.044394119358453,0.0034327557012699622
749,KVD20,Role of phospholipids in phagocytosis,8.5,0.017316172672680402,0.5,0.0,1.0,0.0098170333793322,True,0,17,17,33,5.044394119358453,0.0034327557012699622
750,KVD20,Scavenging of heme from plasma,32.5,0.017316172672680402,0.5,0.0,1.0,0.0098170333793322,True,0,17,17,33,5.044394119358453,0.0034327557012699622
751,Keratan sulfate/keratin metabolism,Glycosaminoglycan metabolism,1874.5,0.0040044710013144,0.5,1.0,2.0,0.0379052610163303,True,1,1,2,6,2.584962500721156,0.0015491408483477914
752,Keratinization,Developmental Biology,2374.5,3.8789583846555786e-07,0.5,3.0,4.0,9.067057422927287e-06,True,1,1,2,5,2.321928094887362,1.6705764460133933e-07
753,LBP,Interleukin-4 and Interleukin-13 signaling,1682.5,0.018709400477053897,0.5,0.0,1.0,0.0106068940557695,True,0,3,3,10,3.321928094887362,0.005632090744483223
754,LBP,Regulation of TLR by endogenous ligand,1680.5,0.018709400477053897,0.5,0.0,1.0,0.0106068940557695,True,0,3,3,10,3.321928094887362,0.005632090744483223
755,LBP,Toll Like Receptor 4 (TLR4) Cascade,1678.5,0.018709400477053897,0.5,0.0,1.0,0.0106068940557695,True,0,3,3,10,3.321928094887362,0.005632090744483223
756,LCAT,HDL remodeling,1300.5,0.004937061336569,0.5,0.0,1.0,0.0027989612285037498,True,0,1,1,6,2.584962500721156,0.0019099160375408355
757,LDHB,Pyruvate metabolism,1578.5,0.0008705074282634,0.5,0.0,1.0,0.00049351554998645,True,0,1,1,6,2.584962500721156,0.0003367582423422176
758,LDL clearance,Plasma lipoprotein clearance,2008.5,0.0016010987596213,0.5,1.0,2.0,0.015155576448536452,True,1,1,2,6,2.584962500721156,0.0006193895498192424
759,LDL remodeling,Plasma lipoprotein remodeling,2000.5,0.0067724807460227,0.5,1.0,2.0,0.06410650753165595,True,3,1,4,8,3.0,0.002257493582007567
760,LG3BP,Platelet degranulation ,1844.5,0.0025295721093951,0.5,0.0,1.0,0.0014340867524691501,True,0,1,1,6,2.584962500721156,0.0009785720716216954
761,LUM,Diseases associated with glycosaminoglycan metabolism,1764.5,0.0075486930508264,0.5,0.0,1.0,0.00427956991715675,True,0,4,4,13,3.700439718141092,0.00203994487839366
762,LUM,ECM proteoglycans,1768.5,0.0075486930508264,0.5,0.0,1.0,0.00427956991715675,True,0,4,4,13,3.700439718141092,0.00203994487839366
763,LUM,Integrin cell surface interactions,1766.5,0.0075486930508264,0.5,0.0,1.0,0.00427956991715675,True,0,4,4,13,3.700439718141092,0.00203994487839366
764,LUM,Keratan sulfate/keratin metabolism,1762.5,0.0075486930508264,0.5,0.0,1.0,0.00427956991715675,True,0,4,4,13,3.700439718141092,0.00203994487839366
765,LV140,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,432.5,0.0069865521284619,0.5,0.0,1.0,0.0039608761559512505,True,0,17,17,33,5.044394119358453,0.0013850131379802755
766,LV140,CD22 mediated BCR regulation,430.5,0.0069865521284619,0.5,0.0,1.0,0.0039608761559512505,True,0,17,17,33,5.044394119358453,0.0013850131379802755
767,LV140,Cell surface interactions at the vascular wall,434.5,0.0069865521284619,0.5,0.0,1.0,0.0039608761559512505,True,0,17,17,33,5.044394119358453,0.0013850131379802755
768,LV140,FCERI mediated Ca+2 mobilization,420.5,0.0069865521284619,0.5,0.0,1.0,0.0039608761559512505,True,0,17,17,33,5.044394119358453,0.0013850131379802755
769,LV140,FCERI mediated MAPK activation,418.5,0.0069865521284619,0.5,0.0,1.0,0.0039608761559512505,True,0,17,17,33,5.044394119358453,0.0013850131379802755
770,LV140,FCERI mediated NF-kB activation,422.5,0.0069865521284619,0.5,0.0,1.0,0.0039608761559512505,True,0,17,17,33,5.044394119358453,0.0013850131379802755
771,LV140,FCGR activation,410.5,0.0069865521284619,0.5,0.0,1.0,0.0039608761559512505,True,0,17,17,33,5.044394119358453,0.0013850131379802755
772,LV140,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,436.5,0.0069865521284619,0.5,0.0,1.0,0.0039608761559512505,True,0,17,17,33,5.044394119358453,0.0013850131379802755
773,LV140,Initial triggering of complement,406.5,0.0069865521284619,0.5,0.0,1.0,0.0039608761559512505,True,0,17,17,33,5.044394119358453,0.0013850131379802755
774,LV140,Leishmania parasite growth and survival,426.5,0.0069865521284619,0.5,0.0,1.0,0.0039608761559512505,True,0,17,17,33,5.044394119358453,0.0013850131379802755
775,LV140,Parasite infection,424.5,0.0069865521284619,0.5,0.0,1.0,0.0039608761559512505,True,0,17,17,33,5.044394119358453,0.0013850131379802755
776,LV140,Potential therapeutics for SARS,428.5,0.0069865521284619,0.5,0.0,1.0,0.0039608761559512505,True,0,17,17,33,5.044394119358453,0.0013850131379802755
777,LV140,Regulation of Complement cascade,408.5,0.0069865521284619,0.5,0.0,1.0,0.0039608761559512505,True,0,17,17,33,5.044394119358453,0.0013850131379802755
778,LV140,Regulation of actin dynamics for phagocytic cup formation,412.5,0.0069865521284619,0.5,0.0,1.0,0.0039608761559512505,True,0,17,17,33,5.044394119358453,0.0013850131379802755
779,LV140,Role of LAT2/NTAL/LAB on calcium mobilization,416.5,0.0069865521284619,0.5,0.0,1.0,0.0039608761559512505,True,0,17,17,33,5.044394119358453,0.0013850131379802755
780,LV140,Role of phospholipids in phagocytosis,414.5,0.0069865521284619,0.5,0.0,1.0,0.0039608761559512505,True,0,17,17,33,5.044394119358453,0.0013850131379802755
781,LV140,Scavenging of heme from plasma,438.5,0.0069865521284619,0.5,0.0,1.0,0.0039608761559512505,True,0,17,17,33,5.044394119358453,0.0013850131379802755
782,LV151,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,398.5,0.0062193154078029,0.5,0.0,1.0,0.0035259077227453,True,0,17,17,33,5.044394119358453,0.0012329162354574059
783,LV151,CD22 mediated BCR regulation,396.5,0.0062193154078029,0.5,0.0,1.0,0.0035259077227453,True,0,17,17,33,5.044394119358453,0.0012329162354574059
784,LV151,Cell surface interactions at the vascular wall,400.5,0.0062193154078029,0.5,0.0,1.0,0.0035259077227453,True,0,17,17,33,5.044394119358453,0.0012329162354574059
785,LV151,FCERI mediated Ca+2 mobilization,386.5,0.0062193154078029,0.5,0.0,1.0,0.0035259077227453,True,0,17,17,33,5.044394119358453,0.0012329162354574059
786,LV151,FCERI mediated MAPK activation,384.5,0.0062193154078029,0.5,0.0,1.0,0.0035259077227453,True,0,17,17,33,5.044394119358453,0.0012329162354574059
787,LV151,FCERI mediated NF-kB activation,388.5,0.0062193154078029,0.5,0.0,1.0,0.0035259077227453,True,0,17,17,33,5.044394119358453,0.0012329162354574059
788,LV151,FCGR activation,376.5,0.0062193154078029,0.5,0.0,1.0,0.0035259077227453,True,0,17,17,33,5.044394119358453,0.0012329162354574059
789,LV151,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,402.5,0.0062193154078029,0.5,0.0,1.0,0.0035259077227453,True,0,17,17,33,5.044394119358453,0.0012329162354574059
790,LV151,Initial triggering of complement,372.5,0.0062193154078029,0.5,0.0,1.0,0.0035259077227453,True,0,17,17,33,5.044394119358453,0.0012329162354574059
791,LV151,Leishmania parasite growth and survival,392.5,0.0062193154078029,0.5,0.0,1.0,0.0035259077227453,True,0,17,17,33,5.044394119358453,0.0012329162354574059
792,LV151,Parasite infection,390.5,0.0062193154078029,0.5,0.0,1.0,0.0035259077227453,True,0,17,17,33,5.044394119358453,0.0012329162354574059
793,LV151,Potential therapeutics for SARS,394.5,0.0062193154078029,0.5,0.0,1.0,0.0035259077227453,True,0,17,17,33,5.044394119358453,0.0012329162354574059
794,LV151,Regulation of Complement cascade,374.5,0.0062193154078029,0.5,0.0,1.0,0.0035259077227453,True,0,17,17,33,5.044394119358453,0.0012329162354574059
795,LV151,Regulation of actin dynamics for phagocytic cup formation,378.5,0.0062193154078029,0.5,0.0,1.0,0.0035259077227453,True,0,17,17,33,5.044394119358453,0.0012329162354574059
796,LV151,Role of LAT2/NTAL/LAB on calcium mobilization,382.5,0.0062193154078029,0.5,0.0,1.0,0.0035259077227453,True,0,17,17,33,5.044394119358453,0.0012329162354574059
797,LV151,Role of phospholipids in phagocytosis,380.5,0.0062193154078029,0.5,0.0,1.0,0.0035259077227453,True,0,17,17,33,5.044394119358453,0.0012329162354574059
798,LV151,Scavenging of heme from plasma,404.5,0.0062193154078029,0.5,0.0,1.0,0.0035259077227453,True,0,17,17,33,5.044394119358453,0.0012329162354574059
799,LV208,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,534.5,0.004971941425698701,0.5,0.0,1.0,0.0028187357482971,True,0,17,17,33,5.044394119358453,0.0009856369879225522
800,LV208,CD22 mediated BCR regulation,532.5,0.004971941425698701,0.5,0.0,1.0,0.0028187357482971,True,0,17,17,33,5.044394119358453,0.0009856369879225522
801,LV208,Cell surface interactions at the vascular wall,536.5,0.004971941425698701,0.5,0.0,1.0,0.0028187357482971,True,0,17,17,33,5.044394119358453,0.0009856369879225522
802,LV208,FCERI mediated Ca+2 mobilization,522.5,0.004971941425698701,0.5,0.0,1.0,0.0028187357482971,True,0,17,17,33,5.044394119358453,0.0009856369879225522
803,LV208,FCERI mediated MAPK activation,520.5,0.004971941425698701,0.5,0.0,1.0,0.0028187357482971,True,0,17,17,33,5.044394119358453,0.0009856369879225522
804,LV208,FCERI mediated NF-kB activation,524.5,0.004971941425698701,0.5,0.0,1.0,0.0028187357482971,True,0,17,17,33,5.044394119358453,0.0009856369879225522
805,LV208,FCGR activation,512.5,0.004971941425698701,0.5,0.0,1.0,0.0028187357482971,True,0,17,17,33,5.044394119358453,0.0009856369879225522
806,LV208,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,538.5,0.004971941425698701,0.5,0.0,1.0,0.0028187357482971,True,0,17,17,33,5.044394119358453,0.0009856369879225522
807,LV208,Initial triggering of complement,508.5,0.004971941425698701,0.5,0.0,1.0,0.0028187357482971,True,0,17,17,33,5.044394119358453,0.0009856369879225522
808,LV208,Leishmania parasite growth and survival,528.5,0.004971941425698701,0.5,0.0,1.0,0.0028187357482971,True,0,17,17,33,5.044394119358453,0.0009856369879225522
809,LV208,Parasite infection,526.5,0.004971941425698701,0.5,0.0,1.0,0.0028187357482971,True,0,17,17,33,5.044394119358453,0.0009856369879225522
810,LV208,Potential therapeutics for SARS,530.5,0.004971941425698701,0.5,0.0,1.0,0.0028187357482971,True,0,17,17,33,5.044394119358453,0.0009856369879225522
811,LV208,Regulation of Complement cascade,510.5,0.004971941425698701,0.5,0.0,1.0,0.0028187357482971,True,0,17,17,33,5.044394119358453,0.0009856369879225522
812,LV208,Regulation of actin dynamics for phagocytic cup formation,514.5,0.004971941425698701,0.5,0.0,1.0,0.0028187357482971,True,0,17,17,33,5.044394119358453,0.0009856369879225522
813,LV208,Role of LAT2/NTAL/LAB on calcium mobilization,518.5,0.004971941425698701,0.5,0.0,1.0,0.0028187357482971,True,0,17,17,33,5.044394119358453,0.0009856369879225522
814,LV208,Role of phospholipids in phagocytosis,516.5,0.004971941425698701,0.5,0.0,1.0,0.0028187357482971,True,0,17,17,33,5.044394119358453,0.0009856369879225522
815,LV208,Scavenging of heme from plasma,540.5,0.004971941425698701,0.5,0.0,1.0,0.0028187357482971,True,0,17,17,33,5.044394119358453,0.0009856369879225522
816,LV211,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,500.5,0.0028646709848183,0.5,0.0,1.0,0.00162406388584555,True,0,17,17,33,5.044394119358453,0.0005678919840590547
817,LV211,CD22 mediated BCR regulation,498.5,0.0028646709848183,0.5,0.0,1.0,0.00162406388584555,True,0,17,17,33,5.044394119358453,0.0005678919840590547
818,LV211,Cell surface interactions at the vascular wall,502.5,0.0028646709848183,0.5,0.0,1.0,0.00162406388584555,True,0,17,17,33,5.044394119358453,0.0005678919840590547
819,LV211,FCERI mediated Ca+2 mobilization,488.5,0.0028646709848183,0.5,0.0,1.0,0.00162406388584555,True,0,17,17,33,5.044394119358453,0.0005678919840590547
820,LV211,FCERI mediated MAPK activation,486.5,0.0028646709848183,0.5,0.0,1.0,0.00162406388584555,True,0,17,17,33,5.044394119358453,0.0005678919840590547
821,LV211,FCERI mediated NF-kB activation,490.5,0.0028646709848183,0.5,0.0,1.0,0.00162406388584555,True,0,17,17,33,5.044394119358453,0.0005678919840590547
822,LV211,FCGR activation,478.5,0.0028646709848183,0.5,0.0,1.0,0.00162406388584555,True,0,17,17,33,5.044394119358453,0.0005678919840590547
823,LV211,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,504.5,0.0028646709848183,0.5,0.0,1.0,0.00162406388584555,True,0,17,17,33,5.044394119358453,0.0005678919840590547
824,LV211,Initial triggering of complement,474.5,0.0028646709848183,0.5,0.0,1.0,0.00162406388584555,True,0,17,17,33,5.044394119358453,0.0005678919840590547
825,LV211,Leishmania parasite growth and survival,494.5,0.0028646709848183,0.5,0.0,1.0,0.00162406388584555,True,0,17,17,33,5.044394119358453,0.0005678919840590547
826,LV211,Parasite infection,492.5,0.0028646709848183,0.5,0.0,1.0,0.00162406388584555,True,0,17,17,33,5.044394119358453,0.0005678919840590547
827,LV211,Potential therapeutics for SARS,496.5,0.0028646709848183,0.5,0.0,1.0,0.00162406388584555,True,0,17,17,33,5.044394119358453,0.0005678919840590547
828,LV211,Regulation of Complement cascade,476.5,0.0028646709848183,0.5,0.0,1.0,0.00162406388584555,True,0,17,17,33,5.044394119358453,0.0005678919840590547
829,LV211,Regulation of actin dynamics for phagocytic cup formation,480.5,0.0028646709848183,0.5,0.0,1.0,0.00162406388584555,True,0,17,17,33,5.044394119358453,0.0005678919840590547
830,LV211,Role of LAT2/NTAL/LAB on calcium mobilization,484.5,0.0028646709848183,0.5,0.0,1.0,0.00162406388584555,True,0,17,17,33,5.044394119358453,0.0005678919840590547
831,LV211,Role of phospholipids in phagocytosis,482.5,0.0028646709848183,0.5,0.0,1.0,0.00162406388584555,True,0,17,17,33,5.044394119358453,0.0005678919840590547
832,LV211,Scavenging of heme from plasma,506.5,0.0028646709848183,0.5,0.0,1.0,0.00162406388584555,True,0,17,17,33,5.044394119358453,0.0005678919840590547
833,LV214,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,466.5,0.011221172539869598,0.5,0.0,1.0,0.00636160354031015,True,0,17,17,33,5.044394119358453,0.0022244837089170004
834,LV214,CD22 mediated BCR regulation,464.5,0.011221172539869598,0.5,0.0,1.0,0.00636160354031015,True,0,17,17,33,5.044394119358453,0.0022244837089170004
835,LV214,Cell surface interactions at the vascular wall,468.5,0.011221172539869598,0.5,0.0,1.0,0.00636160354031015,True,0,17,17,33,5.044394119358453,0.0022244837089170004
836,LV214,FCERI mediated Ca+2 mobilization,454.5,0.011221172539869598,0.5,0.0,1.0,0.00636160354031015,True,0,17,17,33,5.044394119358453,0.0022244837089170004
837,LV214,FCERI mediated MAPK activation,452.5,0.011221172539869598,0.5,0.0,1.0,0.00636160354031015,True,0,17,17,33,5.044394119358453,0.0022244837089170004
838,LV214,FCERI mediated NF-kB activation,456.5,0.011221172539869598,0.5,0.0,1.0,0.00636160354031015,True,0,17,17,33,5.044394119358453,0.0022244837089170004
839,LV214,FCGR activation,444.5,0.011221172539869598,0.5,0.0,1.0,0.00636160354031015,True,0,17,17,33,5.044394119358453,0.0022244837089170004
840,LV214,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,470.5,0.011221172539869598,0.5,0.0,1.0,0.00636160354031015,True,0,17,17,33,5.044394119358453,0.0022244837089170004
841,LV214,Initial triggering of complement,440.5,0.011221172539869598,0.5,0.0,1.0,0.00636160354031015,True,0,17,17,33,5.044394119358453,0.0022244837089170004
842,LV214,Leishmania parasite growth and survival,460.5,0.011221172539869598,0.5,0.0,1.0,0.00636160354031015,True,0,17,17,33,5.044394119358453,0.0022244837089170004
843,LV214,Parasite infection,458.5,0.011221172539869598,0.5,0.0,1.0,0.00636160354031015,True,0,17,17,33,5.044394119358453,0.0022244837089170004
844,LV214,Potential therapeutics for SARS,462.5,0.011221172539869598,0.5,0.0,1.0,0.00636160354031015,True,0,17,17,33,5.044394119358453,0.0022244837089170004
845,LV214,Regulation of Complement cascade,442.5,0.011221172539869598,0.5,0.0,1.0,0.00636160354031015,True,0,17,17,33,5.044394119358453,0.0022244837089170004
846,LV214,Regulation of actin dynamics for phagocytic cup formation,446.5,0.011221172539869598,0.5,0.0,1.0,0.00636160354031015,True,0,17,17,33,5.044394119358453,0.0022244837089170004
847,LV214,Role of LAT2/NTAL/LAB on calcium mobilization,450.5,0.011221172539869598,0.5,0.0,1.0,0.00636160354031015,True,0,17,17,33,5.044394119358453,0.0022244837089170004
848,LV214,Role of phospholipids in phagocytosis,448.5,0.011221172539869598,0.5,0.0,1.0,0.00636160354031015,True,0,17,17,33,5.044394119358453,0.0022244837089170004
849,LV214,Scavenging of heme from plasma,472.5,0.011221172539869598,0.5,0.0,1.0,0.00636160354031015,True,0,17,17,33,5.044394119358453,0.0022244837089170004
850,LV301,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,602.5,0.000440073287141,0.5,0.0,1.0,0.0002494901287299,True,0,17,17,33,5.044394119358453,8.724006822785064e-05
851,LV301,CD22 mediated BCR regulation,600.5,0.000440073287141,0.5,0.0,1.0,0.0002494901287299,True,0,17,17,33,5.044394119358453,8.724006822785064e-05
852,LV301,Cell surface interactions at the vascular wall,604.5,0.000440073287141,0.5,0.0,1.0,0.0002494901287299,True,0,17,17,33,5.044394119358453,8.724006822785064e-05
853,LV301,FCERI mediated Ca+2 mobilization,590.5,0.000440073287141,0.5,0.0,1.0,0.0002494901287299,True,0,17,17,33,5.044394119358453,8.724006822785064e-05
854,LV301,FCERI mediated MAPK activation,588.5,0.000440073287141,0.5,0.0,1.0,0.0002494901287299,True,0,17,17,33,5.044394119358453,8.724006822785064e-05
855,LV301,FCERI mediated NF-kB activation,592.5,0.000440073287141,0.5,0.0,1.0,0.0002494901287299,True,0,17,17,33,5.044394119358453,8.724006822785064e-05
856,LV301,FCGR activation,580.5,0.000440073287141,0.5,0.0,1.0,0.0002494901287299,True,0,17,17,33,5.044394119358453,8.724006822785064e-05
857,LV301,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,606.5,0.000440073287141,0.5,0.0,1.0,0.0002494901287299,True,0,17,17,33,5.044394119358453,8.724006822785064e-05
858,LV301,Initial triggering of complement,576.5,0.000440073287141,0.5,0.0,1.0,0.0002494901287299,True,0,17,17,33,5.044394119358453,8.724006822785064e-05
859,LV301,Leishmania parasite growth and survival,596.5,0.000440073287141,0.5,0.0,1.0,0.0002494901287299,True,0,17,17,33,5.044394119358453,8.724006822785064e-05
860,LV301,Parasite infection,594.5,0.000440073287141,0.5,0.0,1.0,0.0002494901287299,True,0,17,17,33,5.044394119358453,8.724006822785064e-05
861,LV301,Potential therapeutics for SARS,598.5,0.000440073287141,0.5,0.0,1.0,0.0002494901287299,True,0,17,17,33,5.044394119358453,8.724006822785064e-05
862,LV301,Regulation of Complement cascade,578.5,0.000440073287141,0.5,0.0,1.0,0.0002494901287299,True,0,17,17,33,5.044394119358453,8.724006822785064e-05
863,LV301,Regulation of actin dynamics for phagocytic cup formation,582.5,0.000440073287141,0.5,0.0,1.0,0.0002494901287299,True,0,17,17,33,5.044394119358453,8.724006822785064e-05
864,LV301,Role of LAT2/NTAL/LAB on calcium mobilization,586.5,0.000440073287141,0.5,0.0,1.0,0.0002494901287299,True,0,17,17,33,5.044394119358453,8.724006822785064e-05
865,LV301,Role of phospholipids in phagocytosis,584.5,0.000440073287141,0.5,0.0,1.0,0.0002494901287299,True,0,17,17,33,5.044394119358453,8.724006822785064e-05
866,LV301,Scavenging of heme from plasma,608.5,0.000440073287141,0.5,0.0,1.0,0.0002494901287299,True,0,17,17,33,5.044394119358453,8.724006822785064e-05
867,LV319,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,568.5,0.0131553474346211,0.5,0.0,1.0,0.0074581425886414005,True,0,17,17,33,5.044394119358453,0.0026079142754004718
868,LV319,CD22 mediated BCR regulation,566.5,0.0131553474346211,0.5,0.0,1.0,0.0074581425886414005,True,0,17,17,33,5.044394119358453,0.0026079142754004718
869,LV319,Cell surface interactions at the vascular wall,570.5,0.0131553474346211,0.5,0.0,1.0,0.0074581425886414005,True,0,17,17,33,5.044394119358453,0.0026079142754004718
870,LV319,FCERI mediated Ca+2 mobilization,556.5,0.0131553474346211,0.5,0.0,1.0,0.0074581425886414005,True,0,17,17,33,5.044394119358453,0.0026079142754004718
871,LV319,FCERI mediated MAPK activation,554.5,0.0131553474346211,0.5,0.0,1.0,0.0074581425886414005,True,0,17,17,33,5.044394119358453,0.0026079142754004718
872,LV319,FCERI mediated NF-kB activation,558.5,0.0131553474346211,0.5,0.0,1.0,0.0074581425886414005,True,0,17,17,33,5.044394119358453,0.0026079142754004718
873,LV319,FCGR activation,546.5,0.0131553474346211,0.5,0.0,1.0,0.0074581425886414005,True,0,17,17,33,5.044394119358453,0.0026079142754004718
874,LV319,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,572.5,0.0131553474346211,0.5,0.0,1.0,0.0074581425886414005,True,0,17,17,33,5.044394119358453,0.0026079142754004718
875,LV319,Initial triggering of complement,542.5,0.0131553474346211,0.5,0.0,1.0,0.0074581425886414005,True,0,17,17,33,5.044394119358453,0.0026079142754004718
876,LV319,Leishmania parasite growth and survival,562.5,0.0131553474346211,0.5,0.0,1.0,0.0074581425886414005,True,0,17,17,33,5.044394119358453,0.0026079142754004718
877,LV319,Parasite infection,560.5,0.0131553474346211,0.5,0.0,1.0,0.0074581425886414005,True,0,17,17,33,5.044394119358453,0.0026079142754004718
878,LV319,Potential therapeutics for SARS,564.5,0.0131553474346211,0.5,0.0,1.0,0.0074581425886414005,True,0,17,17,33,5.044394119358453,0.0026079142754004718
879,LV319,Regulation of Complement cascade,544.5,0.0131553474346211,0.5,0.0,1.0,0.0074581425886414005,True,0,17,17,33,5.044394119358453,0.0026079142754004718
880,LV319,Regulation of actin dynamics for phagocytic cup formation,548.5,0.0131553474346211,0.5,0.0,1.0,0.0074581425886414005,True,0,17,17,33,5.044394119358453,0.0026079142754004718
881,LV319,Role of LAT2/NTAL/LAB on calcium mobilization,552.5,0.0131553474346211,0.5,0.0,1.0,0.0074581425886414005,True,0,17,17,33,5.044394119358453,0.0026079142754004718
882,LV319,Role of phospholipids in phagocytosis,550.5,0.0131553474346211,0.5,0.0,1.0,0.0074581425886414005,True,0,17,17,33,5.044394119358453,0.0026079142754004718
883,LV319,Scavenging of heme from plasma,574.5,0.0131553474346211,0.5,0.0,1.0,0.0074581425886414005,True,0,17,17,33,5.044394119358453,0.0026079142754004718
884,LV321,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,1834.5,0.0062276950481497,0.5,0.0,1.0,0.00353065838044245,True,0,17,17,33,5.044394119358453,0.001234577414213174
885,LV321,CD22 mediated BCR regulation,1832.5,0.0062276950481497,0.5,0.0,1.0,0.00353065838044245,True,0,17,17,33,5.044394119358453,0.001234577414213174
886,LV321,Cell surface interactions at the vascular wall,1836.5,0.0062276950481497,0.5,0.0,1.0,0.00353065838044245,True,0,17,17,33,5.044394119358453,0.001234577414213174
887,LV321,FCERI mediated Ca+2 mobilization,1822.5,0.0062276950481497,0.5,0.0,1.0,0.00353065838044245,True,0,17,17,33,5.044394119358453,0.001234577414213174
888,LV321,FCERI mediated MAPK activation,1820.5,0.0062276950481497,0.5,0.0,1.0,0.00353065838044245,True,0,17,17,33,5.044394119358453,0.001234577414213174
889,LV321,FCERI mediated NF-kB activation,1824.5,0.0062276950481497,0.5,0.0,1.0,0.00353065838044245,True,0,17,17,33,5.044394119358453,0.001234577414213174
890,LV321,FCGR activation,1812.5,0.0062276950481497,0.5,0.0,1.0,0.00353065838044245,True,0,17,17,33,5.044394119358453,0.001234577414213174
891,LV321,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,1838.5,0.0062276950481497,0.5,0.0,1.0,0.00353065838044245,True,0,17,17,33,5.044394119358453,0.001234577414213174
892,LV321,Initial triggering of complement,1808.5,0.0062276950481497,0.5,0.0,1.0,0.00353065838044245,True,0,17,17,33,5.044394119358453,0.001234577414213174
893,LV321,Leishmania parasite growth and survival,1828.5,0.0062276950481497,0.5,0.0,1.0,0.00353065838044245,True,0,17,17,33,5.044394119358453,0.001234577414213174
894,LV321,Parasite infection,1826.5,0.0062276950481497,0.5,0.0,1.0,0.00353065838044245,True,0,17,17,33,5.044394119358453,0.001234577414213174
895,LV321,Potential therapeutics for SARS,1830.5,0.0062276950481497,0.5,0.0,1.0,0.00353065838044245,True,0,17,17,33,5.044394119358453,0.001234577414213174
896,LV321,Regulation of Complement cascade,1810.5,0.0062276950481497,0.5,0.0,1.0,0.00353065838044245,True,0,17,17,33,5.044394119358453,0.001234577414213174
897,LV321,Regulation of actin dynamics for phagocytic cup formation,1814.5,0.0062276950481497,0.5,0.0,1.0,0.00353065838044245,True,0,17,17,33,5.044394119358453,0.001234577414213174
898,LV321,Role of LAT2/NTAL/LAB on calcium mobilization,1818.5,0.0062276950481497,0.5,0.0,1.0,0.00353065838044245,True,0,17,17,33,5.044394119358453,0.001234577414213174
899,LV321,Role of phospholipids in phagocytosis,1816.5,0.0062276950481497,0.5,0.0,1.0,0.00353065838044245,True,0,17,17,33,5.044394119358453,0.001234577414213174
900,LV321,Scavenging of heme from plasma,1840.5,0.0062276950481497,0.5,0.0,1.0,0.00353065838044245,True,0,17,17,33,5.044394119358453,0.001234577414213174
901,LV325,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,636.5,0.0309580532098754,0.5,0.0,1.0,0.01755100549441705,True,0,17,17,33,5.044394119358453,0.006137120232352632
902,LV325,CD22 mediated BCR regulation,634.5,0.0309580532098754,0.5,0.0,1.0,0.01755100549441705,True,0,17,17,33,5.044394119358453,0.006137120232352632
903,LV325,Cell surface interactions at the vascular wall,638.5,0.0309580532098754,0.5,0.0,1.0,0.01755100549441705,True,0,17,17,33,5.044394119358453,0.006137120232352632
904,LV325,FCERI mediated Ca+2 mobilization,624.5,0.0309580532098754,0.5,0.0,1.0,0.01755100549441705,True,0,17,17,33,5.044394119358453,0.006137120232352632
905,LV325,FCERI mediated MAPK activation,622.5,0.0309580532098754,0.5,0.0,1.0,0.01755100549441705,True,0,17,17,33,5.044394119358453,0.006137120232352632
906,LV325,FCERI mediated NF-kB activation,626.5,0.0309580532098754,0.5,0.0,1.0,0.01755100549441705,True,0,17,17,33,5.044394119358453,0.006137120232352632
907,LV325,FCGR activation,614.5,0.0309580532098754,0.5,0.0,1.0,0.01755100549441705,True,0,17,17,33,5.044394119358453,0.006137120232352632
908,LV325,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,640.5,0.0309580532098754,0.5,0.0,1.0,0.01755100549441705,True,0,17,17,33,5.044394119358453,0.006137120232352632
909,LV325,Initial triggering of complement,610.5,0.0309580532098754,0.5,0.0,1.0,0.01755100549441705,True,0,17,17,33,5.044394119358453,0.006137120232352632
910,LV325,Leishmania parasite growth and survival,630.5,0.0309580532098754,0.5,0.0,1.0,0.01755100549441705,True,0,17,17,33,5.044394119358453,0.006137120232352632
911,LV325,Parasite infection,628.5,0.0309580532098754,0.5,0.0,1.0,0.01755100549441705,True,0,17,17,33,5.044394119358453,0.006137120232352632
912,LV325,Potential therapeutics for SARS,632.5,0.0309580532098754,0.5,0.0,1.0,0.01755100549441705,True,0,17,17,33,5.044394119358453,0.006137120232352632
913,LV325,Regulation of Complement cascade,612.5,0.0309580532098754,0.5,0.0,1.0,0.01755100549441705,True,0,17,17,33,5.044394119358453,0.006137120232352632
914,LV325,Regulation of actin dynamics for phagocytic cup formation,616.5,0.0309580532098754,0.5,0.0,1.0,0.01755100549441705,True,0,17,17,33,5.044394119358453,0.006137120232352632
915,LV325,Role of LAT2/NTAL/LAB on calcium mobilization,620.5,0.0309580532098754,0.5,0.0,1.0,0.01755100549441705,True,0,17,17,33,5.044394119358453,0.006137120232352632
916,LV325,Role of phospholipids in phagocytosis,618.5,0.0309580532098754,0.5,0.0,1.0,0.01755100549441705,True,0,17,17,33,5.044394119358453,0.006137120232352632
917,LV325,Scavenging of heme from plasma,642.5,0.0309580532098754,0.5,0.0,1.0,0.01755100549441705,True,0,17,17,33,5.044394119358453,0.006137120232352632
918,LV327,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,670.5,0.0035847731802672,0.5,0.0,1.0,0.0020323104090743498,True,0,17,17,33,5.044394119358453,0.0007106449447536648
919,LV327,CD22 mediated BCR regulation,668.5,0.0035847731802672,0.5,0.0,1.0,0.0020323104090743498,True,0,17,17,33,5.044394119358453,0.0007106449447536648
920,LV327,Cell surface interactions at the vascular wall,672.5,0.0035847731802672,0.5,0.0,1.0,0.0020323104090743498,True,0,17,17,33,5.044394119358453,0.0007106449447536648
921,LV327,FCERI mediated Ca+2 mobilization,658.5,0.0035847731802672,0.5,0.0,1.0,0.0020323104090743498,True,0,17,17,33,5.044394119358453,0.0007106449447536648
922,LV327,FCERI mediated MAPK activation,656.5,0.0035847731802672,0.5,0.0,1.0,0.0020323104090743498,True,0,17,17,33,5.044394119358453,0.0007106449447536648
923,LV327,FCERI mediated NF-kB activation,660.5,0.0035847731802672,0.5,0.0,1.0,0.0020323104090743498,True,0,17,17,33,5.044394119358453,0.0007106449447536648
924,LV327,FCGR activation,648.5,0.0035847731802672,0.5,0.0,1.0,0.0020323104090743498,True,0,17,17,33,5.044394119358453,0.0007106449447536648
925,LV327,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,674.5,0.0035847731802672,0.5,0.0,1.0,0.0020323104090743498,True,0,17,17,33,5.044394119358453,0.0007106449447536648
926,LV327,Initial triggering of complement,644.5,0.0035847731802672,0.5,0.0,1.0,0.0020323104090743498,True,0,17,17,33,5.044394119358453,0.0007106449447536648
927,LV327,Leishmania parasite growth and survival,664.5,0.0035847731802672,0.5,0.0,1.0,0.0020323104090743498,True,0,17,17,33,5.044394119358453,0.0007106449447536648
928,LV327,Parasite infection,662.5,0.0035847731802672,0.5,0.0,1.0,0.0020323104090743498,True,0,17,17,33,5.044394119358453,0.0007106449447536648
929,LV327,Potential therapeutics for SARS,666.5,0.0035847731802672,0.5,0.0,1.0,0.0020323104090743498,True,0,17,17,33,5.044394119358453,0.0007106449447536648
930,LV327,Regulation of Complement cascade,646.5,0.0035847731802672,0.5,0.0,1.0,0.0020323104090743498,True,0,17,17,33,5.044394119358453,0.0007106449447536648
931,LV327,Regulation of actin dynamics for phagocytic cup formation,650.5,0.0035847731802672,0.5,0.0,1.0,0.0020323104090743498,True,0,17,17,33,5.044394119358453,0.0007106449447536648
932,LV327,Role of LAT2/NTAL/LAB on calcium mobilization,654.5,0.0035847731802672,0.5,0.0,1.0,0.0020323104090743498,True,0,17,17,33,5.044394119358453,0.0007106449447536648
933,LV327,Role of phospholipids in phagocytosis,652.5,0.0035847731802672,0.5,0.0,1.0,0.0020323104090743498,True,0,17,17,33,5.044394119358453,0.0007106449447536648
934,LV327,Scavenging of heme from plasma,676.5,0.0035847731802672,0.5,0.0,1.0,0.0020323104090743498,True,0,17,17,33,5.044394119358453,0.0007106449447536648
935,LV657,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,704.5,0.023706924949069,0.5,0.0,1.0,0.013440133564474752,True,0,17,17,33,5.044394119358453,0.004699657558098187
936,LV657,CD22 mediated BCR regulation,702.5,0.023706924949069,0.5,0.0,1.0,0.013440133564474752,True,0,17,17,33,5.044394119358453,0.004699657558098187
937,LV657,Cell surface interactions at the vascular wall,706.5,0.023706924949069,0.5,0.0,1.0,0.013440133564474752,True,0,17,17,33,5.044394119358453,0.004699657558098187
938,LV657,FCERI mediated Ca+2 mobilization,692.5,0.023706924949069,0.5,0.0,1.0,0.013440133564474752,True,0,17,17,33,5.044394119358453,0.004699657558098187
939,LV657,FCERI mediated MAPK activation,690.5,0.023706924949069,0.5,0.0,1.0,0.013440133564474752,True,0,17,17,33,5.044394119358453,0.004699657558098187
940,LV657,FCERI mediated NF-kB activation,694.5,0.023706924949069,0.5,0.0,1.0,0.013440133564474752,True,0,17,17,33,5.044394119358453,0.004699657558098187
941,LV657,FCGR activation,682.5,0.023706924949069,0.5,0.0,1.0,0.013440133564474752,True,0,17,17,33,5.044394119358453,0.004699657558098187
942,LV657,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,708.5,0.023706924949069,0.5,0.0,1.0,0.013440133564474752,True,0,17,17,33,5.044394119358453,0.004699657558098187
943,LV657,Initial triggering of complement,678.5,0.023706924949069,0.5,0.0,1.0,0.013440133564474752,True,0,17,17,33,5.044394119358453,0.004699657558098187
944,LV657,Leishmania parasite growth and survival,698.5,0.023706924949069,0.5,0.0,1.0,0.013440133564474752,True,0,17,17,33,5.044394119358453,0.004699657558098187
945,LV657,Parasite infection,696.5,0.023706924949069,0.5,0.0,1.0,0.013440133564474752,True,0,17,17,33,5.044394119358453,0.004699657558098187
946,LV657,Potential therapeutics for SARS,700.5,0.023706924949069,0.5,0.0,1.0,0.013440133564474752,True,0,17,17,33,5.044394119358453,0.004699657558098187
947,LV657,Regulation of Complement cascade,680.5,0.023706924949069,0.5,0.0,1.0,0.013440133564474752,True,0,17,17,33,5.044394119358453,0.004699657558098187
948,LV657,Regulation of actin dynamics for phagocytic cup formation,684.5,0.023706924949069,0.5,0.0,1.0,0.013440133564474752,True,0,17,17,33,5.044394119358453,0.004699657558098187
949,LV657,Role of LAT2/NTAL/LAB on calcium mobilization,688.5,0.023706924949069,0.5,0.0,1.0,0.013440133564474752,True,0,17,17,33,5.044394119358453,0.004699657558098187
950,LV657,Role of phospholipids in phagocytosis,686.5,0.023706924949069,0.5,0.0,1.0,0.013440133564474752,True,0,17,17,33,5.044394119358453,0.004699657558098187
951,LV657,Scavenging of heme from plasma,710.5,0.023706924949069,0.5,0.0,1.0,0.013440133564474752,True,0,17,17,33,5.044394119358453,0.004699657558098187
952,LV743,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,1332.5,0.0098406341163443,0.5,0.0,1.0,0.0055789368366811,True,0,17,17,33,5.044394119358453,0.001950805960735644
953,LV743,CD22 mediated BCR regulation,1330.5,0.0098406341163443,0.5,0.0,1.0,0.0055789368366811,True,0,17,17,33,5.044394119358453,0.001950805960735644
954,LV743,Cell surface interactions at the vascular wall,1334.5,0.0098406341163443,0.5,0.0,1.0,0.0055789368366811,True,0,17,17,33,5.044394119358453,0.001950805960735644
955,LV743,FCERI mediated Ca+2 mobilization,1320.5,0.0098406341163443,0.5,0.0,1.0,0.0055789368366811,True,0,17,17,33,5.044394119358453,0.001950805960735644
956,LV743,FCERI mediated MAPK activation,1318.5,0.0098406341163443,0.5,0.0,1.0,0.0055789368366811,True,0,17,17,33,5.044394119358453,0.001950805960735644
957,LV743,FCERI mediated NF-kB activation,1322.5,0.0098406341163443,0.5,0.0,1.0,0.0055789368366811,True,0,17,17,33,5.044394119358453,0.001950805960735644
958,LV743,FCGR activation,1310.5,0.0098406341163443,0.5,0.0,1.0,0.0055789368366811,True,0,17,17,33,5.044394119358453,0.001950805960735644
959,LV743,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,1336.5,0.0098406341163443,0.5,0.0,1.0,0.0055789368366811,True,0,17,17,33,5.044394119358453,0.001950805960735644
960,LV743,Initial triggering of complement,1306.5,0.0098406341163443,0.5,0.0,1.0,0.0055789368366811,True,0,17,17,33,5.044394119358453,0.001950805960735644
961,LV743,Leishmania parasite growth and survival,1326.5,0.0098406341163443,0.5,0.0,1.0,0.0055789368366811,True,0,17,17,33,5.044394119358453,0.001950805960735644
962,LV743,Parasite infection,1324.5,0.0098406341163443,0.5,0.0,1.0,0.0055789368366811,True,0,17,17,33,5.044394119358453,0.001950805960735644
963,LV743,Potential therapeutics for SARS,1328.5,0.0098406341163443,0.5,0.0,1.0,0.0055789368366811,True,0,17,17,33,5.044394119358453,0.001950805960735644
964,LV743,Regulation of Complement cascade,1308.5,0.0098406341163443,0.5,0.0,1.0,0.0055789368366811,True,0,17,17,33,5.044394119358453,0.001950805960735644
965,LV743,Regulation of actin dynamics for phagocytic cup formation,1312.5,0.0098406341163443,0.5,0.0,1.0,0.0055789368366811,True,0,17,17,33,5.044394119358453,0.001950805960735644
966,LV743,Role of LAT2/NTAL/LAB on calcium mobilization,1316.5,0.0098406341163443,0.5,0.0,1.0,0.0055789368366811,True,0,17,17,33,5.044394119358453,0.001950805960735644
967,LV743,Role of phospholipids in phagocytosis,1314.5,0.0098406341163443,0.5,0.0,1.0,0.0055789368366811,True,0,17,17,33,5.044394119358453,0.001950805960735644
968,LV743,Scavenging of heme from plasma,1338.5,0.0098406341163443,0.5,0.0,1.0,0.0055789368366811,True,0,17,17,33,5.044394119358453,0.001950805960735644
969,Late endosomal microautophagy,Autophagy,2446.5,0.010999574859435,0.5,3.0,4.0,0.25711484112026955,True,3,2,5,5,2.321928094887362,0.004737259040732093
970,Late endosomal microautophagy,Late endosomal microautophagy,2150.5,0.01785541794505665,0.5,1.5,2.5,0.20660074305119763,False,3,2,5,5,2.321928094887362,0.007689909943538895
971,Leishmania infection,Infectious disease,2324.5,0.0066380987221013,0.5,2.0,3.0,0.0944383227753253,True,3,1,4,40,5.321928094887363,0.0012473108624820293
972,Leishmania parasite growth and survival,Leishmania infection,2028.5,0.0030899989528045003,0.5,1.0,2.0,0.0292491110081204,True,32,1,33,37,5.20945336562895,0.0005931522438019631
973,MAPK family signaling cascades,Signal Transduction,2338.5,0.001458922572423,0.5,3.0,4.0,0.03410228578912615,True,1,1,2,8,3.0,0.000486307524141
974,MAPK1/MAPK3 signaling,MAPK family signaling cascades,2278.5,0.0048120345774203006,0.5,2.0,3.0,0.06845943298725089,True,1,1,2,8,3.0,0.0016040115258067669
975,MASP1,Initial triggering of complement,1756.5,0.0221800182809106,0.5,0.0,1.0,0.0125744865181107,True,0,3,3,13,3.700439718141092,0.005993887205397493
976,MASP1,SARS-CoV-2 Infection,1758.5,0.0221800182809106,0.5,0.0,1.0,0.0125744865181107,True,0,3,3,13,3.700439718141092,0.005993887205397493
977,MASP1,Scavenging by Class A Receptors,1760.5,0.0221800182809106,0.5,0.0,1.0,0.0125744865181107,True,0,3,3,13,3.700439718141092,0.005993887205397493
978,MBL2,Initial triggering of complement,1668.5,0.0018156773566620002,0.5,0.0,1.0,0.0010293594059945,True,0,2,2,10,3.321928094887362,0.0005465733468031508
979,MBL2,SARS-CoV-2 Infection,1670.5,0.0018156773566620002,0.5,0.0,1.0,0.0010293594059945,True,0,2,2,10,3.321928094887362,0.0005465733468031508
980,Membrane Trafficking,Vesicle-mediated transport,2360.5,0.0086058018078712,0.5,3.0,4.0,0.20116044418256673,True,1,1,2,7,2.807354922057604,0.003065448454790932
981,Metabolism,root,2484.5,0.013571046436238299,0.5,4.0,5.0,0.7802084259844808,True,7,1,8,36,5.169925001442312,0.0026249987054845535
982,Metabolism of Angiotensinogen to Angiotensins,Metabolism of Angiotensinogen to Angiotensins,2102.5,0.0082104343444163,0.5,1.0,2.0,0.07771779512959046,False,2,2,4,5,2.321928094887362,0.0035360416037407876
983,Metabolism of Angiotensinogen to Angiotensins,Peptide hormone metabolism,2306.5,0.0075937882527077,0.5,2.0,3.0,0.10803464306865196,True,2,2,4,5,2.321928094887362,0.003270466587414318
984,Metabolism of carbohydrates,Metabolism,2444.5,0.0009286118912678,0.5,3.0,4.0,0.0217062842825178,True,1,1,2,6,2.584962500721156,0.00035923611696832535
985,Metabolism of fat-soluble vitamins,Metabolism of vitamins and cofactors,2166.5,0.0165807212979866,0.5,2.0,3.0,0.23588915672095967,True,1,1,2,9,3.169925001442312,0.005230635201287851
986,Metabolism of lipids,Metabolism,2364.5,0.0033835417178142,0.5,3.0,4.0,0.07909021960547945,True,3,1,4,14,3.807354922057604,0.0008886856589628467
987,Metabolism of porphyrins,Metabolism,2428.5,0.00015581993020042707,0.5,3.0,4.0,0.0036422877346471497,True,1,1,2,5,2.321928094887362,6.710799121795629e-05
988,Metabolism of proteins,root,2488.5,0.010836922913479301,0.5,4.0,5.0,0.6230218582307356,True,4,1,5,37,5.20945336562895,0.002080241851281249
989,Metabolism of steroid hormones,Metabolism of steroids,1904.5,0.0008843824118661,0.5,1.0,2.0,0.0083713294837287,True,1,1,2,6,2.584962500721156,0.00034212581869925534
990,Metabolism of steroids,Metabolism of lipids,2190.5,0.0008946724869672,0.5,2.0,3.0,0.01272824834935075,True,1,1,2,6,2.584962500721156,0.00034610656313877015
991,Metabolism of vitamins and cofactors,Metabolism,2454.5,0.011898643386255101,0.5,3.0,4.0,0.27813054985298413,True,1,1,2,9,3.169925001442312,0.0037536040697622917
992,Metal ion SLC transporters,"Transport of bile salts and organic acids, metal ions and amine compounds",1946.5,0.0062201136680741,0.5,1.0,2.0,0.05887794719007905,True,1,1,2,6,2.584962500721156,0.002406268433812407
993,Metal sequestration by antimicrobial proteins,Antimicrobial peptides,1980.5,0.0088326135027653,0.5,1.0,2.0,0.08360717811885254,True,2,1,3,7,2.807354922057604,0.003146240410632362
994,Miscellaneous transport and binding events,Miscellaneous transport and binding events,2128.5,0.03963798220927035,0.5,1.5,2.5,0.4591173775352361,False,2,2,4,4,2.0,0.019818991104635177
995,Miscellaneous transport and binding events,Transport of small molecules,2356.5,0.0249326029852519,0.5,3.0,4.0,0.5827990933457818,True,2,2,4,4,2.0,0.01246630149262595
996,Molecules associated with elastic fibres,Elastic fibre formation,2244.5,0.0043657646354568,0.5,2.0,3.0,0.062110478777853445,True,3,2,5,6,2.584962500721156,0.0016889083049517483
997,Molecules associated with elastic fibres,Molecules associated with elastic fibres,2074.5,0.0056113170118456,0.5,1.0,2.0,0.05311523941853065,False,3,2,5,6,2.584962500721156,0.00217075373831541
998,MyD88 deficiency (TLR2/4),Diseases associated with the TLR signaling cascade,1956.5,0.014220366499734401,0.5,1.0,2.0,0.13460621983362375,True,5,1,6,10,3.321928094887362,0.004280756865755271
999,NR1H2 and NR1H3-mediated signaling,Signaling by Nuclear Receptors,2330.5,0.0031842999092147,0.5,2.0,3.0,0.0453021196624598,True,1,1,2,7,2.807354922057604,0.0011342705135696986
1000,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,NR1H2 and NR1H3-mediated signaling,2012.5,0.0050071282577923,0.5,1.0,2.0,0.0473961488275381,True,2,1,3,7,2.807354922057604,0.001783575072197287
1001,Neurodegenerative Diseases,Defective Intrinsic Pathway for Apoptosis,1988.5,0.0032823880953666,0.5,1.0,2.0,0.0310702156342072,True,1,1,2,6,2.584962500721156,0.0012698010491258094
1002,Neutrophil degranulation,Innate Immune System,2184.5,0.0250811247642969,0.5,2.0,3.0,0.3568219538785447,True,17,2,19,20,4.321928094887363,0.005803225832000002
1003,Neutrophil degranulation,Neutrophil degranulation,2078.5,0.035920607206467295,0.5,1.0,2.0,0.3400149461887142,False,17,2,19,20,4.321928094887363,0.008311245911045971
1004,Non-integrin membrane-ECM interactions,Extracellular matrix organization,2398.5,0.0110897845883369,0.5,3.0,4.0,0.25922349171908804,True,1,1,2,6,2.584962500721156,0.004290114299624485
1005,Nuclear signaling by ERBB4,Signaling by ERBB4,1868.5,0.0063617020466988,0.5,1.0,2.0,0.06021818525070785,True,1,1,2,6,2.584962500721156,0.0024610422955551594
1006,O-glycosylation of TSR domain-containing proteins,O-linked glycosylation,1952.5,0.0045978270729406,0.5,1.0,2.0,0.0435218123069332,True,2,1,3,7,2.807354922057604,0.0016377790484612823
1007,O-linked glycosylation,Post-translational protein modification,2160.5,0.0028629856448489,0.5,2.0,3.0,0.040730873966842496,True,1,1,2,7,2.807354922057604,0.0010198160632822737
1008,O2/CO2 exchange in erythrocytes,Transport of small molecules,2432.5,0.0034921091288906,0.5,3.0,4.0,0.08162798065592536,True,2,1,3,8,3.0,0.0011640363762968667
1009,Oncogenic MAPK signaling,Diseases of signal transduction by growth factor receptors and second messengers,2232.5,0.0029848583015367,0.5,2.0,3.0,0.042464721228176,True,6,1,7,13,3.700439718141092,0.0008066225986343421
1010,PCOC1,Collagen biosynthesis and modifying enzymes,1852.5,0.0006804806212228,0.5,0.0,1.0,0.00038578391996945,True,0,2,2,7,2.807354922057604,0.00024239208796729308
1011,PCOC1,Crosslinking of collagen fibrils,1850.5,0.0006804806212228,0.5,0.0,1.0,0.00038578391996945,True,0,2,2,7,2.807354922057604,0.00024239208796729308
1012,PHLD,Post-translational modification: synthesis of GPI-anchored proteins,1806.5,0.001772931675264,0.5,0.0,1.0,0.0010051256570571,True,0,1,1,5,2.321928094887362,0.0007635601116019942
1013,PIGR,Neutrophil degranulation,984.5,0.0030630815329496996,0.5,0.0,1.0,0.0017365484983887,True,0,1,1,5,2.321928094887362,0.0013191974117089493
1014,PLF4,Cell surface interactions at the vascular wall,1222.5,0.0582766304335231,0.5,0.0,1.0,0.03303868799503855,True,0,6,6,19,4.247927513443585,0.013718838245024834
1015,PLF4,Class A/1 (Rhodopsin-like receptors),1216.5,0.0582766304335231,0.5,0.0,1.0,0.03303868799503855,True,0,6,6,19,4.247927513443585,0.013718838245024834
1016,PLF4,Common Pathway of Fibrin Clot Formation,1224.5,0.0582766304335231,0.5,0.0,1.0,0.03303868799503855,True,0,6,6,19,4.247927513443585,0.013718838245024834
1017,PLF4,G alpha (i) signalling events,1218.5,0.0582766304335231,0.5,0.0,1.0,0.03303868799503855,True,0,6,6,19,4.247927513443585,0.013718838245024834
1018,PLF4,Platelet degranulation ,1220.5,0.0582766304335231,0.5,0.0,1.0,0.03303868799503855,True,0,6,6,19,4.247927513443585,0.013718838245024834
1019,PLF4,Transcriptional regulation by RUNX1,1214.5,0.0582766304335231,0.5,0.0,1.0,0.03303868799503855,True,0,6,6,19,4.247927513443585,0.013718838245024834
1020,PLMN,Activation of Matrix Metalloproteinases,138.5,0.0153683028366971,0.5,0.0,1.0,0.00871273027726095,True,0,5,5,15,3.9068905956085187,0.003933640438760074
1021,PLMN,Dissolution of Fibrin Clot,136.5,0.0153683028366971,0.5,0.0,1.0,0.00871273027726095,True,0,5,5,15,3.9068905956085187,0.003933640438760074
1022,PLMN,Platelet degranulation ,134.5,0.0153683028366971,0.5,0.0,1.0,0.00871273027726095,True,0,5,5,15,3.9068905956085187,0.003933640438760074
1023,PLMN,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),140.5,0.0153683028366971,0.5,0.0,1.0,0.00871273027726095,True,0,5,5,15,3.9068905956085187,0.003933640438760074
1024,PLMN,Signaling by PDGF,142.5,0.0153683028366971,0.5,0.0,1.0,0.00871273027726095,True,0,5,5,15,3.9068905956085187,0.003933640438760074
1025,PON1,Arachidonic acid metabolism,1728.5,0.0106761788409135,0.5,0.0,1.0,0.00605263103031555,True,0,2,2,8,3.0,0.0035587262803045
1026,PON1,Atorvastatin ADME,1730.5,0.0106761788409135,0.5,0.0,1.0,0.00605263103031555,True,0,2,2,8,3.0,0.0035587262803045
1027,PON3,Arachidonic acid metabolism,1854.5,0.0079206453765582,0.5,0.0,1.0,0.00449044032519965,True,0,2,2,8,3.0,0.0026402151255194
1028,PON3,Atorvastatin ADME,1856.5,0.0079206453765582,0.5,0.0,1.0,0.00449044032519965,True,0,2,2,8,3.0,0.0026402151255194
1029,PPARA activates gene expression,Regulation of lipid metabolism by PPARalpha,1942.5,0.0142279067698799,0.5,1.0,2.0,0.1346775940320901,True,2,1,3,7,2.807354922057604,0.005068082648934105
1030,PRDX2,Detoxification of Reactive Oxygen Species,1754.5,0.0073200166289825,0.5,0.0,1.0,0.0041499267154665,True,0,3,3,14,3.807354922057604,0.0019225989640667786
1031,PRDX2,Neurodegenerative Diseases,1752.5,0.0073200166289825,0.5,0.0,1.0,0.0041499267154665,True,0,3,3,14,3.807354922057604,0.0019225989640667786
1032,PRDX2,Transcriptional Regulation by TP53,1750.5,0.0073200166289825,0.5,0.0,1.0,0.0041499267154665,True,0,3,3,14,3.807354922057604,0.0019225989640667786
1033,PROP,Activation of C3 and C5,1734.5,0.0127411914808755,0.5,0.0,1.0,0.00722334573722265,True,0,6,6,17,4.087462841250339,0.0031171394030283144
1034,PROP,Diseases associated with O-glycosylation of proteins,1738.5,0.0127411914808755,0.5,0.0,1.0,0.00722334573722265,True,0,6,6,17,4.087462841250339,0.0031171394030283144
1035,PROP,Initial triggering of complement,1732.5,0.0127411914808755,0.5,0.0,1.0,0.00722334573722265,True,0,6,6,17,4.087462841250339,0.0031171394030283144
1036,PROP,Neutrophil degranulation,1742.5,0.0127411914808755,0.5,0.0,1.0,0.00722334573722265,True,0,6,6,17,4.087462841250339,0.0031171394030283144
1037,PROP,O-glycosylation of TSR domain-containing proteins,1740.5,0.0127411914808755,0.5,0.0,1.0,0.00722334573722265,True,0,6,6,17,4.087462841250339,0.0031171394030283144
1038,PROP,Regulation of Complement cascade,1736.5,0.0127411914808755,0.5,0.0,1.0,0.00722334573722265,True,0,6,6,17,4.087462841250339,0.0031171394030283144
1039,Paradoxical activation of RAF signaling by kinase inactive BRAF,Oncogenic MAPK signaling,1976.5,0.0003182524973025,0.5,1.0,2.0,0.00301249377892725,True,3,1,4,8,3.0,0.0001060841657675
1040,Parasite infection,Leishmania infection,2024.5,0.0007832648462304,0.5,1.0,2.0,0.007414177411082849,True,32,1,33,37,5.20945336562895,0.00015035451730852274
1041,Peptide hormone metabolism,Metabolism of proteins,2410.5,0.0034684841543091,0.5,3.0,4.0,0.08107574735021865,True,1,1,2,5,2.321928094887362,0.0014937948173099468
1042,Peroxisomal protein import,Peroxisomal protein import,2186.5,0.0017913080396456432,0.5,1.5,2.5,0.02047297184149785,False,2,2,4,4,2.0,0.0008956540198228216
1043,Peroxisomal protein import,Protein localization,2414.5,0.0012256018703572001,0.5,3.0,4.0,0.02864841907078855,True,2,2,4,4,2.0,0.0006128009351786001
1044,Plasma lipoprotein assembly,"Plasma lipoprotein assembly, remodeling, and clearance",2234.5,0.0029842258904267003,0.5,2.0,3.0,0.04245572409706445,True,3,1,4,13,3.700439718141092,0.0008064516970231364
1045,"Plasma lipoprotein assembly, remodeling, and clearance",Transport of small molecules,2408.5,0.0131646916146765,0.5,3.0,4.0,0.3077244017300813,True,3,1,4,26,4.700439718141092,0.0028007361872694776
1046,Plasma lipoprotein clearance,"Plasma lipoprotein assembly, remodeling, and clearance",2216.5,0.0017881038900213,0.5,2.0,3.0,0.025438840154549,True,4,1,5,12,3.584962500721156,0.0004987789662127854
1047,Plasma lipoprotein remodeling,"Plasma lipoprotein assembly, remodeling, and clearance",2192.5,0.011779205137874001,0.5,2.0,3.0,0.167579366233826,True,4,1,5,15,3.9068905956085187,0.0030149820809198596
1048,Platelet Adhesion to exposed collagen,Hemostasis,2400.5,0.0027651676352213,0.5,3.0,4.0,0.06463573786135995,True,2,2,4,4,2.0,0.00138258381761065
1049,Platelet Adhesion to exposed collagen,Platelet Adhesion to exposed collagen,2153.5,0.005272123320133,0.5,1.5,2.5,0.06276404715232035,False,2,2,4,4,2.0,0.0026360616600665
1050,Platelet Aggregation (Plug Formation),"Platelet activation, signaling and aggregation",2152.5,0.0,0.5,2.0,3.0,0.0,True,0,1,1,4,2.0,0.0
1051,"Platelet activation, signaling and aggregation",Hemostasis,2344.5,0.0072896272655198,0.5,3.0,4.0,0.17039489072547465,True,4,1,5,30,4.906890595608519,0.0014855899318488453
1052,Platelet degranulation ,Response to elevated platelet cytosolic Ca2+,1984.5,0.0173329696233405,0.5,1.0,2.0,0.164069295930767,True,21,1,22,26,4.700439718141092,0.0036875208837260152
1053,Platelet homeostasis,Hemostasis,2380.5,0.0020066763140867,0.5,3.0,4.0,0.04690601848431145,True,1,1,2,5,2.321928094887362,0.0008642284481182631
1054,Platelet sensitization by LDL,Platelet homeostasis,2164.5,0.002856978242121,0.5,2.0,3.0,0.04064540837471835,True,2,2,4,5,2.321928094887362,0.0012304335558072452
1055,Platelet sensitization by LDL,Platelet sensitization by LDL,2118.5,0.0041255627444731,0.5,1.0,2.0,0.03905148335876845,False,2,2,4,5,2.321928094887362,0.0017767831629054958
1056,Post-translational modification: synthesis of GPI-anchored proteins,Post-translational modification: synthesis of GPI-anchored proteins,2120.5,0.0012886259602607143,0.5,1.0,2.0,0.0121977917582793,False,2,2,4,5,2.321928094887362,0.0005549809932091054
1057,Post-translational modification: synthesis of GPI-anchored proteins,Post-translational protein modification,2178.5,0.0005185644986456001,0.5,2.0,3.0,0.00737746809035485,True,2,2,4,5,2.321928094887362,0.00022333357341574174
1058,Post-translational protein modification,Metabolism of proteins,2366.5,0.009202474867890598,0.5,3.0,4.0,0.21510766496047073,True,4,1,5,27,4.754887502163468,0.001935371733548582
1059,Post-translational protein phosphorylation,Post-translational protein modification,2230.5,0.0093057179983429,0.5,2.0,3.0,0.13238977556294457,True,13,2,15,16,4.0,0.002326429499585725
1060,Post-translational protein phosphorylation,Post-translational protein phosphorylation,2122.5,0.0132524880078175,0.5,1.0,2.0,0.1254445385887963,False,13,2,15,16,4.0,0.003313122001954375
1061,Potential therapeutics for SARS,SARS-CoV Infections,2030.5,0.0079203315493903,0.5,1.0,2.0,0.07497175897065295,True,34,1,35,39,5.285402218862249,0.0014985295766374528
1062,Programmed Cell Death,root,2468.5,0.0144319571690916,0.5,4.0,5.0,0.829702752818332,True,1,1,2,9,3.169925001442312,0.004552775590124397
1063,Protein localization,root,2456.5,0.0014361636152933402,0.5,4.0,5.0,0.08256599511384756,True,1,1,2,4,2.0,0.0007180818076466701
1064,Pyruvate metabolism,Pyruvate metabolism and Citric Acid (TCA) cycle,1982.5,0.00017839180126398864,0.5,1.0,2.0,0.0016886095036935502,True,1,1,2,6,2.584962500721156,6.901136910660045e-05
1065,Pyruvate metabolism and Citric Acid (TCA) cycle,The citric acid (TCA) cycle and respiratory electron transport,2194.5,0.0001364565675827983,0.5,2.0,3.0,0.0019413283703197063,True,1,1,2,6,2.584962500721156,5.278860623499547e-05
1066,RAF/MAP kinase cascade,MAPK1/MAPK3 signaling,1966.5,0.0059534938417685,0.5,1.0,2.0,0.056354194588317745,True,3,1,4,8,3.0,0.0019844979472561667
1067,RHO GTPase Effectors,Signaling by Rho GTPases,1902.5,0.0067273707266791005,0.5,1.0,2.0,0.06367950804605355,True,2,1,3,7,2.807354922057604,0.002396337803183213
1068,RNA Polymerase II Transcription,Gene expression (Transcription),2448.5,0.0244294663746174,0.5,3.0,4.0,0.5710382851910794,True,1,1,2,13,3.700439718141092,0.006601773906720872
1069,RNAS1,Chaperone Mediated Autophagy,1602.5,0.0369185598838593,0.5,0.0,1.0,0.020930187146292703,True,0,2,2,5,2.321928094887362,0.01589995829980697
1070,RNAS1,Late endosomal microautophagy,1604.5,0.0369185598838593,0.5,0.0,1.0,0.020930187146292703,True,0,2,2,5,2.321928094887362,0.01589995829980697
1071,Regulation of Complement cascade,Complement cascade,1884.5,0.0085608355318965,0.5,1.0,2.0,0.0810345998879492,True,50,1,51,55,5.78135971352466,0.0014807650719033546
1072,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Metabolism of proteins,2418.5,0.0067364189308917,0.5,3.0,4.0,0.15746365702944645,True,15,2,17,17,4.087462841250339,0.0016480685433781352
1073,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),2178.5,0.0117292957446877,0.5,1.5,2.5,0.1341141775690855,False,15,2,17,17,4.087462841250339,0.0028695785626028474
1074,Regulation of TLR by endogenous ligand,Toll-like Receptor Cascades,1898.5,0.0031467797650826003,0.5,1.0,2.0,0.02978658312601355,True,7,1,8,12,3.584962500721156,0.000877772016987511
1075,Regulation of actin dynamics for phagocytic cup formation,Fcgamma receptor (FCGR) dependent phagocytosis,1910.5,0.010412719165065299,0.5,1.0,2.0,0.09856403947287576,True,32,1,33,37,5.20945336562895,0.0019988122427137124
1076,Regulation of lipid metabolism by PPARalpha,Metabolism of lipids,2292.5,0.010889013139307801,0.5,2.0,3.0,0.15491486050529574,True,1,1,2,7,2.807354922057604,0.0038787447407351255
1077,Response to elevated platelet cytosolic Ca2+,"Platelet activation, signaling and aggregation",2150.5,0.0123063297246146,0.5,2.0,3.0,0.17507861623739662,True,1,1,2,26,4.700439718141092,0.0026181230826382027
1078,Retinoid metabolism and transport,Metabolism of fat-soluble vitamins,2096.5,0.0338089862782062,0.5,1.0,2.0,0.32002690221811025,True,5,3,8,11,3.4594316186372973,0.009772988746493528
1079,Retinoid metabolism and transport,Retinoid metabolism and transport,2098.5,0.0338089862782062,0.5,1.0,2.0,0.32002690221811025,False,5,3,8,11,3.4594316186372973,0.009772988746493528
1080,Retinoid metabolism and transport,Visual phototransduction,2204.5,0.0132731020081916,0.5,2.0,3.0,0.18883260767212845,True,5,3,8,11,3.4594316186372973,0.0038367869266975134
1081,Reversible hydration of carbon dioxide,Metabolism,2436.5,0.0048808122235567,0.5,3.0,4.0,0.1140888875647055,True,2,2,4,4,2.0,0.00244040611177835
1082,Reversible hydration of carbon dioxide,Reversible hydration of carbon dioxide,2174.5,0.0082935829075992,0.5,1.5,2.5,0.09583667469532102,False,2,2,4,4,2.0,0.0041467914537996
1083,Role of LAT2/NTAL/LAB on calcium mobilization,Fc epsilon receptor (FCERI) signaling,1924.5,0.0008081312496391,0.5,1.0,2.0,0.007649556194306999,True,32,1,33,37,5.20945336562895,0.00015512784027802356
1084,Role of phospholipids in phagocytosis,Fcgamma receptor (FCGR) dependent phagocytosis,1912.5,0.0011964837937079999,0.5,1.0,2.0,0.011325598434207,True,32,1,33,37,5.20945336562895,0.0002296754975487808
1085,S10A8,Antigen processing-Cross presentation,1408.5,0.047859334825209904,0.5,0.0,1.0,0.02713282527108185,True,0,9,9,23,4.523561956057013,0.010580010905151115
1086,S10A8,IRAK4 deficiency (TLR2/4),1420.5,0.047859334825209904,0.5,0.0,1.0,0.02713282527108185,True,0,9,9,23,4.523561956057013,0.010580010905151115
1087,S10A8,Metal sequestration by antimicrobial proteins,1422.5,0.047859334825209904,0.5,0.0,1.0,0.02713282527108185,True,0,9,9,23,4.523561956057013,0.010580010905151115
1088,S10A8,MyD88 deficiency (TLR2/4),1418.5,0.047859334825209904,0.5,0.0,1.0,0.02713282527108185,True,0,9,9,23,4.523561956057013,0.010580010905151115
1089,S10A8,Neutrophil degranulation,1424.5,0.047859334825209904,0.5,0.0,1.0,0.02713282527108185,True,0,9,9,23,4.523561956057013,0.010580010905151115
1090,S10A8,RHO GTPase Effectors,1416.5,0.047859334825209904,0.5,0.0,1.0,0.02713282527108185,True,0,9,9,23,4.523561956057013,0.010580010905151115
1091,S10A8,Regulation of TLR by endogenous ligand,1414.5,0.047859334825209904,0.5,0.0,1.0,0.02713282527108185,True,0,9,9,23,4.523561956057013,0.010580010905151115
1092,S10A8,Toll Like Receptor 2 (TLR2) Cascade,1412.5,0.047859334825209904,0.5,0.0,1.0,0.02713282527108185,True,0,9,9,23,4.523561956057013,0.010580010905151115
1093,S10A8,Toll Like Receptor 4 (TLR4) Cascade,1410.5,0.047859334825209904,0.5,0.0,1.0,0.02713282527108185,True,0,9,9,23,4.523561956057013,0.010580010905151115
1094,S10A9,Antigen processing-Cross presentation,1550.5,0.015394180728258,0.5,0.0,1.0,0.00872740119386825,True,0,9,9,23,4.523561956057013,0.0034031103979122726
1095,S10A9,IRAK4 deficiency (TLR2/4),1562.5,0.015394180728258,0.5,0.0,1.0,0.00872740119386825,True,0,9,9,23,4.523561956057013,0.0034031103979122726
1096,S10A9,Metal sequestration by antimicrobial proteins,1564.5,0.015394180728258,0.5,0.0,1.0,0.00872740119386825,True,0,9,9,23,4.523561956057013,0.0034031103979122726
1097,S10A9,MyD88 deficiency (TLR2/4),1560.5,0.015394180728258,0.5,0.0,1.0,0.00872740119386825,True,0,9,9,23,4.523561956057013,0.0034031103979122726
1098,S10A9,Neutrophil degranulation,1566.5,0.015394180728258,0.5,0.0,1.0,0.00872740119386825,True,0,9,9,23,4.523561956057013,0.0034031103979122726
1099,S10A9,RHO GTPase Effectors,1558.5,0.015394180728258,0.5,0.0,1.0,0.00872740119386825,True,0,9,9,23,4.523561956057013,0.0034031103979122726
1100,S10A9,Regulation of TLR by endogenous ligand,1556.5,0.015394180728258,0.5,0.0,1.0,0.00872740119386825,True,0,9,9,23,4.523561956057013,0.0034031103979122726
1101,S10A9,Toll Like Receptor 2 (TLR2) Cascade,1554.5,0.015394180728258,0.5,0.0,1.0,0.00872740119386825,True,0,9,9,23,4.523561956057013,0.0034031103979122726
1102,S10A9,Toll Like Receptor 4 (TLR4) Cascade,1552.5,0.015394180728258,0.5,0.0,1.0,0.00872740119386825,True,0,9,9,23,4.523561956057013,0.0034031103979122726
1103,SAA1,Advanced glycosylation endproduct receptor signaling,1658.5,0.0019593916788075002,0.5,0.0,1.0,0.0011108351641923,True,0,16,16,31,4.954196310386875,0.00039550142062386113
1104,SAA1,Amyloid fiber formation,1662.5,0.0019593916788075002,0.5,0.0,1.0,0.0011108351641923,True,0,16,16,31,4.954196310386875,0.00039550142062386113
1105,SAA1,Class A/1 (Rhodopsin-like receptors),1648.5,0.0019593916788075002,0.5,0.0,1.0,0.0011108351641923,True,0,16,16,31,4.954196310386875,0.00039550142062386113
1106,SAA1,G alpha (i) signalling events,1652.5,0.0019593916788075002,0.5,0.0,1.0,0.0011108351641923,True,0,16,16,31,4.954196310386875,0.00039550142062386113
1107,SAA1,G alpha (q) signalling events,1650.5,0.0019593916788075002,0.5,0.0,1.0,0.0011108351641923,True,0,16,16,31,4.954196310386875,0.00039550142062386113
1108,SAA1,Interleukin-1 family signaling,1654.5,0.0019593916788075002,0.5,0.0,1.0,0.0011108351641923,True,0,16,16,31,4.954196310386875,0.00039550142062386113
1109,SAA1,Interleukin-4 and Interleukin-13 signaling,1656.5,0.0019593916788075002,0.5,0.0,1.0,0.0011108351641923,True,0,16,16,31,4.954196310386875,0.00039550142062386113
1110,SAA1,Scavenging by Class B Receptors,1660.5,0.0019593916788075002,0.5,0.0,1.0,0.0011108351641923,True,0,16,16,31,4.954196310386875,0.00039550142062386113
1111,SAA1,TRAF6 mediated NF-kB activation,1646.5,0.0019593916788075002,0.5,0.0,1.0,0.0011108351641923,True,0,16,16,31,4.954196310386875,0.00039550142062386113
1112,SAA1,Toll Like Receptor 10 (TLR10) Cascade,1636.5,0.0019593916788075002,0.5,0.0,1.0,0.0011108351641923,True,0,16,16,31,4.954196310386875,0.00039550142062386113
1113,SAA1,Toll Like Receptor 2 (TLR2) Cascade,1644.5,0.0019593916788075002,0.5,0.0,1.0,0.0011108351641923,True,0,16,16,31,4.954196310386875,0.00039550142062386113
1114,SAA1,Toll Like Receptor 3 (TLR3) Cascade,1638.5,0.0019593916788075002,0.5,0.0,1.0,0.0011108351641923,True,0,16,16,31,4.954196310386875,0.00039550142062386113
1115,SAA1,Toll Like Receptor 4 (TLR4) Cascade,1632.5,0.0019593916788075002,0.5,0.0,1.0,0.0011108351641923,True,0,16,16,31,4.954196310386875,0.00039550142062386113
1116,SAA1,Toll Like Receptor 5 (TLR5) Cascade,1640.5,0.0019593916788075002,0.5,0.0,1.0,0.0011108351641923,True,0,16,16,31,4.954196310386875,0.00039550142062386113
1117,SAA1,Toll Like Receptor 7/8 (TLR7/8) Cascade,1642.5,0.0019593916788075002,0.5,0.0,1.0,0.0011108351641923,True,0,16,16,31,4.954196310386875,0.00039550142062386113
1118,SAA1,Toll Like Receptor 9 (TLR9) Cascade,1634.5,0.0019593916788075002,0.5,0.0,1.0,0.0011108351641923,True,0,16,16,31,4.954196310386875,0.00039550142062386113
1119,SAMP,Amyloid fiber formation,1174.5,0.008565700203570399,0.5,0.0,1.0,0.00485614034956295,True,0,1,1,4,2.0,0.0042828501017851996
1120,SARS-CoV Infections,Infectious disease,2148.5,0.0041433614068351,0.5,2.0,3.0,0.0589464119614138,True,2,1,3,42,5.392317422778761,0.0007683823265544982
1121,SARS-CoV-2 Infection,SARS-CoV Infections,2032.5,0.005266317095439401,0.5,1.0,2.0,0.049849561660421204,True,2,1,3,7,2.807354922057604,0.0018758999989853585
1122,SLC transporter disorders,Disorders of transmembrane transporters,2272.5,0.0006630806471169,0.5,2.0,3.0,0.0094334578017069,True,2,1,3,7,2.807354922057604,0.00023619409213527804
1123,SLC-mediated transmembrane transport,Transport of small molecules,2370.5,0.0027988372244656997,0.5,3.0,4.0,0.06542276383280055,True,1,1,2,6,2.584962500721156,0.0010827380372770887
1124,Scavenging by Class A Receptors,Binding and Uptake of Ligands by Scavenger Receptors,2300.5,0.0123192408084494,0.5,2.0,3.0,0.17526229851655667,True,5,2,7,8,3.0,0.004106413602816467
1125,Scavenging by Class A Receptors,Scavenging by Class A Receptors,2090.5,0.015386064712488,0.5,1.0,2.0,0.14564041011897988,False,5,2,7,8,3.0,0.0051286882374960005
1126,Scavenging by Class B Receptors,Binding and Uptake of Ligands by Scavenger Receptors,2214.5,0.0018027176581872,0.5,2.0,3.0,0.02564674603434845,True,4,2,6,7,2.807354922057604,0.0006421409861728234
1127,Scavenging by Class B Receptors,Scavenging by Class B Receptors,2088.5,0.0033680137621361,0.5,1.0,2.0,0.0318807254986882,False,4,2,6,7,2.807354922057604,0.0011997107083516075
1128,Scavenging by Class F Receptors,Binding and Uptake of Ligands by Scavenger Receptors,2186.5,0.005490731022591001,0.5,2.0,3.0,0.07811505225999435,True,2,2,4,5,2.321928094887362,0.002364729138116294
1129,Scavenging by Class F Receptors,Scavenging by Class F Receptors,2092.5,0.0082799788594238,0.5,1.0,2.0,0.0783760850741923,False,2,2,4,5,2.321928094887362,0.003565992796097101
1130,Scavenging by Class H Receptors,Binding and Uptake of Ligands by Scavenger Receptors,2180.5,0.0044934487736526,0.5,2.0,3.0,0.0639270043164199,True,2,2,4,5,2.321928094887362,0.001935223051715811
1131,Scavenging by Class H Receptors,Scavenging by Class H Receptors,2094.5,0.0040797201125072,0.5,1.0,2.0,0.03861754915627965,False,2,2,4,5,2.321928094887362,0.0017570398159573969
1132,Scavenging of heme from plasma,Binding and Uptake of Ligands by Scavenger Receptors,2252.5,0.0070717239743112,0.5,2.0,3.0,0.10060738461759465,True,39,2,41,42,5.392317422778761,0.0013114443048990632
1133,Scavenging of heme from plasma,Scavenging of heme from plasma,2086.5,0.0090772773263827,0.5,1.0,2.0,0.08592310101913864,False,39,2,41,42,5.392317422778761,0.0016833722154481424
1134,Sensory Perception,root,2472.5,0.0046795296844638,0.5,4.0,5.0,0.26902925331638505,True,2,1,3,11,3.4594316186372973,0.0013526874354889288
1135,Sensory processing of sound,Sensory Perception,2420.5,0.0170957030859187,0.5,3.0,4.0,0.39961171581144644,True,1,1,2,5,2.321928094887362,0.00736271856288815
1136,Sensory processing of sound by outer hair cells of the cochlea,Sensory processing of sound,2310.5,0.021096569581735898,0.5,2.0,3.0,0.30013483243006056,True,2,2,4,5,2.321928094887362,0.009085797974617858
1137,Sensory processing of sound by outer hair cells of the cochlea,Sensory processing of sound by outer hair cells of the cochlea,2140.5,0.0281545237917449,0.5,1.0,2.0,0.2665032591736216,False,2,2,4,5,2.321928094887362,0.01212549340082415
1138,Signal Transduction,root,2470.5,0.0083833959859096,0.5,4.0,5.0,0.48196697412408196,True,6,1,7,41,5.357552004618084,0.0015647810751409058
1139,Signaling by BRAF and RAF1 fusions,Oncogenic MAPK signaling,1974.5,0.0003271323526121,0.5,1.0,2.0,0.0030965481354668,True,3,1,4,8,3.0,0.00010904411753736666
1140,Signaling by ERBB4,Signaling by Receptor Tyrosine Kinases,2212.5,0.004977853179485,0.5,2.0,3.0,0.0708184865836974,True,1,1,2,6,2.584962500721156,0.0019256964764851605
1141,Signaling by GPCR,Signal Transduction,2388.5,0.0094206112184113,0.5,3.0,4.0,0.22020659776682017,True,2,1,3,16,4.0,0.002355152804602825
1142,Signaling by Interleukins,Cytokine Signaling in Immune system,2158.5,0.0115878019768528,0.5,2.0,3.0,0.16485632846993414,True,2,1,3,9,3.169925001442312,0.0036555445228452924
1143,Signaling by Nuclear Receptors,Signal Transduction,2372.5,0.0025030812898889,0.5,3.0,4.0,0.0585094748101899,True,1,1,2,7,2.807354922057604,0.0008916155453740449
1144,Signaling by PDGF,Signaling by PDGF,2130.5,0.006695852667607301,0.5,1.0,2.0,0.06338116645350565,False,3,2,5,6,2.584962500721156,0.0025903094012927784
1145,Signaling by PDGF,Signaling by Receptor Tyrosine Kinases,2220.5,0.004820162453984,0.5,2.0,3.0,0.068575065951227,True,3,2,5,6,2.584962500721156,0.0018646933766502474
1146,Signaling by RAF1 mutants,Oncogenic MAPK signaling,1978.5,0.0020053004105026998,0.5,1.0,2.0,0.01898164213233455,True,3,1,4,8,3.0,0.0006684334701675666
1147,Signaling by RAS mutants,Oncogenic MAPK signaling,1968.5,0.0014355037798653,0.5,1.0,2.0,0.013588098265130698,True,3,1,4,8,3.0,0.0004785012599551
1148,Signaling by Receptor Tyrosine Kinases,Signal Transduction,2390.5,0.0045848827984243,0.5,3.0,4.0,0.10717154320385135,True,2,1,3,9,3.169925001442312,0.001446369487081929
1149,Signaling by Rho GTPases,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",2302.5,0.0039608123848137,0.5,2.0,3.0,0.056349339488452554,True,1,1,2,7,2.807354922057604,0.0014108698382571051
1150,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",Signal Transduction,2334.5,0.00048300800920119996,0.5,3.0,4.0,0.011290302501018399,True,1,1,2,7,2.807354922057604,0.00017205092430820512
1151,Signaling by high-kinase activity BRAF mutants,Oncogenic MAPK signaling,1972.5,0.00015361236741319922,0.5,1.0,2.0,0.0014540539512515,True,3,1,4,8,3.0,5.120412247106641e-05
1152,Signaling by moderate kinase activity BRAF mutants,Oncogenic MAPK signaling,1970.5,0.0006255497430433,0.5,1.0,2.0,0.0059212880505251,True,3,1,4,8,3.0,0.00020851658101443335
1153,Signaling by the B Cell Receptor (BCR),Adaptive Immune System,2170.5,0.0014609983141155,0.5,2.0,3.0,0.0207852031340345,True,2,1,3,40,5.321928094887363,0.00027452424911923235
1154,Syndecan interactions,Non-integrin membrane-ECM interactions,2328.5,0.013074604957747801,0.5,2.0,3.0,0.18600864718215415,True,3,2,5,6,2.584962500721156,0.005057947631387392
1155,Syndecan interactions,Syndecan interactions,2104.5,0.0170707369013658,0.5,1.0,2.0,0.16158707049569426,False,3,2,5,6,2.584962500721156,0.00660386249185564
1156,THRB,Cell surface interactions at the vascular wall,98.5,0.0389190388026315,0.5,0.0,1.0,0.02206431584155695,True,0,11,11,29,4.857980995127572,0.008011360859926434
1157,THRB,Class A/1 (Rhodopsin-like receptors),90.5,0.0389190388026315,0.5,0.0,1.0,0.02206431584155695,True,0,11,11,29,4.857980995127572,0.008011360859926434
1158,THRB,Common Pathway of Fibrin Clot Formation,102.5,0.0389190388026315,0.5,0.0,1.0,0.02206431584155695,True,0,11,11,29,4.857980995127572,0.008011360859926434
1159,THRB,Defective factor VIII causes hemophilia A,96.5,0.0389190388026315,0.5,0.0,1.0,0.02206431584155695,True,0,11,11,29,4.857980995127572,0.008011360859926434
1160,THRB,Defective factor XII causes hereditary angioedema,94.5,0.0389190388026315,0.5,0.0,1.0,0.02206431584155695,True,0,11,11,29,4.857980995127572,0.008011360859926434
1161,THRB,G alpha (q) signalling events,92.5,0.0389190388026315,0.5,0.0,1.0,0.02206431584155695,True,0,11,11,29,4.857980995127572,0.008011360859926434
1162,THRB,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",86.5,0.0389190388026315,0.5,0.0,1.0,0.02206431584155695,True,0,11,11,29,4.857980995127572,0.008011360859926434
1163,THRB,Intrinsic Pathway of Fibrin Clot Formation,100.5,0.0389190388026315,0.5,0.0,1.0,0.02206431584155695,True,0,11,11,29,4.857980995127572,0.008011360859926434
1164,THRB,Regulation of Complement cascade,88.5,0.0389190388026315,0.5,0.0,1.0,0.02206431584155695,True,0,11,11,29,4.857980995127572,0.008011360859926434
1165,THRB,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),104.5,0.0389190388026315,0.5,0.0,1.0,0.02206431584155695,True,0,11,11,29,4.857980995127572,0.008011360859926434
1166,THRB,Thrombin signalling through proteinase activated receptors (PARs),106.5,0.0389190388026315,0.5,0.0,1.0,0.02206431584155695,True,0,11,11,29,4.857980995127572,0.008011360859926434
1167,TRAF6 mediated NF-kB activation,DDX58/IFIH1-mediated induction of interferon-alpha/beta,1900.5,0.0024780287201532003,0.5,1.0,2.0,0.0234563630033882,True,1,1,2,6,2.584962500721156,0.0009586323667990838
1168,TRFE,Cargo recognition for clathrin-mediated endocytosis,1228.5,0.0060921251702785,0.5,0.0,1.0,0.0034537999405635997,True,0,5,5,17,4.087462841250339,0.0014904417255607251
1169,TRFE,Platelet degranulation ,1226.5,0.0060921251702785,0.5,0.0,1.0,0.0034537999405635997,True,0,5,5,17,4.087462841250339,0.0014904417255607251
1170,TRFE,Post-translational protein phosphorylation,1232.5,0.0060921251702785,0.5,0.0,1.0,0.0034537999405635997,True,0,5,5,17,4.087462841250339,0.0014904417255607251
1171,TRFE,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),1230.5,0.0060921251702785,0.5,0.0,1.0,0.0034537999405635997,True,0,5,5,17,4.087462841250339,0.0014904417255607251
1172,TRFE,Transferrin endocytosis and recycling,1234.5,0.0060921251702785,0.5,0.0,1.0,0.0034537999405635997,True,0,5,5,17,4.087462841250339,0.0014904417255607251
1173,TSP1,Diseases associated with O-glycosylation of proteins,1590.5,0.0879093720667467,0.5,0.0,1.0,0.04983833646432425,True,0,7,7,25,4.643856189774724,0.01893025289204988
1174,TSP1,Integrin cell surface interactions,1596.5,0.0879093720667467,0.5,0.0,1.0,0.04983833646432425,True,0,7,7,25,4.643856189774724,0.01893025289204988
1175,TSP1,O-glycosylation of TSR domain-containing proteins,1592.5,0.0879093720667467,0.5,0.0,1.0,0.04983833646432425,True,0,7,7,25,4.643856189774724,0.01893025289204988
1176,TSP1,Platelet degranulation ,1594.5,0.0879093720667467,0.5,0.0,1.0,0.04983833646432425,True,0,7,7,25,4.643856189774724,0.01893025289204988
1177,TSP1,Signaling by PDGF,1600.5,0.0879093720667467,0.5,0.0,1.0,0.04983833646432425,True,0,7,7,25,4.643856189774724,0.01893025289204988
1178,TSP1,Syndecan interactions,1598.5,0.0879093720667467,0.5,0.0,1.0,0.04983833646432425,True,0,7,7,25,4.643856189774724,0.01893025289204988
1179,TSP1,Transcriptional regulation by RUNX1,1588.5,0.0879093720667467,0.5,0.0,1.0,0.04983833646432425,True,0,7,7,25,4.643856189774724,0.01893025289204988
1180,TYB4,Platelet degranulation ,1776.5,0.001570064307949,0.5,0.0,1.0,0.00089011434629265,True,0,1,1,6,2.584962500721156,0.0006073837850688285
1181,Terminal pathway of complement,Complement cascade,1880.5,0.0075121243819602,0.5,1.0,2.0,0.071107778128964,True,6,1,7,11,3.4594316186372973,0.002171490929749696
1182,The citric acid (TCA) cycle and respiratory electron transport,Metabolism,2404.5,6.825520379076172e-05,0.5,3.0,4.0,0.0015954640158878,True,1,1,2,6,2.584962500721156,2.6404717194821896e-05
1183,Thrombin signalling through proteinase activated receptors (PARs),"Platelet activation, signaling and aggregation",2318.5,0.00214932861797,0.5,2.0,3.0,0.03057788054556765,True,2,2,4,5,2.321928094887362,0.0009256654513559625
1184,Thrombin signalling through proteinase activated receptors (PARs),Thrombin signalling through proteinase activated receptors (PARs),2128.5,0.0034037846654067,0.5,1.0,2.0,0.03221932338710255,False,2,2,4,5,2.321928094887362,0.0014659302641203535
1185,Toll Like Receptor 10 (TLR10) Cascade,Toll-like Receptor Cascades,1888.5,0.0013332226952157,0.5,1.0,2.0,0.01261993262991775,True,1,1,2,6,2.584962500721156,0.0005157609423129952
1186,Toll Like Receptor 2 (TLR2) Cascade,Toll-like Receptor Cascades,1896.5,0.0043683859448123,0.5,1.0,2.0,0.04134998340700375,True,6,1,7,11,3.4594316186372973,0.00126274672442667
1187,Toll Like Receptor 3 (TLR3) Cascade,Toll-like Receptor Cascades,1890.5,0.0011342899802547,0.5,1.0,2.0,0.010736888282035,True,1,1,2,6,2.584962500721156,0.0004388032630795435
1188,Toll Like Receptor 4 (TLR4) Cascade,Toll-like Receptor Cascades,1876.5,0.0007846299004381999,0.5,1.0,2.0,0.00742709865237275,True,7,1,8,12,3.584962500721156,0.00021886697567418423
1189,Toll Like Receptor 5 (TLR5) Cascade,Toll-like Receptor Cascades,1892.5,0.0020534416119167,0.5,1.0,2.0,0.0194373339839271,True,1,1,2,6,2.584962500721156,0.0007943796520621975
1190,Toll Like Receptor 7/8 (TLR7/8) Cascade,Toll-like Receptor Cascades,1894.5,0.0037599703135072,0.5,1.0,2.0,0.035590882316381495,True,2,1,3,7,2.807354922057604,0.001339328448984068
1191,Toll Like Receptor 9 (TLR9) Cascade,Toll-like Receptor Cascades,1886.5,0.0014825054587858,0.5,1.0,2.0,0.0140330036988574,True,2,1,3,7,2.807354922057604,0.0005280790993463777
1192,Toll-like Receptor Cascades,Innate Immune System,2172.5,0.006931768736985,0.5,2.0,3.0,0.0986162816783305,True,8,1,9,20,4.321928094887363,0.00160386026440027
1193,Transcriptional Regulation by TP53,Generic Transcription Pathway,1914.5,0.0063914280737922,0.5,1.0,2.0,0.060499563943569104,True,1,1,2,6,2.584962500721156,0.0024725418925841715
1194,Transcriptional regulation by RUNX1,Generic Transcription Pathway,1918.5,0.0266489382675056,0.5,1.0,2.0,0.2522517856931128,True,2,1,3,7,2.807354922057604,0.0094925433396835
1195,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,Generic Transcription Pathway,1916.5,0.0112064530642006,0.5,1.0,2.0,0.1060773141636793,True,1,1,2,6,2.584962500721156,0.004335247827028133
1196,Transcriptional regulation of white adipocyte differentiation,Developmental Biology,2450.5,0.0131610231069044,0.5,3.0,4.0,0.3076386504346891,True,2,2,4,4,2.0,0.0065805115534522
1197,Transcriptional regulation of white adipocyte differentiation,Transcriptional regulation of white adipocyte differentiation,2124.5,0.0144234268068304,0.5,1.5,2.5,0.16846648760798594,False,2,2,4,4,2.0,0.0072117134034152
1198,Transferrin endocytosis and recycling,Iron uptake and transport,2254.5,0.0006870440098050687,0.5,2.0,3.0,0.0097743776757643,True,2,2,4,5,2.321928094887362,0.0002958937493877895
1199,Transferrin endocytosis and recycling,Transferrin endocytosis and recycling,2132.5,0.0006958080734082,0.5,1.0,2.0,0.0065863347820857504,False,2,2,4,5,2.321928094887362,0.0002996682261351224
1200,"Transport of bile salts and organic acids, metal ions and amine compounds",SLC-mediated transmembrane transport,2226.5,0.0042370894537647995,0.5,2.0,3.0,0.060279853948285556,True,1,1,2,6,2.584962500721156,0.0016391299496927832
1201,Transport of small molecules,root,2486.5,0.008228175665269899,0.5,4.0,5.0,0.473043255336728,True,6,1,7,43,5.426264754702098,0.001516360892295169
1202,VLDL assembly,Plasma lipoprotein assembly,1990.5,0.0012777789735892,0.5,1.0,2.0,0.0120951170577037,True,2,1,3,7,2.807354922057604,0.0004551540539279847
1203,VLDL clearance,Plasma lipoprotein clearance,2010.5,0.0005609088688588,0.5,1.0,2.0,0.0053094146701253495,True,2,1,3,7,2.807354922057604,0.00019979977040013563
1204,VTNC,ECM proteoglycans,1248.5,0.0162665067081668,0.5,0.0,1.0,0.00922194773277725,True,0,5,5,13,3.700439718141092,0.004395830751794612
1205,VTNC,Integrin cell surface interactions,1246.5,0.0162665067081668,0.5,0.0,1.0,0.00922194773277725,True,0,5,5,13,3.700439718141092,0.004395830751794612
1206,VTNC,Molecules associated with elastic fibres,1250.5,0.0162665067081668,0.5,0.0,1.0,0.00922194773277725,True,0,5,5,13,3.700439718141092,0.004395830751794612
1207,VTNC,Regulation of Complement cascade,1244.5,0.0162665067081668,0.5,0.0,1.0,0.00922194773277725,True,0,5,5,13,3.700439718141092,0.004395830751794612
1208,VTNC,Syndecan interactions,1252.5,0.0162665067081668,0.5,0.0,1.0,0.00922194773277725,True,0,5,5,13,3.700439718141092,0.004395830751794612
1209,VWF,Defective factor VIII causes hemophilia A,1360.5,0.014062153536129,0.5,0.0,1.0,0.007972236894315,True,0,15,15,31,4.954196310386875,0.002838432846644884
1210,VWF,GP1b-IX-V activation signalling,1372.5,0.014062153536129,0.5,0.0,1.0,0.007972236894315,True,0,15,15,31,4.954196310386875,0.002838432846644884
1211,VWF,GRB2:SOS provides linkage to MAPK signaling for Integrins ,1368.5,0.014062153536129,0.5,0.0,1.0,0.007972236894315,True,0,15,15,31,4.954196310386875,0.002838432846644884
1212,VWF,Integrin cell surface interactions,1366.5,0.014062153536129,0.5,0.0,1.0,0.007972236894315,True,0,15,15,31,4.954196310386875,0.002838432846644884
1213,VWF,Intrinsic Pathway of Fibrin Clot Formation,1364.5,0.014062153536129,0.5,0.0,1.0,0.007972236894315,True,0,15,15,31,4.954196310386875,0.002838432846644884
1214,VWF,Paradoxical activation of RAF signaling by kinase inactive BRAF,1354.5,0.014062153536129,0.5,0.0,1.0,0.007972236894315,True,0,15,15,31,4.954196310386875,0.002838432846644884
1215,VWF,Platelet Adhesion to exposed collagen,1362.5,0.014062153536129,0.5,0.0,1.0,0.007972236894315,True,0,15,15,31,4.954196310386875,0.002838432846644884
1216,VWF,Platelet degranulation ,1358.5,0.014062153536129,0.5,0.0,1.0,0.007972236894315,True,0,15,15,31,4.954196310386875,0.002838432846644884
1217,VWF,RAF/MAP kinase cascade,1344.5,0.014062153536129,0.5,0.0,1.0,0.007972236894315,True,0,15,15,31,4.954196310386875,0.002838432846644884
1218,VWF,Signaling by BRAF and RAF1 fusions,1352.5,0.014062153536129,0.5,0.0,1.0,0.007972236894315,True,0,15,15,31,4.954196310386875,0.002838432846644884
1219,VWF,Signaling by RAF1 mutants,1356.5,0.014062153536129,0.5,0.0,1.0,0.007972236894315,True,0,15,15,31,4.954196310386875,0.002838432846644884
1220,VWF,Signaling by RAS mutants,1346.5,0.014062153536129,0.5,0.0,1.0,0.007972236894315,True,0,15,15,31,4.954196310386875,0.002838432846644884
1221,VWF,Signaling by high-kinase activity BRAF mutants,1350.5,0.014062153536129,0.5,0.0,1.0,0.007972236894315,True,0,15,15,31,4.954196310386875,0.002838432846644884
1222,VWF,Signaling by moderate kinase activity BRAF mutants,1348.5,0.014062153536129,0.5,0.0,1.0,0.007972236894315,True,0,15,15,31,4.954196310386875,0.002838432846644884
1223,VWF,p130Cas linkage to MAPK signaling for integrins,1370.5,0.014062153536129,0.5,0.0,1.0,0.007972236894315,True,0,15,15,31,4.954196310386875,0.002838432846644884
1224,Vesicle-mediated transport,root,2476.5,0.0090578586303585,0.5,4.0,5.0,0.5207422771696605,True,2,1,3,54,5.754887502163468,0.0015739419105852768
1225,Visual phototransduction,Sensory Perception,2440.5,0.0079754117335324,0.5,3.0,4.0,0.18642508887305054,True,1,1,2,8,3.0,0.0026584705778441332
1226,ZA2G,Miscellaneous transport and binding events,1726.5,0.0484031839391083,0.5,0.0,1.0,0.027441148883082148,True,0,1,1,4,2.0,0.02420159196955415
1227,p130Cas linkage to MAPK signaling for integrins,Integrin signaling,2262.5,0.0011543339161190001,0.5,2.0,3.0,0.0164223768769819,True,4,2,6,7,2.807354922057604,0.00041118203724413666
1228,p130Cas linkage to MAPK signaling for integrins,p130Cas linkage to MAPK signaling for integrins,2108.5,0.0050149995594314,0.5,1.0,2.0,0.0474706564823747,False,4,2,6,7,2.807354922057604,0.0017863788864130293
1229,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",Gene Silencing by RNA,2188.5,0.0001363626203304335,0.5,2.0,3.0,0.0019399918097609999,True,2,2,4,5,2.321928094887362,5.872818397378e-05
1230,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis","tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",2084.5,0.00027555226189586126,0.5,1.0,2.0,0.00260830466930005,False,2,2,4,5,2.321928094887362,0.00011867389972264771
